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Abstract  
 
Cutaneous squamous cell carcinoma (cSCC) is one of the most common 
Caucasian skin cancers and is particularly prevalent following chronic ultraviolet 
(UV) radiation exposure and in immunosuppressed patients.  Recent use of 
rapamycin as an immunosuppressant significantly reduces SCC after organ 
transplantation. However the mechanism remains unclear. Rapamycin inhibits 
mammalian target of rapamycin (mTOR) kinase, downstream from 
phosphatidylinositol-3 kinase (PI3K) and Akt kinases previously implicated in 
SCC.  The aim was to find the effects of rapamycin on PI3K-Akt-mTOR 
signalling in epidermis in order to understand rapamycin’s tumour suppressing 
activity in skin.   
 
Rapamycin increases epidermal Akt phosphorylation via inhibition of an mTOR 
complex 1 (mTORC1)-dependent negative feedback loop to insulin receptor 
substrate-1. In a skin experimental model, rapamycin selectively increases 
phosphorylation of Akt1, the epidermal Akt isoform down-regulated in SCC and 
also down-regulated by UV. Epidermal Akt2, up-regulated in tumours and by 
UV, is unaffected. Rapamycin enhances restoration of Akt1 phosphorylation in 
skin recovering from UV radiation, suggesting a mechanism for rapamycin’s 
anti-tumour activity in epidermis in spite of its efficient immunosuppressive 
properties. 
 
As rapamycin targets mTORC1, newer classes of mTOR inhibitors active 
against mTORC1 and mTORC2 are under development. While comparing the 
two drug classes it was found that rapamycin unexpectedly increases epidermal 
mTORC2 activity. Since mTORC2 signalling influences lipid synthesis and 
epidermis requires extensive lipogenesis for formation of its protective barrier, 
the relationship between epidermal mTORC2 signalling, lipogenesis and barrier 
to UV was explored.  Rapamycin increased epidermal lipid levels, but this 
increase was not sufficient to protect against UV-induced DNA damage.  
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In conclusion, rapamycin treatment can increase PI3K/Akt1 and mTORC2 
signalling and lipid levels in epidermis. Rapamycin can increase epidermal Akt1 
phosphorylation during UV recovery, which may contribute to the anti-cancer 
action of rapamycin in skin. Rapamycin’s potential to increase epidermal lipid 
levels makes it an interesting possible therapeutic for treating skin disorders with 
dyslipidemia. 
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Chapter 1 – Introduction 
1.1 Introduction 
 
 
The small inhibitor, rapamycin, significantly reduces cutaneous squamous cell 
carcinoma (cSCC) occurrence in transplant recipients [1, 2], however the 
mechanism for rapamycin’s tumour-suppressing role in epidermis is not fully 
understood [3]. This study will examine the effects of rapamycin in epidermis to 
provide further understanding of rapamycin’s anti-cancer role in skin.  
 
More specifically, this study will focus on the effects of rapamycin on the 
phosphatidylinositol 3-kinase (PI3K)/Akt pathway to determine whether 
rapamycin’s tumour suppressing role in epidermis can be linked to changes in 
Akt signalling. The PI3K/Akt pathway lies upstream from mammalian target of 
rapamycin complex-1 (mTORC1) and is deregulated in cSCCs [4]. Rapamycin 
also inhibits a second mTOR complex, mTORC2, in some cell types [5]. The 
effect of rapamycin treatment on epidermal mTORC2 activity and also the role of 
mTORC2 in skin are unknown. Therefore the effects of rapamycin on mTORC2 
signalling will also be investigated, to determine whether changes in mTORC2 
activity can be linked to rapamycin’s tumour-suppressing role in skin.  
 
 
1.2 Skin 
 
1.2.1 Skin 
 
The skin acts as both a physical and biological barrier (reviewed by [6]). It 
provides permeability resistance against agents from the external environment, 
including microbes and parasites, and also provides protection against 
ultraviolet (UV) radiation. In addition, the skin defends the internal environment 
by maintaining homeostasis and regulating water loss.  
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The skin consists of two layers; the epidermis and the underlying dermis, which 
are separated by the basement membrane. The dermis is a connective tissue 
consisting of fibroblasts and immune cells such as lymphocytes and mast cells. 
Fibroblasts provide support to the epidermis, synthesizing collagen fibres for 
structure and elastin and fibrillin for elasticity. There is also a network of blood 
vessels, which are important for keratinocyte survival due to the epidermis being 
non-vascularized, and nerve endings, which communicate sensation signals. 
The dermis contacts and adheres to the basement membrane via upward 
protrusions, termed dermal papillae.  
 
The basement membrane consists of an extracellular matrix and is the interface 
between the dermis and the epidermis. It contains anchoring filaments, including 
laminin and fibril, and ensures strong adhesional links between the two layers.  
 
The epidermis is the outermost layer and is a self-renewing stratified epithelium 
that is primarily responsible for epidermal barrier function. The epidermis 
consists of keratinocytes as the major cell type and also pigment producing 
melanocytes and immune cells such as mast cells and Langerhan cells.  
 
1.2.2 Epidermis 
 
The epidermis consists of several layers of differentiating keratinocytes, which 
are eventually lost by desquamation. Keratinocytes migrate from the basal layer, 
through the spinous and granular layers, up to the cornified layer, where they 
become terminally differentiated (Figure 1-1) (reviewed by [6]). Terminal 
differentiation is associated with changes in keratin expression and cell 
morphology. Morphological changes include flattening of the keratinocytes and 
organelle degradation. Terminal differentiation results in the formation of 
corneocytes, dead cells filled with covalently-linked keratins, surrounded by a 
network of non-polar lipids and epidermal proteins. As the corneocytes are lost 
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by desquamation there must be a balance between proliferation and 
differentiation to maintain skin homeostasis and barrier function (reviewed by 
[7]). 
 
 
Figure 1-1: Structure of the epidermis. The epidermis is a stratified squamous 
epithelium consisting of proliferating keratinocytes in the basal layer, resting on 
the basement membrane, which differentiate as the migrate up to give rise to the 
spinous layer, the granular layer and the cornified layer. A) Schematic drawing 
representing the different layers of the epidermis. B) Haematoxylin and eosin 
(H&E) staining in newborn CD1 mouse skin. Dotted line=basement membrane. 
Bar=50µm. 
 
1.2.3 The basal layer 
 
Keratinocytes are generated in the highly proliferative, relatively undifferentiated 
basal layer. This is a single layer of cells that are anchored to the basement 
membrane via basal cell-specific adhesion junctions, hemidesmosomal 
junctions. Hemidesmosomes are keratin-associated integrin-based adhesions 
from basal keratinocytes to the laminin and anchoring fibril attached to the 
basement membrane (reviewed by [8]). Basal keratinocytes express keratin-5 
and keratin-14, which assemble into keratin filaments. The basal layer also 
contains a proliferating epidermal stem cell population (reviewed by [9]). The 
proliferating stem cells undergo asymmetric cell division, producing an adjacent 
daughter cell in the basal layer, to enable lateral expansion of the epidermis, 
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and asymmetric mitosis, where their daughter cell enters the spinous layer, to 
repopulate the keratinocytes lost through differentiation. 
 
1.2.4 The spinous layer 
 
As the basal keratinocytes begin to differentiate they lose contact with the 
basement membrane and migrate upwards into the spinous layer. This induces 
expression of keratin-1 and keratin-10 and initiates changes in cell morphology, 
with keratinocytes becoming larger and more flattened than in the basal layer. 
Desmosomes are prominent in the spinous layer (reviewed by [8]). 
Desmosomes are multiprotein complexes which provide strong adhesion 
between adjacent keratinocytes via the cadherin family proteins, desmogleins 
and desmocollins. Intracelluarly they link to the keratin network. 
 
1.2.5 The granular layer 
 
In the granular layer keratinocytes degrade intracellular organelles and secrete 
extracellular lipids to provide the components required for the cornified layer. 
Keratinocytes in the granular layer are characterized by the presence of 
granules within the cells. These granules include the epidermal secretory 
lysosomal organelles, lamellar bodies containing polar lipids [10, 11], and 
keratohyalin granules, which contain terminal differentiation proteins profilaggrin 
and loricrin [12]. Lamellar bodies also contain many defense proteins, lipid 
processing enzymes plus proteases and protease inhibitors [13]. The lamellar 
bodies originate from within the Golgi apparatus and are secreted into the 
extracellular space through exocytosis [14, 15]. 
 
In the granular layer tight junctions link neighboring keratinocytes providing 
additional barrier strength and preventing water loss (reviewed by [16]). They 
consist of transmembrane proteins, such as claudin and occulin, attached to 
intermediate filaments of the neighbouring cells via the zonula occluden (ZO) 
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scaffold proteins. Tight junctions are important for immuno-surveillance in the 
epidermis as the cytoplasmic projections of the basal layer Langerhan cells can 
penetrate tight junctions and also form tight junctions with keratinocytes in the 
granular layers, permitting epidermal antigen surveillance [17].  
 
1.2.6 The cornified layer 
 
The cornified layer is made up of a number of layers of corneocytes, connected 
by corneodesmosomes and embedded in an intracellular matrix enriched in non-
polar lipids (reviewed by [6]). Corneocytes have corneodesmosomes until the 
final stages of differentiation, which help provide mechanical and chemical 
protection [8]. In the outer epidermal layer, the cadherin family proteins in the 
corneodesmosomes are cleaved by serine proteases, which enable proper 
shedding of the outer epidermal layer [18].  
 
Corneocytes are dead, with all organelles degraded and each cell filled with 
keratin. 80-90% of total corneocyte mass is keratin [13]. Corneocytes lack a 
polar phospholipid bilayer and instead have a cornified envelope in its place, a 
protein / non-polar lipid polymer structure. Proteins within the cornified envelope 
include involucrin [19], expressed in the late spinous and granular layers [20, 
21], and loricrin [22], which is only expressed in the granular layers [22]. Loricrin 
is highly insoluble and is therefore contained within the keratohyalin granules 
until the final stages of cornification [12].   
 
There are three classes of epidermal lipids in the cornified envelope; cholesterol, 
ceramides and fatty acids (reviewed by [13]). On total lipid mass there is 50% 
ceramides, 25% cholesterol and 15% fatty acids. These lipids are synthesized in 
the upper layers of the epidermis and packaged into the lamellar bodies, where 
they are arranged in multilayered stacks [10]. The exocytosis of the lamellar 
bodies results in fusion with the plasma membrane and incorporation of the 
lipids into the cornified envelope [15]. 
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1.2.7 Barrier formation 
 
The cornified layer is described as a bricks and mortar model [23]. The keratin-
filled corneocytes surrounded by an array of covalently linked proteins acts as 
the brick and the mortar is the lipid-enriched extracellular space. This makes the 
cornified layer extremely insoluble and minimizes transepidermal water loss 
(TEWL) and penetration by external agents. 
 
The internal networks of keratin filaments within the corneocytes are stabilized 
by the scaffold protein filaggrin (reviewed by [24]). Filaggrin aggregates with 
keratin filaments and causes the flattened shape of the corneocytes. Filaggrin is 
synthesized into keratohyalin granules in the granular layer as profilaggrin. 
Profilaggrin consists of ten to twelve repeated units, which are then cleaved to 
form mature filaggrin. Filaggrin is important in barrier function, with reduced 
filaggrin expression associated with the dry scaly skin condition, atopic 
dermatitis [25] and the scaly phenotype seen in ichthyosis vulgaris [26]. 
Mutations in the filaggrin gene are reported in 15-25% of atopic dermatitis 
patients [27]. 
 
Specialized epidermal proteins within the cornified envelope, including involucrin 
and loricrin, are also important in barrier function. These proteins are covalently 
cross-linked by the activity of transglutaminases and are incorporated into the 
cornified envelope. Involucrin is important in the assembly of the early envelope 
scaffolding [28], whereas loricrin, the major constituent of the cornified envelope, 
may play a role in epidermal plasticity [29]. Although deletions of individual 
proteins of the cornified envelope produce only minor phenotypes, suggesting 
that there are compensation mechanisms involved in barrier function [30, 31], 
mutations in cornified envelope proteins may contribute to genetic susceptibility 
of chronic barrier defects, such as atopic dermatitis [32, 33] 
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All three classes of epidermal lipids are important for barrier function. This is 
demonstrated by the messenger ribonucleic acid (RNA) levels for ceramide, 
fatty acid and cholesterol biosynthesis enzymes all increasing in response to 
barrier disruption [34]. Reduced levels of certain classes of ceramides are also 
linked to atopic dermatitis [35-38]. The synthesis and regulation of epidermal 
lipids is discussed in more detail in section 1.9. 
 
 
1.3 Cutaneous Squamous Cell Carcinoma (cSCC) 
 
cSCC is the second most common skin cancer in Europe with the incidence 
increasing steadily [39, 40]. In the UK there are at least 30,000 new cases and 
approximately 500 deaths per year. The largest risk factors associated with the 
disease are chronic UV exposure and immunosuppression with age and skin 
type also having a role [41, 42]. A better understanding of epidermal 
carcinogenesis is required for the development of novel therapies or 
interventions.  
 
1.3.1 Pathology of cSCC 
 
cSCC presents as a keratotic and/or ulcerated nodule on the surface of the skin 
and originates from malignant proliferation of keratinocytes from the suprabasal 
layers of the epidermis [43]. Transformed keratinocytes invade the dermis and 
form irregular nests and keratin whorls (Figure 1-2).  Hyperkeratosis (thickening 
of the cornified layer) and parakeratosis (retention of nuclei in the cornified layer) 
are present with varying degrees of keratinization [43]. cSCCs are graded by 
how significantly the tumour cells differ from normal keratinocytes. In general, 
the greater the degree of keratinization, the better differentiated the tumour. 
cSCCs can metastasize with adjacent lymph nodes as the primary site for 
metastasis [43]. The differentiation, depth and irregularity of invasion of the 
tumour all have an impact on prognosis and treatment [43]. Most cSCCs are 
 24 
treated by excision, however some advanced SCC may require radiation and 
chemotherapy. 
 
 
Figure 1-2: Histology of normal skin and cSCC. H&E staining of normal skin, 
well differentiated cSCC and poorly differentiated cSCC from adult dorsal mouse 
skin.  UV-induced SCCs were from human papilloma virus (HPV8) transgenic 
FVB/n mice obtained from Herbert Pfister, University of Cologne [44, 45]. Mice 
received 1 J cm–2 of UVB and 10 J cm–2 of UVA using UV lamp 801 (as reported 
in [44, 45]) on a 4 cm2 sized area. Mice were collected in sequence with 
increasing malignances. Non-irradiated dorsal skin was used as a control. 
Bar=500µm.  
 
1.3.2 UV radiation and cSCC 
 
UV radiation is cytotoxic and can be detrimental leading to apoptosis of 
keratinocytes (reviewed by [46]). UV radiation also results in inflammation, 
including leukocyte infiltration, oedema (swelling) and erythema (reddening of 
the skin) and systemic immunosuppression. Excessive UV exposure can lead to 
peeling and even blistering in extreme cases. 
 
UV radiation is emitted from the sun at various wavelengths; UVA 400-315 nm, 
UVB 315-280 nm, and UVC 280-200 nm, however UVC does not reach the 
earth’s surface due to its absorption in the stratospheric ozone layer and is 
therefore not physiologically relevant (reviewed by [46]). The ability of UV 
radiation to penetrate skin is proportional to its wavelength (Figure 1-3). UVC 
has a short wavelength and can only penetrate the upper most layer of skin, the 
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cornified layer. UVB is medium-wave and is therefore absorbed further than 
UVC, penetrating the epidermis. UVA is longwave and penetrates through the 
epidermis and down into the dermis.  
 
 
Figure 1-3: Penetration of skin by UV radiation. UVA, with a longer 
wavelength than UVB and UVC, penetrates through the epidermis and into the 
dermis. UVB, with a shorter wavelength, only penetrates the epidermis and 
UVC, with the shortest wavelength, only penetrates the cornified layer. Adapted 
from [46]. 
 
UVB is absorbed by deoxyribonucleic acid (DNA) and induces chemical 
reactions. UVB excites DNA, resulting in the formation of covalent bonds 
between adjacent thymidine bases, creating cyclobutane pyrimidine dimers 
(CPDs) and 6-4 photoproducts (6-4PPs) [47]. CPDs and 6-4PPs are primarily 
repaired via the nucleotide excision repair pathway (reviewed by [48]). Damaged 
DNA bases are excised by nucleotide excision repair machinery and replaced by 
newly synthesised DNA using the opposite strand as a template. UVA is far less 
effective in causing DNA damage, however it can induce some DNA lesions, 
primarily through the indirect effects of reactive oxygen species, adding to the 
carcinogenic effect of UV radiation [49].  
 
Over time, the accumulation of DNA damage can lead to permanent DNA 
mutations. CPDs and 6-4PPs characteristically lead to mostly cytosine (C) and 
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thymine (T) single base changes at dipyrimidine sites and also fewer CC- to TT- 
tandem mutations, all termed UV-signature mutations [50]. If the damaged DNA 
fails to be corrected by DNA repair mechanisms then the cell is more likely to 
enter cell cycle arrest to allow more time for repair. However if the DNA damage 
is too great to repair then the cells are instructed to self destruct via apoptosis, a 
definitive cancer preventing pathway [51], forming so-called ‘sunburn cells’. 
Sunburn cells are characterized by pyknotic nuclei and eosinophilic cytoplasms 
[51]. 
 
An important protein in UV-induced cell-cycle arrest and apoptosis is the 
transcription factor protein 53 (p53) [52]. UV radiation deactivates murine double 
minute 2 (MDM2), a p53-binding protein that promotes p53 degradation, leading 
to stabilization of p53 [53]. p53 induces apoptosis, via cysteine-aspartic acid 
protease (caspase)-dependent mechanisms, and also increases expression of 
key proteins involved in the production and secretion of melanin [52, 54]. By 
activating apoptosis, p53 protects cells against the accumulation of DNA 
damage and acts as a tumour suppressor in skin. 
 
Apoptosis is a major defence mechanism against UV damage in epidermis. 
However an accumulation of genetic mutations and an imbalance of too little 
apoptosis or too much keratinocyte survival can lead to the malignant 
transformation of the cell. For example, this may be due to UV-signature 
mutations in the p53 protein reducing apoptosis [55] or promotion of cell survival 
pathways such as the PI3K/Akt pathway [56]. 
 
UV radiation also causes immunosuppression in skin with UVB a more powerful 
immunosuppressant than UVA (reviewed by [46]). UVB causes isomerization of 
the chemical urocanic acid in the cornified layer [57]. This produces cis-urocanic 
acid, from the trans-isomer form, which is a potent immunosuppressant [58].  
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UVB radiation also increases immunosuppression by reducing the number of 
Langerhan cells (reviewed by [46]). Langerhan cells reside in the basal layer 
and are the primary antigen presenting cell of the skin. Langerhan cells are 
sensitive to UV radiation, with UVB inducing apoptosis [59] and migration out of 
the skin and into the surrounding lymph nodes [60, 61], leading to a reduction in 
immuno- surveillance in the epidermis.  
 
1.3.3 Immunosuppression and cSCC 
 
cSCCs are highly antigenic, meaning that the keratinocytes express altered-self 
proteins [62]. cSCC formation is mostly prevented through apoptosis of UV-
induced DNA-damaged cells, however the immune system acts as a final 
safeguard to destroy cells expressing mutated proteins. Therefore the immune 
cells involved in antigen recognition and presentation, such as Langerhan cells, 
play an important role in preventing skin cancer progression [62]. A reduction in 
immune surveillance, either by chronic UV radiation or by administration of 
immunosuppressive drugs, permits the growth of epidermal tumours. 
 
Organ transplant patients on immunosuppressants have accelerated skin 
cancers in part due to precancerous changes being undetected because of the 
lack of immune-surveillance caused by long-term immunosuppressive therapy. 
Transplant recipients have a 65-250-fold higher occurrence of cSCCs than the 
general population, with incidence generally proportional to the level of 
immunosuppression [63-65]. Furthermore, cSCCs are usually multiple and more 
aggressive in immunosuppressed patients than the general population, with an 
increased risk of metastasis and death [66-69].  
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1.3.4 Immunosuppressant therapy of organ transplant patients and cSCC 
 
Organ transplant recipients require immunosuppression to reduce the risk of 
organ rejection (reviewed by [42]). Post-transplantation, intense 
immunosuppression is required to prevent acute allograft rejection by the host 
immune systems. Over time this level of immunosuppression is lowered to a 
maintenance level to prevent chronic rejection. Immunosuppression in these 
patients is achieved using multiple immunosuppressive regimens.  
 
Calcineurin inhibitors, such as ciclosporin and tacrolimus, dominate as 
immunosuppressant therapies in transplant patients.  These drugs inhibit the 
transcription of the pro-inflammatory cytokine interleukin-2 (IL-2), under the 
control of calcineurin, and reduce T-cell activation, producing potent 
immunosuppressive effects [70-72]. Tacrolimus activity is accomplished through 
an interaction with the low molecular weight cytosolic protein, FK-06 binding 
protein 12 (FKBP12) [73]. Calcineurin inhibitors can also be directly carcinogenic 
independently from their immunosuppressive activities. Both ciclosporin and 
tacrolimus promote tumour progression [74-76], meaning that improved 
therapies are required for long-term immunosuppression.  
 
Another class of immunosuppressants is mycophenolic acid (MPA) prodrugs. 
MPA prodrugs are selective for lymphocytic activation and proliferation and, in 
contrast to the calcineurin inhibitors, may reduce the risk of malignancy [77]. 
However this reduction in tumour development may be related to high 
bioavailability of the drug and may also be specific to selected tumour types [78]. 
 
More recently, mTOR inhibitors, including rapamycin (sirolimus), are used for 
immunosuppression in organ transplant recipients (reviewed by [79]). 
Rapamycin binds FKBP12, similar to tacrolimus. However, rapamycin has a 
different mode of action from calcineurin inhibitors [80]. Rapamycin interacts and 
inhibits the mTOR kinase, which has a central role in mRNA translation, and 
inhibits IL-2 production as well as other cytokines (reviewed by [81]).  
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Interestingly, renal transplant patients on rapamycin have a lower incidence of 
non-melanoma skin cancers (NMSC), including SCCs, than patients on other 
immunosuppressive treatments [1, 2]. After only six months of treatment, 
patients on rapamycin had significantly delayed tumour development, regression 
of pre-existing malignances and a reduction in the incidence of new skin 
tumours [2]. Other immunosuppressants with similar actions, such as calcineurin 
inhibitors, which also inhibit IL-2 production, result in no reduction in skin cancer 
prevalence [82], suggesting that rapamycin’s anti-cancer activity in skin is 
independent from its immunosuppressive activities. This raises the question; 
how does rapamycin reduce cSCC occurrence in these patients? 
 
 
1.4 Rapamycin 
 
1.4.1 Rapamycin and the development of rapamycin analogues  
 
Rapamycin is a naturally occurring product of the bacterium Streptomyces 
hygroscopicus and was found originally in the soil of Easter Island (Rapa Nui)  
[83, 84]. This small inhibitor contains a macrolide ring (Figure 1-4) and was 
originally used as an antifungal reagent [83]. Later, rapamycin was 
demonstrated to have both immunosuppressive and anti-cancer activity [85].  
 
Rapamycin has poor solubility and chemical stability leading to low 
bioavailability in patients [86]. Therefore rapamycin analogues (rapalogs) have 
been developed. Derivatives of rapamycin currently in clinical development 
include; everolimus (RAD-001, Novartis Pharmaceuticals), temsirolimus (CCI-
779, Wyeth Research) and ridaforolimus (AP23573; Ariad pharmaceuticals) 
(reviewed by [86]).  
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Figure 1-4: The structure of rapamycin. Rapamycin structure demonstrating 
FKBP12 and mTOR interaction sites. 
 
1.4.2 Rapamycin and rapalogs for the treatment of cancer 
 
Rapamycin and its analogues are not only in clinical trials for prevention of 
cSCC following organ transplantation. These drugs are also being tested for the 
treatment of other solid tumours, including breast, pancreatic and metastatic 
renal cell carcinoma (reviewed by [86]). Although these drugs successfully 
inhibit tumour cell growth in multiple in vitro and in vivo models, only a minority 
of patients respond to rapamycin treatment in the clinic. For example, there has 
been success in the treatment of renal cancer [87], sarcomas [88] and 
lymphomas [86], but little response in advanced solid tumours and only disease 
stabilization in lung, glioma and neuroendrocrine tumours [86]. The limited 
effectiveness of rapamycin and its analogues as cancer therapies suggests that 
only a subset of malignances are sensitive to treatment with these inhibitors and 
reflects the incomplete understanding of mTOR functions. 
 
Rapamycin therapy in organ transplant recipients stops tumour progression of 
existing cSCCs and even causes regression of preexisting premalignancies, 
making mTOR inhibitors an attractive therapeutic target for NMSC [2]. However, 
rapamycin is associated with significant side-effects. The most commonly 
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reported side-effects are aphthous ulcers (mouth ulcers), oedema, acneform 
eruptions, hyperlipidemia, thrombocytopenia and leucopenia (reduced platelets 
and white blood cells in blood), and delayed wound healing with higher surgical 
wound complication rates (reviewed by [89]). Therefore it is important to 
understand the mechanism for rapamycin’s tumour-suppressing role in skin for 
the development of improved therapies. 
 
1.4.3 Mammalian target of rapamycin (mTOR) 
 
mTOR is a large (289 kDa) serine/threonine kinase that is a member of the 
PI3K-related kinase family. mTOR regulates various intracellular proteins which 
influence cell growth, cell division, cell survival and angiogenesis, making mTOR 
an attractive target for cancer therapy.  
 
mTOR can exist as two distinct intracellular multi-protein complexes, mTORC1 
and mTORC2. mTORC1 consists of regulatory associated protein of mTOR 
(Raptor), mammalian Lethal with SE13 protein 8 (mLST8) and TOR (Figure 1-5) 
[90, 91]. mTORC2 also contains mLST8 and TOR along with rapamycin 
insensitive companion of mTOR (Rictor) and mammalian stress-activated 
protein kinase interacting protein 1 (mSIN1) (Figure 1-5) [91-94]. These protein 
sub-units are important in complex assembly, substrate binding and complex 
regulation [90, 92, 95]. Both complexes have additional subunits that are not 
required for core complex function, including proline-rich Akt substrate 40 kDa 
(PRAS40), which negatively regulates mTORC1 [96, 97], and protein observed 
with rictor (PROTOR), which associates with mTORC2 [94]. Dishevelled, Egl-10 
and Pleckstrin (DEP) domain-containing mTOR-interacting protein (DEPTOR) 
have also been shown to negatively regulate mTOR [98]. 
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Figure 1-5: Sub-units of the mTOR complexes. mTORC1 contains raptor, 
mLST8 and TOR. mTORC2 contains rictor, mSIN1, mLST8 and TOR. 
 
The mTOR complexes can be distinguished by their sensitivity to rapamycin, 
with the rapamycin-FKBP12 complex only recognizing raptor-bound mTOR and 
not rictor-bound mTOR [99]. The rapamycin-FKBP12 complex binds to the 
FKBP12-rapamycin binding (FRB) domain of mTOR, and may displace raptor, 
resulting in a decrease in mTORC1 substrate association and subsequent 
phosphorylation [90, 100]. mTORC2 activity was thought to be insensitive to 
rapamycin treatment [91]. However, more recently prolonged rapamycin 
treatment has been shown to indirectly inhibit mTORC2 in some cell types [5, 
101].  
 
 
1.5 mTORC1 signalling 
 
mTORC1 signalling is an evolutionary conserved pathway. Knock-out of mTOR 
and raptor in mice is embryonically lethal, demonstrating the importance of 
mTORC1 signalling in development [102-105]. mTORC1 signalling is also 
important in controlling life span in yeast, nematodes, drosophila (reviewed by 
[106]) and, more recently, in mice [107].  
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1.5.1 Upstream of mTORC1 
 
mTORC1 is a key regulator of protein synthesis and also lipid biosynthesis, 
which are both essential for cell growth. However mTORC1 signalling must be 
heavily regulated due to a large energy commitment required for cell growth in 
order to link cellular growth with adequate cellular conditions and maintain cell 
viability (reviewed by [108]). mTORC1 is activated by several stimuli, including 
nutrients, growth factors, energy and stress. These inputs can cooperate or 
antagonize one another, to enable careful regulation of the mTORC1 pathway.  
 
Amino acids, the building blocks of proteins, are essential for mTORC1 
signalling.  The precise mediators of amino acid signalling to mTORC1 are 
unclear. However the sterile 20 (STE20) family kinase mitogen-activated protein 
kinase kinase kinase kinase 3 (MAP4K3) [109, 110], PI3K catalytic subunit type 
3 (Vps34) [111, 112] and the Rag family of small guanosine-triphosphate (GTP)-
ases [113, 114], all regulate mTORC1 in an amino acid sensitive manner 
suggesting they have an important role in regulating mTORC1 activity in 
response to amino acid availability (Figure 1-6).  
 
Growth factors, such as insulin and epidermal growth factor (EGF), also activate 
mTORC1. This activation is achieved by negative regulation of the tumour 
suppressor tuberous sclerosis complex, consisting of tuberous sclerosis 
complex 1 (TSC1, hamartin) and TSC2 (Tuberin) (Figure 1-6). The TSC1:TSC2 
complex negatively regulates mTORC1 via the small GTP-ase Ras homologue 
enriched in brain (Rheb) [115, 116]. TSC2 has a GTPase-activating protein 
(GAP) domain that converts active Rheb.GTP to the inactive Rheb.Guanosine 
diphosphate (GDP) form [117, 118]. Extracellular signal-related kinase (ERK), 
which lies downstream of EGF signalling and the Ras/Raf/MAPK pathway, and 
also Akt, downstream from insulin and the PI3K pathway, directly phosphorylate 
TSC2 leading to a down-regulation of TSC1:TSC2 activity and subsequent 
 34 
activation of mTORC1 [119-122]. Akt can also activate mTORC1 via 
phosphorylation of PRAS40 [123]. 
 
mTORC1 also senses cellular stress. Starvation or energy depletion results in 
reduced adenosine-triphosphate (ATP) and activation of adenosine-
monophosphate-activated protein kinase (AMPK). The energy sensor AMPK 
phosphorylates TSC2 at S1345, enhancing its GAP activity towards Rheb 
resulting in subsequent inhibition of mTORC1 signalling (Figure 1-6) [124, 125]. 
AMPK also negatively regulates mTORC1 activity by directly phosphorylating 
raptor [126]. 
 
Wnt signalling can also negatively regulate mTORC1 (Figure 1-6). Glycogen 
synthase kinase 3β (GSK3β), downstream from the Wnt signalling pathway, 
phosphorylates TSC2 at S1341 and S1337, stimulating the GAP activity of 
TSC1:TSC2 towards Rheb [124, 127]. However this phosphorylation event 
requires a priming event by AMPK first. 
 
Hypoxia also leads to a reduction in mTORC1 activity (Figure 1-6). Hypoxia 
inducible factor 1α (HIF1α) is stabilized under hypoxic conditions and drives 
expression of regulated in development and DNA damage response-1 (REDD1). 
REDD1 promotes the assembly of TSC1:TSC2 complex and reduces mTORC1 
signalling [128-130].  
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Figure 1-6: Regulation of mTORC1. Growth factors, such as insulin (In) and 
EGF, activate mTORC1 signalling via inhibition of the TSC1:TSC2 complex. Akt 
and ERK phosphorylate TSC2 and inhibit GAP activity towards Rheb, resulting 
in increased Rheb activity and downstream signalling to mTORC1. Akt can also 
activate mTORC1 independently from TSC1:TSC2 via PRAS40. mTORC1 is 
also positively regulated by nutrients. Amino acid (AA) availability activates 
mTORC1 via the Rag GTPases. Energy depletion reduces mTORC1 signalling. 
An increase in AMPK levels results in activation of the TSC1:TSC2 complex and 
a down-regulation of Rheb and mTORC1. Hypoxia and Wnt signalling also 
reduce mTORC1 activity. Phosphorylation of TSC2 by GSK3β and REDD1 
increases TSC1:TSC2 activity, reducing Rheb and mTORC1 activity. 
 
1.5.2  Downstream of mTORC1 
 
mTORC1 has multiple downstream effects and is a key regulator of cellular 
metabolism, growth and proliferation (reviewed by [131]). mTORC1 signalling 
promotes protein synthesis and lipid biosynthesis, providing the cellular building 
blocks required for cell growth, and negatively regulates autophagy, the self-
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eating process that is responsible for the degradation of damaged and 
redundant cellular components. 
 
mTORC1 promotes protein synthesis by regulating mRNA translation via 
phosphorylation of its two substrates, the ribosomal S6 kinases (S6K1 and 
S6K2) and the eukaryotic initiation factor 4 E (eIF4E)-binding protein-1 (4EBP1) 
(Figure 1-7) [90, 95, 132, 133]. S6K is a member of the protein kinase AGC 
family and contains a conserved regulatory site within its hydrophobic motif (HM) 
[134]. mTORC1 phosphorylates S6K1 within its HM at T389, leading to full 
activation of the kinase and subsequent phosphorylation of its downstream 
substrates [134]. This includes ribosomal protein S6, eukaryotic elongation 
factor 2 kinase (eEF2K) and eIF4B, which are important components of the 
translational machinery required for cap-independent mRNA translation [135]. 
mTORC1 phosphorylates 4EBP1 at multiple sites to regulate cap-dependent 
protein translation [136]. Phosphorylation of 4EBP1 by mTORC1 results in 
dissociation of 4EBP1 from eIF4E, which allows eIF4E to interact with mRNA 
cap structures and recruitment of eIF4G to increase mRNA translation [137].  
 
Rapamycin treatment inhibits S6K phosphorylation and subsequent 
phosphorylation of its downstream target S6, however, rapamycin has been 
shown to have a less significant effect on 4EBP1 with some mTORC1- regulated 
phosphorylation sites on 4EBP1 resistant to rapamycin treatment [138-140]. 
Therefore some of the cap-dependent protein translation activity is due to 
rapamycin-insensitive mTORC1 activity. 
 
The up-regulation of mTORC1 signalling increases protein synthesis for 
vascular endothelial growth factor (VEGF) and HIF1α, which are both key 
tumour angiogenesis promoting genes [141]. Therefore mTORC1 promotes 
angiogenesis (Figure 1-7). mTORC1 inhibition with rapamycin treatment inhibits 
VEGF translation and angiogenesis. This has positive clinical outcomes in the 
treatment of some tumour types including renal cell carcinoma [142].  
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mTORC1 also regulates autophagy (Figure 1-7), the process that maximizes 
cellular energy resources during periods of low nutrients. mTORC1 negatively 
regulates autophagy by phosphorylating unc-51 (Caenorhabditis elegans)-like 
kinase 1 (ULK1) and autophagy-related protein 13 (ATG13), two of the 
components required for the initiation of autophagy [143]. However during 
periods of low nutrient supply when mTORC1 is inhibited, autophagy is up-
regulated. For example, autophagy is important in liver and white adipose tissue 
for breaking down lipid droplets into free fatty acids [144]. Interestingly, 
mTORC1 inhibition by rapamycin only results in partial activation of the 
autophagic response compared to amino acid withdrawal, suggesting that 
rapamycin-insensitive mTORC1 activity is partly responsible for regulating 
autophagy [145].  
 
Along with protein biosynthesis, mTORC1 signalling is also important in lipid 
biosynthesis. mTORC1 positively regulates the activity of the sterol regulatory 
element-binding transcription factor (SREBP) family proteins (Figure 1-7) [146-
149]. There are three SREBP proteins, SREBP1a and SREBP1c, which are 
products of alternative splicing, and SREBP2, which is encoded on another 
gene (reviewed by [150]). SREBP1c regulates fatty acid biosynthesis [151-153], 
with highest expression in the liver [154], and SREBP2 predominantly regulates 
cholesterol synthesis [155]. SREBP1a can regulate both fatty acid and 
cholesterol biosynthesis [156].  
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Figure 1-7: mTORC1 signalling. mTORC1 promotes protein synthesis by 
regulating mRNA translation by phosphorylation of S6K and 4EBP1. This 
includes increasing protein synthesis of HIF1α and VEGF resulting in increased 
angiogenesis. mTORC1 also positively regulates lipid biosynthesis via the 
SREBP transcription factors. In periods of abundant nutrient availability, 
mTORC1 negatively regulates autophagy by phosphorylation of ULK1 and 
ATG13.  
 
SREBPs are held in the endoplasmic reticulum (ER) as full-length inactive 
precursors (FL-SREBP) [157]. FL-SREBP is bound to SREBP cleavage 
activating protein (SCAP), which is anchored to the membrane protein insulin 
induced gene (Insig) (Figure 1-8) [158, 159]. Upon activation, SCAP dissociates 
from Insig, releasing the FL-SREBP-SCAP complex [159, 160]. The FL-SREBP-
SCAP complex is transported to the Golgi apparatus in coat-protein II (COPII) 
coated vesicles [161]. At the Golgi apparatus, SREBP is sequentially cleaved by 
two proteases, S1P and S2P, releasing the N-terminus domain of SREBP 
(nSREBP), which contains a basic helix-loop-helix-leucine zipper (bHLH-LZ) 
transcription factor region (reviewed by [162]). nSREBP is then localized to the 
nucleus, by interaction with importin β, and promotes the expression of fatty acid 
and cholesterol biosynthesis regulating genes [163-165]. nSREBP binds to 
genes containing E-boxes (5’-CANNTG-3’) in their promoter, like all bHLH-LZ 
transcription factors, and also the sterol regulatory element (SRE) (5’-
TCACNCCAC-3’) to promote transcription [166]. 
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Figure 1-8: Regulation of SREBP. 1) FL-SREBP is held in the ER bound to 
SCAP and Insig. 2) Upon activation, SCAP and Insig dissociate, allowing FL-
SREBP1-SCAP to be incorporated into COPII vesicles and transported to the 
Golgi apparatus. 3) At the Golgi apparatus FL-SREBP1 is cleaved by two 
proteases, S1P and S2P, releasing nSREBP. 4) nSREBP translocates into the 
nucleus with importin β. 5) nSREBP binds to target genes containing SRE/E 
box. 
 
Inhibition of mTORC1 by rapamycin treatment acutely reduces nSREBP1 [149], 
resulting in a reduction in the expression of several SREBP target genes [167, 
168]. Raptor knockdown demonstrates similar results showing that mTORC1, 
but not mTORC2, regulates SREBP1 [167]. mTORC1 regulates the nuclear 
entry of nSREBP via phosphorylation of lipin1 [148]. Rapamycin inhibits the 
mTORC1-dependent phosphorylation of lipin1, leading to a down-regulation of 
nSREBP [148].  
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1.5.3 mTORC1 signalling in epidermis 
 
The precise role of mTORC1 in epidermis is unclear. mTORC1 signalling is 
important in the wound healing process, with an increase in phosphorylation of 
mTORC1 substrate, S6, in epidermis in response to wounding [169]. Activation 
of mTORC1 signalling, by deletion of epidermal TSC1, increases epithelial cell 
proliferation, migration and cutaneous wound healing, whilst inhibition with 
rapamycin delays wound closure [169].  
 
mTORC1 has also been shown to play a positive role downstream from the Wnt 
signalling pathway in proliferation of the epidermal stem cell population in the 
hair follicle [127]. mTORC1 is activated downstream from the Wnt signalling 
pathway by inhibition of GSK3β and the TSC1:TSC2 complex [124]. However, 
over-activation of the mTORC1 pathway can lead to exhaustion of the stem cell 
population, demonstrating a role for mTORC1 in accelerating epidermal aging 
[127].  
 
However, mTORC1 signalling may not regulate basal keratinocyte proliferation 
in normal epidermis as S6 phosphorylation is predominantly found in the upper 
layers of the epidermis and not in the basal layer [170]. Furthermore, TSC1 
knockout leads to increased mTORC1 activity in the granular layers, but not in 
the basal layers [169]. The lack of regulation of keratinocyte proliferation by 
mTORC1 may explain why mTORC1 inhibitors have low cytotoxic effects on 
epidermis in vivo [127, 171, 172]. 
 
mTORC1 is also not an important modulator of keratinocyte differentiation, as 
treatment of mouse epidermis in vitro with rapamycin has no significant effect on 
the expression of epidermal differentiation markers [173]. However rapamycin 
treatment does rescue the accelerated differentiation demonstrated in the 
insulin-like growth factor-1 receptor (IGF-1R) knockout mice, suggesting a more 
subtle role for mTORC1 in epidermal homeostasis [173]. 
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In the clinic, transplant recipients on rapamycin frequently report acneform 
eruptions as a side-effect [174]. In a study of eighty rapamycin treated patients. 
46% reported acne in response to rapamycin treatment, with a striking male 
predominance [174]. Acne is associated with altered amounts of triglycerides 
and fatty acids secreted from the sebocytes in the sebaceous gland (reviewed 
by [175]). This suggests that rapamycin treatment promotes fatty acid synthesis 
in epidermis, resulting in the formation of acne. This is surprising as rapamycin 
inhibits fatty acid biosynthesis in other cell types [149, 167, 168], suggesting a 
different effect for rapamycin treatment in lipid homeostasis in skin. 
  
Dyslipidemia (abnormal lipids in the blood) is another common side-effect with 
sirolimus treatment [176]. Patients usually have hyperlipidemia (increased lipids) 
with marked hypertrigyceridemia (increased triglycerides) and increased 
cholesterol [176]. However this is thought to be a result of inhibited lipid 
clearance from the circulation and not due to an increase in lipid synthesis [176]. 
 
1.5.4 mTORC1 signalling in cSCC 
 
Inhibition of mTORC1 by rapamycin reduces cSCC tumour growth and also 
tumour occurrence in immunosuppressed transplant patients [1, 2]. Rapamycin 
reduces epidermal tumour growth by inhibition of angiogenesis [75]. Inhibition of 
angiogenesis has little effect on the rate of initial tumour formation but is 
sufficient to reduce tumour growth due to a reduction in vascularization to the 
tumour [75]. The mechanism for rapamycin reducing tumour incidence is less 
clear and there are a number of proposed mechanisms, discussed below 
(reviewed by [3]): 
 
1) Rapamycin inhibits mTORC1 substrates S6K and 4EBP1 and reduces mRNA 
translation, leading to reduced cell growth and proliferation (reviewed by [135]). 
Rapamycin inhibits proliferation in many other tumour types making this a likely 
mechanism (reviewed by [79]). 
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2) cSCCs are associated with mutations that lead to an over-activation of the 
mTORC1 pathway. For example, Cowden disease, which most commonly 
results from a mutation in the phosphatase and tensin homolog deleted on 
chromosome 10 (PTEN) [177], a tumour suppressor upstream from mTORC1, 
results in hyper-activation of mTORC1 signalling and the development of 
epidermal tumours [171]. mTORC1 inhibition, by rapamycin, inhibits the 
development of these tumours [171]. Also, tuberous sclerosis patients, who 
have genetic defects in the TSC1:TSC2 complex in fibroblasts in the dermis, 
also have hyper-activation of mTORC1 signalling and epidermal tumours [170]. 
These tumours originate from effects of tumour mesenchymal cells and not 
directly from the keratinocytes [170].  
 
However, Cowden disease and tuberous sclerosis both result in benign 
epidermal tumours [170, 171], suggesting that hyper-activation of mTORC1 
signalling in either keratinocytes or dermal fibroblasts is not sufficient to produce 
the aggressive forms of cSCCs seen in immunosuppressed patients [66-69]. In 
support of this, epidermal deletion of TSC1 in mouse has little effect on skin 
phenotype and does not lead to spontaneous tumour formation [169]. In 
contrast, overexpression of Rheb in basal keratinocytes in mice leads to an 
increase in cancer progression with everolimus treatment reducing neoplasia 
development [178].  Therefore it is unclear whether hyper-activation of the 
mTORC1 pathway is responsible for cSCC development. 
 
3) Rapamycin promotes the enhanced anti-tumour effect of cluster of 
differentiation 8 positive (CD8+) T-cell functional fate. mTORC1 promotes CD8+ 
transition of short-lived effector cells into long-lived memory T cells [179]. 
Therefore rapamycin treatment has other effects on the immune system besides 
inhibiting IL-2 production. 
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4) Rapamycin-induced inhibition of tumour-associated ion channel activity. Ion 
channels have a positive role in tumourigenesis by supporting the proliferation 
and development of cancer cells (reviewed by [180]). Rapamycin inhibits the 
dysregulation of potassium channels in intestinal tumours in mice [181]. 
However, the mechanism for mTORC1 regulation of ion channel activity remains 
unclear [181] and it is unknown whether this phenomenon occurs in skin. 
 
5) Rapamycin reduces UV-signature mutations in skin. Rapamycin treated mice 
receiving sunburn doses of UV radiation have reduced p53 UV-signature 
mutations compared to the control group [182]. Rapamycin also causes 
apoptosis in p53-null cells [183] and reduces tumour growth in p53 null mice 
[184]. cSCCs have a high number of p53 mutations [185] and therefore 
rapamycin may promote apoptosis of the DNA damaged keratinocytes and 
inhibit tumourigenesis [182]. 
 
Therefore, there are probably a number of mechanisms responsible for 
rapamycin’s tumour suppressing role in epidermis. These effects may contribute 
to the reduction in tumour progression and/or the initial tumour formation. 
 
 
 
1.6 The PI3K/Akt pathway 
 
The PI3K/Akt pathway lies upstream from mTORC1 and is involved in cell 
proliferation and survival (Figure 1-9) [91]. Receptor tyrosine kinases (RTKs), 
such as insulin receptors (IRs) and IGF-1Rs, are activated in response to growth 
factors leading to phosphorylation of their intracellular phospho-tyrosine binding 
(PTB) motifs. PI3K interacts, via its src Homology 2 (SH2) domain, with the PTB 
motif on either the receptor or on accessory proteins, including insulin receptor 
substrate 1 (IRS-1) [186]. Activated PI3K then converts phosphatidylinositol-
(4,5)biphosphate (PIP2) into phosphatidylinositol-(3,4,5)triphosphate (PIP3), a 
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reaction reversed by PTEN [187]. PIP3 recruits Akt to the plasma membrane, 
via its plekstrin homology (PH) domain, where it is then phosphorylated on two 
sites [188, 189]. Akt is phosphorylated at T308, by phosphoinositide-dependent 
kinase 1 (PDK1) and also at S473, predominantly by mammalian target of 
rapamycin complex 2 (mTORC2), resulting in full activation of Akt [190, 191]. Akt 
then translocates to the cytoplasm or the nucleus and phosphorylates its 
substrates at the minimal consensus sequence RXRXX(S/T), where X is any 
amino acid [192, 193]. Akt has a number of substrates with diverse downstream 
effects including cell survival, cell growth, proliferation, metabolism and 
migration (reviewed by [194]).  
 
 
Figure 1-9: The PI3K/Akt pathway. Insulin binds to the IR leading to 
phosphorylation of IRS-1 and activation of PI3K. PI3K converts PIP2 to PIP3, a 
reaction reversed by PTEN, and recruits PDK1 and Akt to the plasma 
membrane. Akt is phosphorylated by PDK1 at T308 and at S473 by mTORC2, 
leading to full activation of the kinase. Akt has diverse downstream effects.  
 
Akt is a member of the AGC kinase family, similar to S6K, and contains an N- 
terminal PH domain, a central serine/theonine kinase domain and a C-terminal 
HM, characteristic of the AGC kinases (reviewed by [195]) (Figure 1-10). The 
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PH domain interacts with membrane lipid proteins enabling protein translocation 
to the plasma membrane and leading to a conformational change and 
unmasking of the T308 phosphorylation site, within the activation loop between 
subkinase domain VII and VIII [188, 196]. Akt is also phosphorylated at S473, in 
the HM, which precedes and facilitates T308 phosphorylation [191]. However, 
these phosphorylation events can occur independently from one another in 
some cell types [197, 198]. 
 
 
Figure 1-10: Akt domain structure. Human Akt1 domain structure consisting of 
an N-terminus PH domain, for interaction with PIP3, a central kinase domain 
and a C-terminus HM. Akt is phosphorylated at T308, within the kinase domain, 
by PDK1 and at S473, within the HM, by mTORC2. 
 
There are three Akt isoforms (Akt1/PKBα, Akt2/PKBβ and Akt3/PKBγ). Akt1 is 
ubiquitously expressed and Akt2 is expressed in insulin target cells such as fat 
cells, liver and skeletal muscle [199]. Akt3 expression is more restricted, with 
highest expression in testes and the brain [199]. Knock-out studies have 
demonstrated a role for Akt1 in cell survival [200, 201], Akt2 in glucose 
homeostasis [202] and Akt3 in brain development [203]. However, double Akt 
isoform knock-out mice have demonstrated some compensation between the 
isoforms. Simultaneous deletion of Akt1 and Akt2 causes death shortly after 
birth [204] and Akt1/Akt3 double knock-out are embryonically lethal [205]. 
Therefore the Akt isoforms have some specific and some overlapping functions. 
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Despite over 150 Akt substrates being characterized, only a few are isoform 
specific. Well-known generic Akt substrates include; forkhead box protein O 
(FOXO) proteins which are involved in cell cycle progression [206], GSK3β, 
which regulates glucose metabolism and cell-cycle progression [207] and Bcl-2-
associated death promoter (BAD), which regulates cell survival [208, 209] 
(reviewed by [194]).  
 
Akt also positively regulates fatty acid biosynthesis via at least three 
mechanisms acting on SREBP1. Akt increases SREBP1 activity via mTORC1 
signalling [149, 210]. Akt can also regulate SREBP1 via inhibition of GSK3β 
activity. Upon nSREBP1 binding to DNA, GSK3β phosphorylates nSREBP1 at 
multiple sites (S434, S430 and T246) targeting nSREBP1 for ubiquitination and 
degradation [211, 212]. Therefore activation of Akt inhibits nSREBP1 
degradation. Lastly Akt can directly phosphorylate FL-SREBP1c, enhancing 
association of the FL-SREBP1c-SCAP complex with COPII vesicles and leading 
to increased Golgi transport and proteolytic cleavage [213]. These mechanisms 
may also apply for SREBP2, however a robust effect of the regulation of Akt on 
SREBP2 and cholesterol synthesis has not yet been shown [210, 214]. 
 
1.6.1 The PI3K/Akt pathway in epidermis 
 
In epidermis, the PI3K/Akt pathway is important in keratinocyte homeostasis. 
PI3K is present throughout the epidermis and plays a positive role in the early 
stages of keratinocyte differentiation and prevents cell death [215-217].  
 
There are two active Akt isoforms in epidermis, Akt1 and Akt2, each with 
opposing roles [218]. Akt1/Akt2 double knock out mice have impaired skin 
development, however Akt1 and Akt2 specific knock-out mice have a normal 
skin phenotype, suggesting that the epidermal Akt isoforms can compensate for 
one another [204]. Akt1/Akt2 double knock out mice have translucent skin and 
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thinner individual skin layers [204]. These mice also lack a cornified layer, 
suggesting a lack of epidermal barrier function [204].  
 
Akt1 is expressed and phosphorylated in the granular layer of the epidermis 
from embryonic day (E) 17.5 (Figure 1-11) [218]. Akt1 is important in terminal 
differentiation and formation of the cornified layer [218] and therefore may have 
a role in epidermal lipid biosynthesis. In contrast, Akt2 is ubiquitously expressed 
in epidermis and present from E15 upwards, but predominantly phosphorylated 
in the para-basal layers during development (Figure 1-11) [218]. Akt1 is the 
predominant isoform in adult skin [204] and interacts with the chaperone protein 
heat shock protein 27 (Hsp27 / HspB1) in the granular layers of the epidermis, 
which is important for filaggrin processing [218].  
 
Figure 1-11: Expression and phosphorylation of Akt1 and Akt2 during late 
development in mouse epidermis. Immunofluorescence for Akt (S473) 
phosphorylation, Akt1 and Akt2 during epidermal development from E15.5 to 
E18.5 in CD1 mice. Bar=50µm (Sully et al, unpublished and [218]).  
 
Akt1 is important in wound healing [219], similar to mTORC1 signalling [169]. 
Akt1 expression is increased at the wound margin and phosphorylated at both 
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T308 and S473, suggesting full activation of the kinase [219, 220]. Furthermore, 
Akt1 promotes VEGF translation in response to insulin, promoting angiogenesis 
into the wound area, demonstrating mTORC1 to be downstream from Akt1 in 
wounded keratinocytes [220].  
 
Akt1 expression and activation is also elevated in harlequin ichthyosis patients 
[221]. Harlequin ichthyosis children have severe hyperkeratosis and impaired 
skin barrier function due to a loss of lipid transport function by the ATP-binding 
cassette transporter A12 (ABCA12) [222-224]. The increase in Akt1 is predicted 
to act as a compensatory mechanism against apoptosis and to promote 
keratinocyte survival during the keratinization process [221]. 
 
Activation of the PI3K/Akt pathway in epidermis has also been linked to Proteus 
syndrome, characterized by epidermal hyperplasia and also overgrowth of other 
tissues, further demonstrating the important role of Akt in epidermal 
homeostasis. Patients have been identified with a somatic Akt1 mutation leading 
to constitutive phosphorylation at S473 and T308 [225]. Proteus syndrome has 
also been linked with PTEN mutations, leading to hyper-activation of PI3K/Akt 
pathway, similar to Cowden disease [226-228]. 
 
1.6.2 The PI3K/Akt pathway in cSCC 
 
Somatic mutations in PI3K/Akt pathway genes are found in a number of cancer 
types (reviewed by [229]). However, no mutations in the PI3K/Akt pathway have 
been identified in cSCC at present (according to the Catalogue Of Somatic 
Mutations In Cancer, Sanger Institute, UK). 
 
cSCC is linked to changes in Akt signalling. Akt1 activity is down-regulated in 
cSCC (Figure 1-12), suggesting a tumour suppressor role for Akt1 in epidermis 
[4]. However, Akt1 does not act as a primary tumour suppressor in epidermis as 
Akt1 null mice do not spontaneously form skin tumours [201].  
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In contrast Akt2 activity is up-regulated in cSCC (Figure 1-12), suggesting a 
tumour promoting role for Akt2 in skin [4]. Akt2 activity probably correlates with 
cSCC malignancy suggesting that Akt2 activation may be important for tumour 
progression in epidermis [4]. Up-regulation of Akt2 is also linked with the 
promotion of tumourigenesis in other tumour types, including pancreatic, ovarian 
and breast [230].  
 
 
Figure 1-12: Akt expression in UV-induced mouse cSCC. 
Immunofluorescence for Akt (S473) phosphorylation and total Akt1 and Akt2 in 
serial sections of UV-induced mouse cSCC. Female Skh:hr-1 (hairless) mice 
were obtained from Dr. Vivienne Reeve at the Veterinary Science breeding 
colony, University of Sydney. Mice received continuing daily single exposure of 
3 × the Minimal Edematous Dose (MEdD) of solar simulated UV (SSUV) from a 
fluorescent UVA and UVB tube source on the dorsum for up to 30 weeks. Mice 
were killed at 30 weeks and dorsal skin collected. The MEdD of SSUV radiation 
in the Skh:hr-1 mouse, previously established as 1.33 J cm–2 of UVB and 21.3 J 
cm–2 of UVA [231], is equivalent to a minimal erythemal dose in humans. 
Bar=50µm. (Sully et al unpublished). 
 
UV radiation, the most important skin carcinogen, is also linked to changes in 
Akt signalling (reviewed by [232]). UVB increases Akt signalling in skin as part of 
the immediate response [233], within 30 minutes, and also part of the later 
response, hours and days after exposure [234]. In murine epidermis, Akt isoform 
activity changes in response to UV radiation (Sully et al 2012 [235]). Two days 
after acute UV treatment Akt1 phosphorylation and total levels fall, whilst Akt2 
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phosphorylation levels rise strongly (Figure 1-13) (Sully et al 2012 [235]). Hence, 
Akt1 and Akt2 respond in opposite ways to UV, reflecting the changes during 
tumourigenesis.  
 
Furthermore, Akt2 promotes cell survival in response to UV radiation. Akt2, but 
not Akt1, protects cells from UV-induced cell death in fibroblasts, endothelial 
cells and ovarian epithelial cells [236, 237] suggesting a crucial role for UV-
induced epidermal Akt2 activity. UV-induced Akt2 inhibits apoptosis by inhibiting 
activation of UV-induced JNK and p38 [236]. Akt2 enhanced survival of mutated 
cells could provide a mechanism for Akt2-mediated tumourigenesis. This raises 
the question; can rapamycin’s tumour suppressive activity in skin be linked to 
changes in Akt activity in epidermis?  
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Figure 1-13: UV radiation reduces Akt1 levels and increases phospho-Akt2 
levels in mouse epidermis. Immunofluorescence for Akt (S473) 
phosphorylation and total Akt1 levels in mouse epidermis, 0-5 days after UV 
radiation. Female Skh:hr-1 mice 8-10 weeks old,  obtained from Dr. Vivienne 
Reeve at the Veterinary Science breeding colony, University of Sydney , were 
irradiated with a single exposure of 3 × the MEdD of SSUV radiation from a 
fluorescent UVA and UVB tube source on the dorsum, and mid-dorsal skin 
samples were taken before and at 1-5 days after.  Bar=50µm (Adapted from 
Sully et al 2012 [235]). 
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1.7 The mTORC1-dependent negative regulation of the PI3K/Akt 
pathway 
 
In some cell types, negative feedback loops exist between mTORC1 signalling 
and the IRS proteins resulting in a down-regulation of the PI3K/Akt pathway 
(Figure 1-14) [238-241]. These mTORC1-dependent negative feedback loops 
provide an important link between insulin signalling and other stimuli regulating 
cell growth, for example nutrient availability. 
 
 
Figure 1-14: The mTORC1-dependent negative feedback loops to IRS-1. 
mTORC1 and S6K1 negatively regulate IRS-1 at the plasma membrane 
resulting in a down-regulation of the PI3K/Akt pathway. 
 
The mTORC1-dependent negative feedback loops can regulate both IRS-1 and 
IRS-2, depending on cell type [242-244]. IRS-1 and IRS-2 are closely related 
proteins and both contain PH and PTB domains and a long C-terminal tail which 
contains over 20 potential phosphorylation sites (Figure 1-15) [245]. In response 
to insulin and IGF-1, IRS proteins become phosphorylated on multiple tyrosine 
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residues within their C-terminus, which recruit SH2 domain containing proteins, 
including PI3K (reviewed by [246]). The phosphorylation of Y612 and Y632 on 
IRS-1 generates a major docking site for PI3K (Figure 1-15) [247].  
 
IRS-1 signalling is regulated by phosphorylation of serine and theonine residues 
within the C-terminus (reviewed by [248]). mTORC1 signalling regulates multiple 
serine sites on IRS-1, leading to a reduction in IRS-1 signalling via two different 
mechanisms. mTORC1 directly phosphorylates IRS-1 at S636/639, which 
interrupts the docking of IRS-1 to PI3K and down-regulates the PI3K/Akt 
pathway in response to growth factor stimulation (Figure 1-15) [249]. S6K1 also 
phosphorylates IRS-1 at S302 and S307, which leads to protein instability and 
targets IRS-1 for degradation (Figure 1-15) [238, 242, 250-252]. 
 
 
Figure 1-15: IRS-1 domain structure. Human IRS protein domain structure 
containing PH domain, PTB domain, which interacts with the RTK, and a long C-
terminus containing several tyrosine phosphorylation sites. Y612 and Y632 
interact with PI3K to promote downstream signalling. mTORC1 and S6K1 
phosphorylate multiple serine phosphorylation sites on IRS-1 to either target 
IRS-1 degradation (S302 and S307) or to prevent docking of downstream 
substrates (S636/639).  
 
IRS-1 is degraded via the 26S proteasome degradation pathway [252]. Initially 
IRS-1 is tagged by multi-ubiquitin chains via its N-terminus region, termed 
ubiquitin conjugation, followed by degradation by the proteasome [242]. The 
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proteasome is a large multimeric protein that quickly eliminates proteins in an 
ATP-dependent manner (reviewed by [253]). 
 
Fewer studies have been done on IRS-2 and therefore less is understood about 
the effects of serine and theonine phosphorylation on IRS-2 signalling. 
Conflicting results on IRS-2 suggest that the effects of insulin and IGFs on IRS-2 
may be cell-type specific and controlled by a different regulatory mechanism 
from IRS-1 [242-244]. 
 
1.7.1 The mTORC1-dependent negative regulation of the PI3K/Akt 
pathway in epidermis 
 
 
Whether the mTORC1-dependent negative feedback loops are active in 
keratinocytes and what the effects of rapamycin treatment are on Akt signalling 
in epidermis remains unclear. Prolonged rapamycin treatment has little effect of 
Akt phosphorylation in wild-type mouse epidermis [171] and over-expression of 
Rheb in mouse epidermis also has little effect on Akt phosphorylation, despite 
activation of mTORC1 targets [178].  
 
However, Akt phosphorylation at S473 is significantly increased in human skin of 
patients on the rapamycin analogue, everolimus [254]. Also, rapamycin 
increases Akt T308 phosphorylation in mice with epithelial deletion of PTEN, 
suggesting that rapamycin treatment can activate the PI3K/Akt pathway in 
epidermis under certain conditions [171]. Rapamycin treatment also rescues the 
IGF-1R knock-out phenotype in vitro, further suggesting that rapamycin 
treatment has the potential to increase PI3K/Akt signalling in epidermis [173]. 
 
 
The roles of IRS-1 and IRS-2 in epidermis have been investigated by the use of 
knock-out mice [255]. IRS-2 null mice have a normal epidermal phenotype, 
suggesting that IRS-2 does not play a direct role in keratinocyte differentiation. 
 55 
In contrast, the IRS-1 null mice have a thinner spinous layer, with fewer cells 
and a reduction in keratin-1 expression, but no change in keratinocyte 
proliferation. This suggests a role for IRS-1, but not IRS-2, in keratinocyte 
differentiation. However, IRS-2 over-expression normalizes the accelerated 
differentiation and reduced proliferation in IGF-1R deficient skin cultures, 
suggesting that both IRS proteins are involved in epidermal homeostasis [173].  
 
1.7.2 The mTORC1-dependent negative regulation of the PI3K/Akt 
pathway in cSCC 
  
In tumours where these mTORC1-dependent negative feedback loops on IRS 
proteins are active, rapamycin treatment leads to activation of the PI3K/Akt 
pathway [256, 257]. Activation of the PI3K/Akt pathway in response to 
rapamycin can have undesired effects when treating some tumour types due to 
activating proliferative and pro-survival effectors and counteracting the effects of 
mTORC1 inhibition. Rapamycin causes further activation of the PI3K/Akt 
pathway in these tumours, resulting in a poor clinical outcome. For example, 
cancers containing hot-spot mutations in the PI3K catalytic domain, including 
some breast, prostate, colon and endometrium cancers, result in further 
activation of Akt in response to rapamycin (reviewed by [258]).  
 
It is unclear whether these mTORC1-dependent feedback loops are present in 
epidermis and what their effects are on cSCC. However mTORC1-dependent 
feedback loops may explain the low malignant potential of tumours in tuberous 
sclerosis patients [259]. These tumours have hyper-activation of mTORC1 
signalling which may inhibit PI3K/Akt signalling via IRS-1 regulation resulting in 
reduced cell survival [259]. 
 
If the mTORC1-dependent negative feedback loops are active in epidermis, then 
rapamycin treatment would lead to an up-regulation of the PI3K/Akt pathway. 
Activation of Akt could have different outcomes in epidermis depending on which 
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of the two Akt isoforms are phosphorylated. The most likely Akt isoform 
activated in response to rapamycin in epidermis is Akt1 due to its suggested 
tumour-suppressor role in epidermis [4].  It is possible that rapamycin promotes 
Akt1 activation, by inhibition of the mTORC1-dependent negative feedback 
loops acting on IRS-1, which is sufficient to reduce the development of cSCCs. 
 
 
1.8 mTORC2 signalling 
 
Similar to mTORC1, mTORC2 is evolutionarily conserved. Mice lacking the 
expression of rictor and mLST8 die embryonically at E10.5 [105], surviving 
slightly longer than mice lacking raptor and mTOR, which die earlier in 
development [105].   
1.8.1 Upstream of mTORC2 
 
The role of mTORC1 in cell growth in response to stimuli has been well studied. 
However, less is understood about the regulation of mTORC2. Insulin and 
amino acids, via class I PI3K, both activate mTORC2 (Figure 1-16) [260, 261]. 
Consequently, mTORC2 could be indirectly regulated by mTORC1 via the 
mTORC1-dependent negative feedback loops to IRS-1 and the down-regulation 
of PI3K [238-241].  
 
The TSC1:TSC2 complex also increases mTORC2 activity, independently from 
its regulation on Rheb and mTORC1, by interaction of TSC2 with rictor (Figure 
1-16) [262, 263]. S6K1 can also interact with rictor, directly phosphorylating 
rictor at T1135 [264]. However, this phosphorylation event only has a minor 
effect on mTORC2 activity [265]. This puts mTORC2 downstream of mTORC1 
and demonstrates another feedback loop acting in parallel with the mTORC1-
dependent negative regulation of IRS-1. These regulations add complexity to the 
relationship between mTORC1 and mTORC2 and demonstrate the close 
interconnections between the two complexes. 
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Figure 1-16: Regulation of mTORC2. mTORC2 is positively regulated by the 
TSC1:TSC2 complex and also by insulin and amino acids, via PI3K. mTORC2 
activity is inhibited by mTORC1 signalling, via regulation of IRS-1, and also by 
prolonged rapamycin treatment in some cell types. S6K1 can directly 
phosphorylate rictor, but this has little effect on mTORC2 activity.  
 
1.8.2 Downstream of mTORC2 
 
mTORC2 regulates cell proliferation and cell survival in response to growth 
factors by promoting phosphorylation of the AGC kinases; Akt, protein kinase C 
(PKC) and serum-glucocorticoid-induced protein-kinase (SGK) (Figure 1-17) [92, 
105, 191, 266, 267]. mTORC2 is responsible for phosphorylating AGC kinases 
within both the HM (Figure 1-17), which regulates kinase activity and is 
dependent on growth factor signalling [92, 105, 267], and within the turn motif 
(TM), facilitating protein folding and increasing protein stability [266, 268]. The 
phosphorylation of the TM is independent of growth factor signalling [266]. 
 
There are three SGK isoforms that share over 70% identity in their kinase 
domain, with SGK1 being the most studied [269]. SGK1 has been implicated in 
the regulation of ion channels [270]. SGK1 phosphorylates and inhibits neural 
precursor cell expressed, developmentally down-regulated 4-2 (NEDD4-2), 
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leading to increased epithelial sodium channel (ENaC) expression at the cell 
membrane [271, 272]. However epithelial sodium channels of the kidney are 
only moderately affected in SGK1 knockout mice demonstrating a more complex 
regulation of ion channels in vivo [273]. 
 
SGK1 phosphorylates n-myc downstream-regulated gene 1 (NDRG1) at T328, 
T346, T356 and T366, which are read-outs for mTORC2 activity (Figure 1-17) 
[267, 274]. NDRG1 is ubiquitously expressed and highly responsive to stress 
signals, including DNA damage [275]. During DNA damage NDRG1 is induced 
in a p53-dependent manner and is necessary for p53-mediated apoptosis [275, 
276]. 
 
 
Figure 1-17: mTORC2 signalling. mTORC2 phosphorylates the HM of the 
AGC kinases; Akt S473, SGK1 S422 and PKCα S657. SGK1 phosphorylates 
NDRG1 at threonine sites including T346.   
 
NDRG1 has a positive role in cellular differentiation in some cell types, although 
this has not been determined for keratinocytes (reviewed by [277]). NDRG1 
expression is down-regulated in tumours [275, 278], induced in response to 
differentiation stimuli in cancer cell lines [279] and suppresses metastasis [280, 
281], suggesting a tumour-suppressing role for NDRG1. 
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There are at least twelve PKC isoforms in mammals, which are categorized into 
three groups; conventional (α, β and γ), novel (δ, ε, θ and η) and atypical PKCs 
(ζ and ι) [282]. mTORC2 is required for phosphorylation of all of the conventional 
PKCs and novel PKCε [268]. Both conventional and novel PKCs are also 
regulated by diacylglycerol, but only the conventional PKCs are sensitive to 
calcium [282]. Atypical PKCs are not sensitive to diacylglycerol or calcium and 
do not contain the same conserved region within the HM as other PKCs [282]. 
PKCs have a multitude of cellular substrates and are responsible for numerous 
biological processes, including cell-cycle regulation, cellular survival, malignant 
transformation and apoptosis (reviewed by [283]). 
 
TORC2 has also been implicated in lipid biosynthesis. In yeast, TORC2 
positively regulates ceramide synthesis, via ypk1 (the yeast homolog of SGK), 
allowing for the production of more complex sphingolipids [284]. Yeast cells 
deficient in TORC2 have impaired de novo ceramide biosynthesis both in vitro 
and in vivo [284]. Caenorhabditis elegans deficient in TORC2 activity also have 
disrupted lipids, displaying increased fat storage [285]. This lipid storage effect is 
regulated through SGK1 with loss of SGK1 demonstrating the same phenotype  
as rictor mutants [285]. 
 
It is unknown whether TORC2 regulates ceramide synthesis in mammals. In 
contrast to Caenorhabditis elegans and yeast, which contain a single SGK gene, 
mammals have three SGK genes, meaning that the regulation of ceramide 
synthesis in mammals is likely to be more complex. This is shown by SGK1 and 
SGK3 knockout mice which have surprisingly mild phenotypes, perhaps due to 
redundant functions of the two genes [273, 286].  
 
A second argument against TORC2 regulating ceramide synthesis in mammals 
is that TORC2 and ceramides have opposing functions. TORC2 activity is 
associated with increases in growth and survival and ceramides are associated 
with promoting stress-induced growth inhibition and apoptosis in mammals [287, 
 60 
288]. This makes it unlikely that mTORC2 would regulate ceramide synthesis in 
mammals.  
 
1.8.3 mTORC2 signalling in epidermis 
 
Little is known about the role of mTORC2 signalling in epidermis. mTORC2 
substrates, the Akt isoforms, have opposing roles in epidermis, with Akt2 being 
induced developmentally in the parabasal layer and Akt1 expressed in the 
granular layer and involved in terminal differentiation [218]. This raises the 
question; are both Akt isoforms under the control of mTORC2 in epidermis?  
 
Both SGK1 and SGK3 are expressed in epidermis, however little is known about 
their functions. SGK3 is important for normal post-natal hair follicle development 
with SGK3 knock-out mice displaying a reduction in proliferation and an 
abnormality in β-catenin accumulation [286].  
 
It is unknown whether SGK1 regulates ENaC expression in epidermis. ENaCs 
are expressed in keratinocytes, with increased expression of the α- and βENaC 
subunits, two of the three highly homologous ENaC subunits [289], in more 
differentiated keratinocytes [290, 291]. Knock-out of αENaC demonstrates an 
important role for αENaC in skin barrier function after birth [292, 293]. αENaC 
knock-out mice demonstrate normal barrier function directly after birth, but have 
severe TEWL and major impairment of barrier function a few hours later [293]. 
Furthermore, these mice have disrupted levels of epidermal lipids and impaired 
lamellar bodies [293]. 
 
Of the four PKC isoforms (α, β, γ and ε) that are regulated by mTORC2 [268], 
only α and ε are expressed in epidermis [294, 295]. PKCε is mostly localized to 
the proliferating basal layer of the epidermis and has a growth-promoting role 
[296-299]. PKCα is present in the suprabasal layers [296] and has a central role 
in keratinocyte differentiation [297, 298, 300-302]. The novel PKCs, η and δ, and 
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atypical PKCζ are also expressed in epidermis [294, 295], although they are not 
directly regulated by mTORC2 [268]. PKCη are PKCδ are both important in 
keratinocyte differentiation [298, 303], with high levels of PKCη expressed in the 
granular layers [294].   
 
 
1.8.4 mTORC2 signalling in cSCC 
 
mTORC2 activity is linked with cancer, with mTORC2 activity important for 
malignant transformation in some settings [304-306]. However, very little is 
known about the role of mTORC2 signalling in cSCC.  
 
mTORC2 signalling may be tumour suppressing in epidermis. In support of this, 
PKCα is predicted to have a tumour suppressing role in skin, with PKCα 
deficient mice susceptible to skin tumour formation [307] and PKCα down-
regulated in epidermal basal cell carcinomas (BCCs) [308]. Akt1 is also thought 
to have a tumour suppressing role in epidermis due to its down-regulation in 
cSCC [4]. Furthermore, NDRG1 may be important for p53-dependent apoptosis 
in keratinocytes [275, 276]. However, Akt2, which may also be regulated by 
mTORC2, is up-regulated in cSCC and thought to act as a tumour promoter [4]. 
PKCε may also act as a tumour promoter in epidermis as PKCε over expression 
in vivo increases cSCC development [296] and acts as a photosensitizer to UV-
induced cutaneous damage [299]. Therefore it is unclear whether mTORC2 has 
a tumour promoting or tumour suppressing role in epidermis.  
 
The novel PKCs, η and δ, have opposing roles in epidermal tumourigenesis. 
PKCδ enhances caspase-3 activity in response to UVB radiation in cultured 
keratinocytes [309] and reduces epidermal tumour formation in mice [296, 310], 
although this may not be true for UV-induced carcinomas [311], suggesting a 
tumour-suppressor role. In contrast, over-expression of PKCη reduces caspase-
3 activity in response to UVB radiation in cultured keratinocytes [309], 
suggesting a tumour-promoting role in epidermis. 
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1.8.5 ATP-competitive mTOR inhibitors 
 
The link between mTORC2 and tumourigenesis has led to the development of 
mTORC1 and mTORC2 inhibitors (reviewed by [312]). This includes; Torin-1 
[313], WYE-132 (WYE-125132, Wyeth Research) [314], KU-0063794 
(AstraZeneca) [315] and Pp242 [316]. These compounds compete with ATP for 
the active site of mTOR, termed ATP-competitive mTOR inhibitors, and are 
highly selective for mTOR over related kinases [312]. ATP-competitive mTOR 
inhibitors reduce phosphorylation of both mTORC1 and mTORC2 substrates 
and have provided invaluable tools for deciphering novel insights into the mTOR 
signalling network [312]. This includes the discovery of rapamycin resistant 
mTORC1 function in mRNA translation and autophagy [139, 140, 145, 314]. 
 
The introduction of these ATP-competitive mTOR inhibitors raises the question; 
would inhibition of mTORC1 and mTORC2 have the same effect as rapamycin 
treatment in epidermis and reduce SCC occurrence? The additional inhibition of 
mTORC2 may be more effective than rapamycin as an epidermal tumour 
suppressor due to inhibiting PKCε and preventing the hyper-activation of Akt2, 
by the inhibition of mTORC1-dependent negative-feedback loops acting on IRS 
proteins, to reduce pro-survival pathways. However, mTORC2 signalling may 
have a tumour suppressing role in epidermis, through activation of Akt1, PKCα 
and NDRG1. Therefore, ATP-competitive mTOR inhibitors may not have the 
same effects as rapamycin in skin. 
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1.9 Epidermal lipids 
 
The epidermis is a major site of lipid biosynthesis and contains a unique 
composition of lipids very different from other biological membranes (reviewed 
by [317]). The epidermal lipids, free fatty acids, ceramides and cholesterol, are 
synthesized in the upper layers of the epidermis and packaged into lamellar 
bodies as polar lipids; phospholipids, glucosylceramides, sphingomyelins and 
cholesterol sulphate [10, 318]. The lamellar bodies are secreted into the 
extracellular matrix where the lipids are enzymatically converted back into non-
polar lipids [318].   
 
mTORC1 and Akt are both implicated in regulating lipid biosynthesis via SREBP 
proteins in other cell types (reviewed by [319]). Furthermore, mTORC2 may 
regulate ceramide synthesis in mammals [284]. This raises the question what is 
the effect of rapamycin treatment on lipid biosynthesis in epidermis?  
 
1.9.1 Fatty acid synthesis 
 
Fatty acids are the building blocks for phospholipids and glycolipids and consist 
of a carboxylate group with long hydrocarbon side chains that are either 
saturated or unsaturated [320]. The long hydrocarbon chain makes fatty acids 
hydrophobic, an important property for incorporation into biological membranes, 
and usually contain an even number of carbon atoms, typically between 14 and 
24 [320]. Saturated fatty acids contain no double bonds and are flexible 
molecules that can be densely packed, due to having free rotation around their 
single bonds [320]. Unsaturated fatty acids contain double bonds and have a 
more rigid structure, resulting in lipids being less densely packed [320].  
 
Fatty acid synthesis takes place in the cytosol, but begins in the mitochondria 
with carboxylation of acetyl CoA into malonyl CoA, catalyzed by acetyl CoA 
carboxylase (Figure 1-18) [320]. This reaction is irreversible, with malonyl CoA 
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destined to feed into the fatty acid synthesis pathway, and is the rate limiting 
step in fatty acid biosynthesis [320]. The synthesis of saturated long chain fatty 
acids from malonyl CoA and acetyl CoA is catalyzed by the protein complex fatty 
acid synthase (FASN) (reviewed by [321]). Elongation involves sequential 
addition of two carbon atoms, derived from acetyl CoA, onto the donor 
intermediate, which is linked to an acyl carrier protein (ACP) [320]. Elongation by 
FASN stops upon formation of palmitate, a saturated 16 carbon chain fatty acid, 
which can be further modified to form more complex fatty acids and also 
ceramides (Figure 1-18) [321]. The SREBP1 proteins regulate the expression of 
a number of key enzymes involved in de novo fatty acid synthesis, including 
FASN [152].   
 
 
Figure 1-18: Fatty acid biosynthesis. Malonyl CoA is formed from acetyl CoA 
by acetyl CoA carboxylase, the rate-limiting step in fatty acid biosynthesis. The 
saturated 16C long-chain fatty acid (FA) palmitate is synthesized by sequential 
addition of two carbon atoms, derived from acetyl CoA, onto the donor malonyl 
ACP by FASN. Palmitate can be further elongated and have double bonds 
inserted to form more complex fatty acids and unsaturated fatty acids. 
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1.9.2 Cholesterol synthesis  
 
Cholesterol is a sterol, consisting of four cycloalkane rings, and is the precursor 
for many molecules in the body [320]. Cholesterol regulates fluidity of the 
plasma membrane by interacting with the hydrocarbon chains of the 
phospholipid bilayer to make the bilayer more rigid (reviewed by [322]).   
 
Cholesterol is derived from acetyl CoA through a series of enzymatic reactions 
(Figure 1-19) [320]. Synthesis within the body starts with one molecule of acetyl 
CoA and one molecule of acetoacetyl CoA, which condense to form 3-hydroxy-
3-methylglutaryl CoA (HMG CoA), catalyzed by HMG CoA synthase [320]. This 
molecule is then reduced to mevalonate by the enzyme HMG CoA reductase, 
the rate-limiting and irreversible step of cholesterol synthesis [320]. Mevalonate 
is converted to 3-isopentenyl pyrophosphate (PP) by three consecutive 
reactions that require ATP [320]. Six molecules of 3-isopentenyl PP are used to 
synthesize squalene, which is then cyclized to form lanosterol. Finally, lanosterol 
is converted into cholesterol [320].  
 
Cholesterol biosynthesis is regulated by SREBP1a and SREBP2 in response to 
sterols. These transcription factors regulate the expression of key enzymes 
involved in cholesterol biosynthesis [155], similar to the regulation of fatty acid 
biosynthesis. This includes transcription of HMG CoA reductase, the enzyme 
responsible for the rate-limiting and irreversible step of cholesterol biosynthesis 
[155]. 
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Figure 1-19: Cholesterol biosynthesis. Cholesterol is synthesized from acetyl 
CoA through a series of reactions requiring numerous enzymes. The conversion 
of HMG CoA to mevalonate by HMG CoA reductase is the rate-limiting step of 
cholesterol synthesis. 
 
1.9.3 Ceramide synthesis  
 
Ceramides consist of a sphingosine base and a fatty acid carbon chain [323]. 
Sphingosines are C18 alcohols with an unsaturated poly-carbon chain. The fatty 
acid carbon chain of ceramides ranges from C14-26.  
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Ceramide synthesis occurs via three routes; the de novo ceramide synthesis 
pathway, sphingomyelin hydrolysis and from the salvage pathway. De novo 
ceramide synthesis takes place on the cytoplasmic side of the ER (Figure 1-20) 
[323]. Palmitoyl CoA and L-serine are condensed to form 3-ketodihydro-
sphingosine, catalyzed by serine palmitoyltransferase. This first reaction is the 
rate-limiting step in de novo ceramide synthesis. 3-keto-dihydro-sphingosine is 
reduced to dihydrosphingosine by 3-keto-dihydro-sphingosine reductase. 
Dihydrosphingosine is N-acylated by ceramide synthase to produce dihydro-
ceramide. Formation of ceramide is achieved by desaturation of dihydro-
ceramide by dihydro-CER 4-desaturase (DES1). Ceramides are then 
transported to the Golgi apparatus where they are the precursors for more 
complex sphingolipids.  
 
 
Figure 1-20: De novo ceramide synthesis. 3-ketodihydro-sphingosine (-Sph) 
is produced from serine and palmitoyl CoA, the rate-limiting step which is 
catalyzed by serine pamlityltransferase. 3-ketodihydro-Sph is converted into 
dihydro-Sph and then dihydro-ceramide (CER). Finally dihydro-CER is 
converted into ceramide. 
 
The salvage pathway produces ceramides by re-acylating the sphingosine 
generated by the deacylation of ceramide [324]. Ceramide synthesis also occurs 
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by hydrolysis of sphingomyelins by sphingomyelinases [323]. These ceramides 
act as signalling molecules and can induce apoptosis in response to cellular 
stress [323]. 
 
1.9.4 The regulation of lipid synthesis in epidermis 
 
Fatty acid biosynthesis in epidermis is predicted to be regulated by SREBP1 as 
SREBP1c and FASN expression increase during keratinocyte differentiation 
[325]. Furthermore, SREBP1 is expressed in the suprabasal layers [326] and 
FASN is expressed in the granular layer [327], with increased expression in 
response to barrier disruption [328]. This suggests a role for SREBP1 in 
epidermal lipid metabolism. 
 
The epidermis on a weight basis is a very active site of cholesterol synthesis 
[329]. Epidermal cholesterol synthesis is regulated by SREBP2. SREBP2 
regulates HMG CoA reductase and HMG CoA synthase expression in response 
to sterols and is the predominant SREBP isoform in murine epidermis [330]. 
Topical application of HMG CoA reductase inhibitors delays barrier recovery 
following barrier disruption with acetone, demonstrating a role for cholesterol 
synthesis in barrier repair [331]. 
 
Cholesterol is exported into the extracellular space as the cholesterol 
metabolite, cholesterol sulphate, with synthesis catalyzed by cholesterol 
sulphotransferase [329]. Cholesterol sulphate is then metabolized back into 
cholesterol by steroid sulphatase in the extracellular matrix [332]. Cholesterol 
sulphate plays an important role in the desquamation process by acting as a 
protease inhibitor [332, 333]. 
 
There are at least eleven subclasses of ceramides in the cornified layer 
(reviewed by [324]).  These differ in their sphingolipid head group (sphingosine, 
phytosphingosine or dihydrosphingosine), whether they are linked to a non-
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hydroxylated fatty acid or an α-hydroxyl fatty acid and have varying hydrocarbon 
chain length [324]. ω-hydroceramides are unique to the epidermis (reviewed by 
[334]). ω-hydroceramides contain sphingosines coupled to highly saturated, 
uniquely long-chained (C30-36) fatty acids with a hydroxyl group at the chain 
terminal [334]. ω-hydroceramides are important in lamellar bodies, where they 
hold together the multilayered stacks of lipids [335], and are incorporated into 
the cornified envelope where they covalently bind to proteins, including loricrin 
[336, 337].   
 
Epidermal ceramides are packaged into lamellar bodies as the polar lipids 
glucosyl-ceramides and sphingomyelins [334]. The majority of ceramide species 
within the lamellar bodies are glycosylated, however there are still substantial 
quantities of sphingomyelins also present [334]. Once secreted into the 
extracellular space, these lipids are converted back into non-polar ceramides by 
hydrolysis by β-glucocerebrosidase and sphingomyelinase [334].  
 
1.9.5 Lipids in cSCC 
 
Many cancers have increased lipid synthesis due to cancer cells preferring 
glycolosis over oxidative phosphorylation for energy, even under oxidative 
conditions; a phenomenon known as the Warburg effect [338]. An increase in de 
novo fatty acid synthesis in the early stages of cancer provides a survival 
advantage by inhibiting apoptosis and promoting cell cycle progression [339]. 
FASN up-regulation is a common molecular change in cancer and its expression 
is a potential prognostic marker for selected tumours [340]. It is not yet known 
whether FASN is up-regulated in cSCC. 
 
mTORC1 inhibition by rapamycin reduces fatty acid synthesis through inhibition 
of SREBP proteins [149, 167, 168]. Therefore rapamycin may inhibit cSCC 
formation by inhibiting fatty acid biosynthesis, providing an alternative 
mechanism for rapamycin’s anti-cancer activity in skin. However, Akt signalling 
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can also regulate lipid biosynthesis independently from mTORC1 [211-213]. 
Rapamycin may activate Akt, via inhibition of the mTORC1-dependent negative 
feedback loops acting on IRS-1, resulting in activation of SREBP and increased 
lipid biosynthesis in epidermis. Therefore it is important to determine the effect 
of rapamycin on SREBP proteins to determine whether rapamycin’s tumour-
suppressing role in epidermis is linked to fatty acid biosynthesis.   
 
UV radiation also induces changes in epidermal lipid species. UVB radiation 
leads to oxidation of some lipids, leading to increased epidermal lipid fluidity, 
lamellar granule disorder and reduced epidermal barrier function [341-346]. This 
reduction in barrier function results in increased lipid biosynthesis of all three 
epidermal lipid classes to enhance barrier regeneration [347, 348].  
 
A reduction in epidermal fatty acid biosynthesis by rapamycin may disrupt lipid 
homeostasis and barrier function. This would result in delayed epidermal 
recovery from UV exposure and increased DNA damage in response to further 
UV radiation. However, rapamycin treatment may activate mTORC2 signalling 
and promote ceramide synthesis in epidermis. An increase in ceramide 
production may overcome the UV-induced damage to epidermal lipids, resulting 
in faster barrier recovery following UV exposure [347, 348]. Therefore the 
predicted effects of rapamycin treatment on epidermal lipids are unclear and 
have the potential to be both tumour-suppressive and tumour-promoting. 
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1.10  Overall hypothesis 
 
Rapamycin treatment inhibits both cSCC tumour formation and tumour 
development in transplant recipients [1, 2]. Several mechanisms have been 
proposed for rapamycin’s tumour-suppressing activity in epidermis (reviewed by 
[3]). I hypothesise that there are additional mechanisms, involving regulation of 
epidermal Akt isoforms, mTORC2 signalling and lipid biosynthesis, responsible 
for rapamycin’s anti-cancer role in skin.   
 
CSCC has been linked with changes in the epidermal Akt signalling [4]. I 
propose that mTORC1 signalling down-regulates the PI3K/Akt pathway in 
keratinocytes, due to the presence of negative feedback loops acting on IRS 
proteins. Therefore epidermal rapamycin treatment will inhibit these feedback 
loops and result in an increase in PI3K/Akt signalling and up-regulation of Akt 
phosphorylation. 
 
Due to the opposing roles of the epidermal Akt isoforms [4], rapamycin 
treatment could have different effects depending on which of the isoforms are 
affected. I predict that rapamycin treatment activates Akt1 and promotes Akt1’s 
tumour suppressing role in epidermis. This provides a mechanism for 
rapamycin’s anti-cancer role in skin. 
 
mTORC2 activity is insensitive to acute rapamycin treatment, however 
prolonged rapamycin treatment inhibits mTORC2 signalling in some cell types 
[5, 101]. The effect of rapamycin on mTORC2 signalling in epidermis is 
unknown. mTORC2 signalling may have a tumour-suppressor role in epidermis 
[275, 276, 307], therefore I hypothesise that rapamycin will not inhibit epidermal 
mTORC2 signalling.  
 
mTOR signalling is implicated in fatty acid biosynthesis [149, 167, 168]. I predict 
that rapamycin will inhibit fatty acid biosynthesis in epidermis, via regulation of 
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SREBP1 by mTORC1. The down-regulation of fatty acids may reduce tumour 
cell growth and tumour progression due to the Warburg effect [338].  
 
The recent development of ATP-competitive mTOR inhibitors opens the door to 
inhibition of mTORC2 and rapamycin-insensitive mTORC1 activity in epidermis 
(reviewed by [312]). I predict that these inhibitors will not have the same tumour-
suppressing role in epidermis as rapamycin. This is due to ATP-competitive 
mTOR inhibitors inhibiting the tumour-suppressing effects of Akt1 and mTORC2 
in epidermis. 
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1.11  Aims 
 
The overall aim of this study is to determine the effects of rapamycin treatment 
on the PI3K/Akt pathway and mTORC2 signalling in epidermis in order to try and 
link them to rapamycin’s tumour-suppressive activity in skin. The aims are -  
 
1) To determine the effects of rapamycin on the epidermal PI3K/Akt 
pathway. This will be achieved by monitoring Akt phosphorylation in response 
to acute and prolonged rapamycin treatment in cultured keratinocytes and 
murine epidermis. Also, changes in IRS proteins in response to rapamycin will 
be measured to establish whether the mTORC1-dependent negative feedback 
loops acting on IRS proteins are active in epidermis and if they are responsible 
for any change in Akt phosphorylation.  
 
2) To establish which of the Akt isoforms are affected by rapamycin 
treatment as they have opposing roles in epidermis. Changes in epidermal 
Akt isoform phosphorylation will be monitored in response to rapamycin in 
cultured keratinocytes and murine epidermis to determine whether rapamycin 
treatment affects Akt1 and Akt2 phosphorylation. Furthermore the effect of UV 
radiation on Akt isoform phosphorylation in the presence of rapamycin will be 
determined to establish whether rapamycin-induced changes in epidermal Akt 
isoforms have a tumour-suppressor role. 
 
3) To show the effect of prolonged rapamycin treatment on mTORC2 
activity in epidermis. mTORC2 activity is insensitive to acute rapamycin 
treatment, however prolonged rapamycin treatment inhibits mTORC2 signalling 
in some cell types [5, 101]. Changes in mTORC2 substrate phosphorylation will 
be monitored in response to rapamycin in cultured keratinocytes and murine 
epidermis to determine whether rapamycin inhibits mTORC2 signalling in 
keratinocytes.  
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4) To compare the effects of rapamycin and ATP-competitive mTOR 
inhibitors in epidermis in order to predict whether ATP-competitive mTOR 
inhibitors would have the same tumour-suppressing role in the skin as 
rapamycin. This will be achieved by comparing changes in mTORC1 and 
mTORC2 signalling in cultured keratinocytes and murine epidermis in response 
to rapamycin and ATP-competitive mTOR inhibitors. 
 
5) To determine whether rapamycin affects epidermal SREBP proteins to 
establish whether mTORC1 signalling regulates lipid biosynthesis in 
epidermis. This will be accomplished by monitoring changes in SREBP proteins 
and expression of their target genes in response to rapamycin treatment in 
cultured keratinocytes and murine epidermis.  
 
6) To establish whether rapamycin treatment protects against UV-induced 
DNA damage in epidermis. This will be achieved by monitoring DNA damage 
and keratinocyte apoptosis in response to rapamycin treatment following UV 
radiation. 
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Chapter 2 – Materials and Methods 
2.1 Cell culture 
2.1.1 Materials and solutions 
DMEM+ 
Dulbecco’s Modified Eagle Medium (DMEM) (Invitrogen) 
10% (v/v) foetal bovine serum (FBS) (Biosera)  
4 mM L-glutamine (Sigma-Aldrich) 
1 mM Sodium pyruvate (Invitrogen) 
100 U Penicillin/streptomycin (Invitrogen) 
 
Serum-free DMEM+  
Same as DMEM+ media, but no FBS added 
 
Phosphate Buffered Saline (PBS) 
137 mM Sodium chloride (NaCl) (Sigma-Aldrich) 
10 mM Sodium phosphate dibasic (Na2HPO4) (Sigma-Aldrich) 
2.7 mM Potassium chloride (KCl) (BDH) 
1.8 mM Potassium phosphate monobasic (KH2PO4) (Sigma-Aldrich) 
pH 7.4 
 
154CF Low Calcium Media 
154CF media (Invitrogen) 
1% (v/v) Human Keratinocyte Growth Supplement (HKGS) (Invitrogen) 
(containing 5 µg/ml insulin, 0.18 µg/ml hydrocortisone and 0.2 ng/ml human 
epidermal growth factor) 
0.2 mM Calcium chloride (CaCl2) (Sigma-Aldrich) 
100 U Penicillin/streptomycin  
 
154CF High Calcium Media 
Same as 154CF Low Calcium Media, but 1.2 mM CaCl2 
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2.1.2 Rat epidermal keratinocyte culture 
Rat epidermal keratinocytes (REKs), originally isolated from neonatal Sprague-
Dawley rat skin [349], were cultured according to Pasonen-Seppanan et al [350]. 
This cell line differentiates in culture in a similar fashion to human keratinocytes 
and maintains its growth characteristics to at least passage 40 [349, 350]. 
Therefore, REKs were cultured to a maximum of 40 passages.  
 
For the following culture methods, all volumes given are for a 10 cm2 culture 
dish (Falcon). REKs were removed from long-term storage in liquid nitrogen by 
‘quick-thawing’ at 370C and plated onto culture dishes at 1 x 105 cells/ml in 10 ml 
of pre-warmed DMEM+ media. Cells were cultured in an humidified incubator at 
370C with 5% CO2, replacing the DMEM
+ media every 48 hours. Sub-culture 
was performed at ~90% confluence. In brief, growth media was removed and 
cells were washed with 5 ml PBS. Cells were trypsinized by adding 2 ml 0.5% 
trypsin (Invitrogen) and incubating for 5 minutes at 370C. An equal volume of 
DMEM+ media was immediately added to the cells to neutralize the trypsin and 
cells were centrifuged for 5 minutes at 1200 rotations per minute (rpm). Media 
was aspirated and cells were gently re-suspended in 10 ml of DMEM+ and 2 ml 
cell suspension plus 8 ml DMEM+ media was seeded onto each 10 cm2 dish 
required.  
 
For long-term cell storage, REKs were re-suspended in 80% DMEM+ and 10% 
dimethyl sulphoxide (DMSO) (BDH), following trypsinization and centrifugation, 
and aliquoted into cryotubes. Each cryotube contained 1 x 106 cells in 1 ml. The 
cells were slowly frozen in an insulated box at -800C overnight and then 
transferred to liquid nitrogen for long term storage.  
 
For all experiments, unless otherwise stated, cells were seeded overnight prior 
to stimulation at 2 x 105 cells/ml in either a 6-well culture plate (Falcon) or a 10 
cm2 culture dish. 
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2.1.3 Human primary keratinocyte culture 
Neonatal human epidermal keratinocytes (nHEKs) (Invitrogen), isolated from 
neonatal foreskin, were used for experiments at passage 3 to ensure good cell 
growth and viability. nHEKs were grown on bovine type I collagen (BD 
Biosciences) coated dishes. To coat dishes, 2 ml of 50 µg/ml type I collagen in 
0.01M hydrochloric acid (HCl) (BDH) was incubated on a 10 cm2 dish for 1 hour 
at room temperature (RT). The remaining solution was then aspirated and the 
dish was washed 3 times in 4 ml PBS and stored in sterile conditions at 40C for 
up to one week or -200C for up to one month. 
 
For the following culture methods, all volumes given are for a 10 cm2 culture 
dish. nHEKs were removed from long-term storage in liquid nitrogen by ‘quick-
thawing’ at 370C. Cells were seeded at 1 x 105 cells/ml in pre-warmed 154CF 
Low Calcium Media on type-1 collagen-coated culture dishes. Cells were 
cultured in an humidified incubator at 370C with 5% CO2, replacing the 154CF 
Low Calcium Media twice a week. Sub-culture was performed at between 80 
and 90% confluence. In brief, growth media was removed and cells were 
washed with 5 ml PBS. Cells were trypsinized by adding 2 ml 0.5% trypsin for 5 
minutes at 370C. An equal volume of media was immediately added to the cells 
to neutralize the trypsin and cells were centrifuged for 5 minutes at 1200 rpm. 
Media was aspirated and cells were gently re-suspended in 10 ml of media at 5 
x 104 cells/ml and seeded onto a 10 cm2 dish.  
 
For all experiments, unless otherwise stated, cells were seeded overnight prior 
to stimulation at 4 x 105 cells/ml in 154CF Low Calcium Media in a type-1 
collagen-coated 12-well culture plate (Falcon). For experiments on 
undifferentiated nHEKs, cells remained in 154CF Low Calcium Media. For 
experiments on differentiating/differentiated nHEKs, the media was changed to 
154CF High Calcium Media and cells were grown for a further 48 hours. The 
increase in CaCl2 concentration from 0.2 mM to 1.2 mM CaCl2 initiated 
keratinocyte differentiation [351]. 
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2.1.4 Inhibitors used in cell culture  
All inhibitors were diluted in DMSO to 1000x the desired concentration and then 
diluted 1 in 1000 directly into the media in the well to produce a final DMSO 
concentration of 0.1%. Final concentrations (unless otherwise stated) for 
inhibitors are shown in Table 1. For insulin stimulation of REKs, cells were 
serum-starved overnight using serum-free DMEM+ media, and then treated with 
insulin for 15 minutes.  
 
Table 1: Inhibitor concentrations for cell culture 
 
Inhibitor Concentration 
Cycloheximide (Sigma) 25 µg/ml 
Insulin (Sigma) 1 µg/ml 
Lactacystin (Sigma) 10 µM 
LY-294002 (Sigma) 10 µM 
Rapamycin (Sigma) 10 nM 
 Torin-1 (Sabatini-Gray 
Laboratory, USA [140]) 
10 nM 
 
 
2.1.5 Akt constructs used in cell culture  
REKS were transfected with pcDNA and HA-tagged Akt1 and 2 constructs using 
Lipofectamine 2000 (Invitrogen) according to manufacturer’s instructions. In 
brief, REKs were cultured in DMEM+ media in a 6-well plate and transfected at 
90-95% confluency. Cells were gently rinsed with Opti-MEM media (Invitrogen), 
to remove DMEM+, followed by addition of 1.5 ml Opti-MEM media (Invitrogen) 
immediately prior to the transfection. The transfection complexes were prepared 
as follows; 4 µg DNA was added to 250 µl Opti-MEM media in an eppendorf 
tube and gently mixed. In a second tube, 10 µl Lipofectamine 2000 was added 
 80 
to 250 µl Opti-MEM media, gently mixed and incubated for 5 minutes at RT. The 
diluted DNA was then added to the diluted Lipofectamine 2000 and incubated 
for a further 20 minutes at RT. The 500 µl complexes were added to each well of 
REKs and incubated at 370C for 8 hours when the media was replaced with 
DMEM+ media. Drug treatment was performed 48 hours after transfection. 
 
Akt constructs were Addgene Plasmid 9021: 1477 pcDNA3 flag HA Akt1 from 
William Sellers [352] and Addgene  plasmid 16000: pcDNA3 Hygro HA Akt2 
from Morris Birnbaum Lab, University of Pennsylvania School of Medicine. 
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2.2  Tissue culture and fixation 
2.2.1 Materials and solutions 
Williams E+ Media  
Williams E medium (Invitrogen)  
2 mM L-glutamine  
10 μg/ml Insulin (Sigma-Aldrich) 
10 ng/ml Hydrocortisone (Sigma-Aldrich) 
100 U Penicillin/streptomycin 
 
Bouin’s Solution (Sigma-Aldrich) 
9% (v/v) Formaldehyde 
5% (v/v) Acetic acid  
0.9% (w/v) Picric acid 
 
2.2.2 Mouse developmental series 
For collection of mouse embryo tissue during late stages of development, CD1 
mouse embryos were removed from the uterus and embryonic sac at E 15.5, 
16.5, 17.5 and 18.5. Individual embryo weights were measured and the ages of 
the embryos were confirmed using linear regression on the weight versus the 
age of the embryo, using data collected previously by the group. Various regions 
of the embryo were dissected and fixed for immunohistochemical analysis (see 
section 2.2.7). 
 
2.2.3 Mouse embryo explant cultures 
The mouse embryo explant model used in this study shows authentic epidermal 
differentiation marker expression and levels of cell death comparable to skin 
controls (Appendix 1-3), while modeling the epidermal stress response 
(Appendix 1-3), validating it as a skin experimental model. 
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For mouse embryo explant cultures, E15.5 mice were collected as described in 
section 2.2.2. The dorsal skin of the embryo was isolated from the underlying 
tissue using tweezers and a dissecting microscope whilst being immersed in 
Williams E+ Media. The tissue was laid flat, dermis side down, on a piece of anti-
aliasing filter paper (Millipore) and incubated at the air-liquid interface on a mesh 
grid for 3 days at 370C with 10% CO2 in Williams E
+ Media (Figure 2-1). The 
media was replaced once every 24 hours over the 3 day culture.  
 
 
 
Figure 2-1: Mouse embryo explant cultures. Embryos were removed from a 
pregnant CD1 mouse at E15.5. The dorsal skin was dissected from the embryo 
and laid dermis side down on a piece of filter paper. The dorsal skin and filter 
paper were placed on a mesh grid and incubated at the air-liquid interface, so 
that the bottom of the dermis media made contact with the Williams E+ Media. 
Explant cultures were incubated for 3 days at 370C with 10% CO2.  
 
On the day of harvest, explant cultures were either paraffin embedded (see 
section 2.2.7), made into frozen sections (see section 2.2.8) or used to make 
protein lysates (see section 2.5.3). 
 
2.2.4 UV irradiation of mouse embryo explant cultures 
Embryo explants were UV irradiated after 3 days in culture using a UV cross-
linker (CX-2000, UVP). Samples were irradiated with 6 mJ/cm2 UV and either 
harvested immediately or cultured for a further 24 or 66 hours at 370C with 10% 
CO2 in Williams E
+ Media.  
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The 6 mJ/cm2 UV dose was previously established by our group by testing 0-15 
mJ/cm2 UV radiation on embryo explant cultures. The 6 mJ/cm2 UV dose 
resulted in activated caspase 3 and the presence of sunburn cells in the 
epidermis, whist having no significant effect on epidermal differentiation marker 
expression. Furthermore, the UV dose of 6 mJ/cm2 lies below the minimal 
erythemal dose making it physiologically relevant [353-355]. 
  
2.2.5 Mouse adult explant cultures 
For adult skin cultures, adult C57 black mouse dorsal ear skin was isolated 
according to Stoitzner P et al [356]. Mouse ears were cut off from the base and 
the dorsal skin was isolated from ventral skin and the underlying cartilage using 
tweezers and a dissecting microscope whilst being immersed in DMEM+ media 
(see section 2.1.1 for details). The tissue was laid flat, dermis side down, on a 
piece of anti-aliasing filter paper (Millipore) and incubated at the air-liquid 
interface on a grid for 24 hours at 370C with 10% CO2 in DMEM
+ media. On day 
of harvest explant cultures were paraffin embedded (see section 2.2.7).  
 
2.2.6 Inhibitors for explant cultures 
Inhibitors for explants cultures were all diluted in DMSO to 1000x the desired 
concentration and then diluted 1 in 1000 directly into media to produce a final 
DMSO concentration of 0.1%. Final inhibitor concentrations (unless otherwise 
stated) were 1 or 5 μM rapamycin (Sigma-Aldrich), 2.5 or 5 μM Torin-1 
(Sabatini-Gray Laboratory, USA [140]) and 20 μM KU-0063974 (AstraZeneca 
[315]).  
 
The rapamycin concentration for the emrbyo explant experiments was 
established by testing 0-10 µM rapamycin in a 72 hour embryo explant model. 1 
µM was the minimal dose required to inhibit epidermal S6 phosphorylation, with 
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phosphorylated S6 present in the epidermis with 0.5 µM rapamycin (data not 
shown). 
 
2.2.7 Tissue fixation and paraffin embedded sections 
Tissue samples were fixed in Bouin’s Solution for 2 hours at RT followed by 
washing three times, each for 1 hour, in 70% ethanol (Fisher Scientific) followed 
by a further wash in 70% ethanol overnight. Samples were then de-hydrated, by 
slowly moving up an ethanol gradient (80-100%), and embedded in paraffin, by 
using xylene (Fisher Scientific) as an intermediate between the ethanol and the 
paraffin. The samples were finally embedded in 100% paraffin ready for 
sectioning. Samples were sectioned at 5 µm using a microtome (Leica RM2235) 
onto superfrost slides (VWR) and incubated overnight at 370C to adhere the 
section to the slide. Sections were then stored at RT ready for analysis by 
histological techniques (see section 2.4). 
 
2.2.8 Frozen tissue sections 
For frozen sections, tissues were embedded in Cryo-M-Bed compound (Bright 
Instrument Company Ltd) and cut at 5 µm at -200C, the optimum cutting 
temperature, using a cryostat (Bright Instrument Company Ltd) onto superfrost 
slides. Sections were air-dried for 10 minutes and stored at -800C. Sections 
were analysed by histological techniques (see section 2.4). 
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2.3  Rapamycin-treated mice in vivo  
Rapamycin-treated C57 black mice were obtained from Dr. Matthew Hardman, 
University of Manchester, and treated with doses experimentally related to 
clinical rapamycin treatments [357]. A 20 mg/ml stock of rapamycin (ENZO Life 
Sciences) was made in ethanol and stored at -20°C for up to one week. The 
stock solution was diluted to 1.2 mg/ml in vehicle, 0.25% polyethylene glycol 
(PEG) (Sigma), 0.25% Tween-80 (Sigma), to obtain the 8 mg/kg dose (0.24 
mg/dose, assuming average mouse weight of 30 g). Male 5 week old C57 black 
mice were treated with 8 mg/kg rapamycin administered by intraperitoneal (IP) 
injection on day 1, 3, 5 and 8 and then skin was harvested on day 10.  
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2.4 General histology and immunohistochemical analysis 
2.4.1 Materials and solutions 
1% Acid Alcohol 
70% (v/v) Ethanol  
1% (v/v) HCl  
 
Citrate Buffer 
10 mM Citric acid (Sigma-Aldrich) 
pH 6.0 with 5M Sodium hydroxide (NaOH) (Sigma-Aldrich) 
Stored at 40C 
 
Blocking Buffer 
PBS 
5% (v/v) Normal goat / horse serum (Vector Laboratories) 
1% (w/v) Bovine serum albumin (BSA) (Sigma-Aldrich)  
Stored at 40C 
 
Anti-fade 
PBS 
90% (v/v) Glycerol (BDH) 
100 mM p-Phenylenediamine (Sigma-Aldrich) 
Stored at -800C in the dark 
 
Nile Red Stock Solution 
Acetone (BDH) 
0.5% (w/v) Nile red (Sigma-Aldrich)  
Stored at 40C in the dark 
 
Nile Red Working Solution 
75% (v/v) Glycerol  
0.1% (v/v) Nile Red Stock Solution  
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2.4.2 Haematoxylin and eosin (H&E) staining 
For H&E staining, paraffin embedded sections were dewaxed in xylene for 10 
minutes followed by hydration in a decreasing alcohol series; 100% ethanol, 
90% ethanol, 70% ethanol and water, each for 3 minutes. The cell nuclei of the 
sections were stained by immersion in haematoxylin (Sigma-Aldrich) for 1 
minute, briefly washing in water to remove excess stain, followed by dipping the 
sections three times in 1% Acid Alcohol and returning to be washed in water for 
5 minutes or until the nuclei stained blue under the microscope. Sections were 
counter-stained by immersion in eosin (Sigma-Aldrich) for 2 minutes followed by 
washing in water for a further 3 minutes. The sections were dehydrated in 70% 
ethanol, 90% ethanol, 100% ethanol, each for 2 minutes and a further 4 minutes 
in xylene. Finally, the sections were mounted using Depex (BDH). Mounted 
sections were stored at RT. 
 
2.4.3 Immunofluorescence on fixed sections 
For immunofluorescence on Bouin’s Solution fixed, paraffin embedded samples 
(see section 2.2.7) sections were hydrated through xylene/alcohol series as 
described in section 2.4.2. Antigen retrieval was performed using Citrate Buffer 
and heating in a microwave on high power for 3 minutes followed by 10 minutes 
on defrost setting. Sections were then left to cool for 20 minutes at RT. All 
further steps were performed at RT unless otherwise stated. Sections were 
briefly washed in PBS and then blocked for 1 hour in Blocking Buffer. The 
Blocking Buffer contained either horse or goat serum depending on the species 
that the secondary antibody was raised against. Primary antibodies (see Table 
2), diluted in Blocking Buffer, were incubated with the sections overnight at 40C. 
Sections were then washed three times for 5 minutes in PBS + 0.1% Tween-20 
(Sigma-Aldrich), before incubation with the secondary antibody (see Table 3), 
also diluted in Blocking Buffer, for 1.5 hours in the dark. The secondary antibody 
was conjugated to either a fluorescein isothiocyanate (FITC), Alexa Fluor 488 or 
Alexa Fluor 555 probe and was raised against the host immunoglobulin G (IgG) 
of the primary antibody. Sections were washed three times for 5 minutes in PBS 
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+ 0.1% Tween-20 in the dark, and incubated with 1μg/ml 4'-6-diamidino-2-
phenylindole (DAPI) (Sigma-Aldrich) for 5 minutes in the dark. Sections were 
then washed once in PBS for 5 minutes and mounted using Anti-fade. Mounted 
sections were stored in the dark at 40C. Samples were photographed within 1 
week to minimize loss of fluorescence (see section 2.4.6). 
 
Table 2: Primary antibodies for immunofluorescence 
Antibody Host Dilution 
Phospho-Akt S473 (9271) Cell Signalling Rabbit 1:10 
Akt2 (ab13991) Abcam Chicken 1:50 
Cleaved caspase 3 D175 (9661) Cell Signalling Rabbit 1:100 
FASN (ab22759) Abcam Rabbit 1:50 
Filaggrin (#219-234) Zymed Rabbit 1:400 
HMG CoA Reductase (07-457) Upstate Rabbit 1:50 
Keratin-1 AF109 (PRB-149P) Covance Rabbit 1:400 
Keratin-6 (PRB-169P) Covance Rabbit 1:200 
Keratin-14 AF64 (PRB-155P) Covance Rabbit 1:2000 
Ki-67 (NCL-Ki67-MM1) Novocastra Labs Ltd Mouse 1:25 
Loricrin AF62 (PRB-145P) Covance Rabbit 1:500 
Phospho-mTOR S2448 (2971) Cell Signalling Rabbit 1:200 
Phospho-mTOR S2481 (2974) Cell Signalling  Rabbit   1:50 
Phospho-mTOR S2481 (ab45996) Abcam Rabbit 1:50 
Phospho-PKCα S657 (sc-12356) Santa Cruz Rabbit 1:200 
Phospho-S6 S240/244 (2215) Cell Signalling Rabbit 1:100 
SREBP1 H160 (sc-8984) Santa Cruz Rabbit 1:25 
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Table 3: Secondary antibodies for immunofluorescence 
Antibody Host Dilution 
Raised 
against 
Alexa Fluor 488 anti-rabbit (A11034) 
Molecular Probes 
Goat 1:800 Rabbit IgG 
Alexa Fluor 488 anti-mouse (A11029) 
Molecular Probes 
Goat 1:800 Mouse IgG 
Alexa Fluor 555 anti-mouse (A21424) 
Molecular Probes 
Goat 1:800 Mouse IgG 
FITC anti-chicken (ab6873) Abcam Goat 1:800 Chicken IgY 
    
2.4.4 Immunoperoxidase staining on fixed sections 
For immunoperoxidase staining on Bouin’s Solution fixed, paraffin embedded 
samples (see section 2.2.7), sections were hydrated through xylene/alcohol 
series and antigen retrieval was performed using Citrate Buffer as described in 
section 1.4.3. All further steps were performed at RT unless otherwise stated. 
Sections were incubated in 0.3% hydrogen peroxide (Sigma) solution for 30 
minutes, washed three times for 5 minutes in PBS and then blocked for 30 
minutes in Blocking Buffer containing horse serum. Primary antibodies (see 
Table 4), diluted in Blocking Buffer, were incubated with the sections for either 2 
hours or overnight at 40C. Sections were then washed three times for 5 minutes 
in PBS + 0.1% Tween-20. Sections were incubated with a biotinylated anti-
mouse secondary antibody (Vector Laboratories), diluted 1:200 in Blocking 
Buffer, for 30 minutes. Sections were washed three times for 5 minutes in PBS + 
0.1% Tween-20, and incubated for a further 30 minutes in avidin-biotin-
peroxidase complex using Vectastain ABC Kit (Vector Laboratories) according 
to manufacturer’s instructions. Sections were then washed once in PBS + 0.1% 
Tween-20 for 5 minutes and stained with 3,3’-diaminobenzidine (DAB 
Peroxidase Substrate Kit, Vector Laboratories) for 1-5 minutes until the desired 
staining density was achieved. Samples were then counterstained with 
haematoxylin for 30 seconds, briefly washed in water to remove excess stain, 
followed by dipping the sections three times in 1% Acid Alcohol and returning to 
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be washed in water for 5 minutes or until the nuclei stained blue under the 
microscope. The sections were then dehydrated in 70% ethanol, 90% ethanol, 
100% ethanol, each for 2 minutes and a further 4 minutes in xylene. Finally, the 
sections were mounted using Depex. Mounted sections were stored at RT. 
 
Table 4: Primary antibodies for immunoperoxidase staining 
Antibody Host Dilution 
Akt1 2H10 (2967) Cell Signalling Mouse 1:100 
Thymine dimer KTM53 ( MC-062) Kamiya 
Biomedical 
Mouse 1:400 
 
 
 
2.4.5 Nile red assay 
The Nile red assay was based on a method of Talreja P. et al [358]. Nile red is a 
fluorescence probe that stains polar lipids red and non-polar lipids green. To 
stain lipids on sections, 100 µl Nile Red Working Solution was added to each 
section and then sections were immediately mounted onto coverslips, which 
were secured using nail-varnish. Mounted sections were stored in the dark at 
40C. Samples were photographed within 24 hours to minimize loss of 
fluorescence (see section 2.4.6). 
 
2.4.6 Photography, quantification and statistical analysis 
Images were taken with a microscope (Nikon Eclipse E600), with either x20 (NA 
0.4) or x60 oil immersion (NA 0.4) objectives, using a Spot RT digital camera 
(Diagnostics Instruments Inc.) and Spot advanced software. Average 
immunostaining was determined using Image J software (see Appendix 8.10 for 
data tables). Mean immunostaining was taken for x3 fields per sample unless 
otherwise stated. Two-tailed Student’s T-test performed using Microsoft Excel 
TTEST function. Analysis of variance (ANOVA) performed using program from 
Kirkman, T.W. [359]. 
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2.5 Protein analysis 
2.5.1 Materials and solutions 
Radioimmunoprecipitation (RIPA) Buffer  
150 mM NaCl 50 mM Tris-HCl pH 8.0 (BDH) 
1% (v/v) Igepal (Sigma-Aldrich) 
0.5% (w/v) Sodium deoxycholate (Sigma-Aldrich) 
0.1% (w/v) Sodium dodecyl sulphate (SDS) (Sigma-Aldrich) 
100 μM Sodium orthovanadate (Na3VO4) (Sigma-Aldrich) 
1 mM Phenylmethanesulphonyl-fluoride (PMSF) (Sigma-Aldrich) 
1 mM Sodium fluoride (NaF) (Sigma-Aldrich)  
Ethylenediaminetetra-acetic acid (EDTA)-free protease inhibitors (Roche) 
 
5X Sample Buffer 
125 mM Tris-HCl pH 6.8  
20% (v/v) Glycerol 
2% (w/v) SDS  
0.02% (w/v) Bromophenol blue (Sigma-Aldrich) 
10% (v/v) β-mercaptoethanol (Sigma-Aldrich) 
 
2X Sample Buffer 
40% (v/v) 5X Sample Buffer  
 
Epidermal Lysis Buffer 
10 mM Tris-HCl pH 7.5  
20% (v/v) β-mercaptoethanol  
5% (w/v) SDS  
0.02% (w/v) Bromophenol blue  
 
10% SDS- Polyacrylamide gel electrophoresis (PAGE) resolving gel 
33% (v/v) Acrylamide solution, 30% (w/v) (National Diagnostics) 
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40% (v/v) 1M Tris-HCl pH 8.8  
10% (w/v) SDS  
5% (w/v) Ammonium persulphate (APS) (Sigma-Aldrich) 
0.07% (v/v) Tetramethylethylenediamine (TEMED) (Sigma-Aldrich) 
 
4% SDS-PAGE stacking gel 
13% (v/v) Acrylamide solution, 30% (w/v)  
12% (v/v) 1M Tris-HCl pH 6.8  
10% (w/v) SDS  
5% (w/v) APS  
0.1% (v/v) TEMED  
 
Running Buffer 
384 mM Glycine (Sigma-Aldrich) 
50 mM Tris base  
0.1% (w/v) SDS  
 
Coomassie Blue Solution 
20% (v/v) Methanol (Fisher Scientific) 
0.5% (v/v) Acetic acid (BDH) 
0.2% (w/v) Coomassie blue (BDH) 
 
Transfer Buffer 
150 mM Glycine  
20 mM Tris-HCl pH 7.5  
20% (v/v) Methanol  
 
Ponceau S Stain 
0.5% (v/v) Acetic acid  
0.2% (w/v) Ponceau S (Sigma-Aldrich) 
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Blocking Buffer 
PBS / TBS 
5% (w/v) milk (Marvel) 
Stored at 40C 
 
Tris-Buffered Saline (TBS) 
150 mM NaCl 
50 mM Tris-HCl pH 7.5 
pH 7.5 with HCl 
 
Wash Buffer 
PBS / TBS 
0.1% (v/v) Tween-20  
 
Stripping Buffer 
62.5 mM Tris-HCl pH 6.8  
20% (w/v) SDS  
100 mM β-mercaptoethanol  
 
2.5.2 Protein lysate preparation from cell culture 
For protein lysate preparation, all volumes given are for a 6-well cell-culture 
plate (Falcon) and all steps performed on ice or at 40C unless otherwise stated. 
Media was aspirated and cells were washed in 1 ml pre-chilled PBS. The PBS 
was removed and cells were lysed in 200 μl RIPA Buffer and incubated for 10 
minutes. Lysates were removed from well using a cell-scraper, transferred into 
pre-chilled eppendorf (Eppendorf) and pre-cleared by centrifugation at 14,000 
rpm for 10 minutes. The supernatant was then transferred into a fresh pre-
chilled eppendorf and stored at -200C and analysed by SDS-PAGE (see section 
2.5.5). 
 
 94 
Protein lysate concentrations were determined using a bicinchoninic acid (BCA) 
protein assay (Pierce) according to manufacturer’s instructions. The BCA assay 
combines the biuret reaction (reduction of Cu+2 to Cu+ by protein in an alkaline 
medium) with the chelation of two molecules of BCA with one Cu+ ion, producing 
a purple final product. In brief, 10 µl of protein lysate, diluted 1:2 in RIPA buffer, 
was incubated with 200 µl BCA Working Reagent (50 parts BCA Reagent A with 
1 part BCA Reagent B) in a 96-well plate. 10 µl of BSA standards (0, 0.125, 
0.250, 0.325, 0.500, 0.750, 1 and 2 mg/ml) were also added to the plate with 
200 µl BCA Working Reagent. Both the protein lysates and the BSA standards 
were set up in triplicate. The plate was incubated for 30 minutes at 370C, cooled 
to RT and then the absorbance was read at 562 nm on a plate reader (Wallac 
Victor2 1420, Perkin Elmer). The unknown protein lysate concentrations were 
then determined using linear regression on the BSA standard curve. 
 
2.5.3 Epidermal isolation and protein lysate preparation from mouse 
embryo explant cultures 
 
Protein lysates were generated from mouse epidermis following separation from 
the dermis. Explant cultures were incubated on ice in PBS containing 5 mM 
EDTA and 1 mM PMSF for 3 minutes and then the epidermis was carefully 
separated from the dermis using tweezers under a dissecting microscope. The 
epidermis was then added to 100 µl Epidermis Lysis Buffer and heated at 1000C 
for 10 minutes. Protein concentrations were checked by running 1 µl of sample 
on a Coomassie gel (see section 2.5.6). Samples were stored at -200C. 
 
2.5.4 Protein immunoprecipitation 
Immunoprecipitations of IRS-1 and IRS-2 were performed based on a protocol 
from Bonifacino et al, 1999 [360]. Immunoprecipitations were carried out using 
400 μg of REK protein lysate with all steps performed on ice or at 4 0C. 400 µl of 
pre-cleared lysates (at 1 mg/ml) were incubated with either 2.5 μg of IRS-1 
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(Millipore) or IRS-2 (Cell signalling) antibody and rotated overnight. 50 μl of pre-
washed protein A-sepharose beads (Sigma-Aldrich) were then incubated with 
the rotating sample for a further 2 hours. Beads were pre-washed 5 times in 1 ml 
RIPA Buffer to remove the ethanol-containing storage buffer. Following 
incubation with the protein A-sepharose beads, samples were washed five times 
by adding 0.5 ml RIPA Buffer, centrifuging at 14,000 rpm for 30 seconds 
followed by removal of the supernatant, in order to remove any un-bound 
antibody and proteins. On the final wash, the beads were pelleted by 
centrifuging at 14,000 rpm for 2 minutes followed by the removal of the 
supernatant. The beads were re-suspended in 20 μl 2X Sample Buffer and 
boiled for 5 min at 1000C. Samples were then centrifuged at 14,000 rpm for 30 
seconds to pellet the beads and the supernatant was transferred into a fresh 
tube. Samples were stored at -200C and analysed by SDS PAGE (see section 
2.5.5). 
 
Immunoprecipitation of phospho-Akt and HA antigen were carried out using 200 
μg of REK protein lysate with all steps performed on ice or at 4 0C. 200 µl of pre-
cleared lysates (at 1 mg/ml) were incubated with 10 µl of immobilized phospho-
Akt (S473) antibody (Cell Signalling) or 40 µl monoclonal anti-HA agar 
monoclonal conjugated beads (Clone HA-7, A2095, Sigma) and rotated 
overnight for pAkt or 2 hours for HA. Samples were then washed five times by 
adding 0.5 ml RIPA Buffer, centrifuging at 14,000 rpm for 30 seconds followed 
by removal of the supernatant, in order to remove any un-bound protein lysate. 
On the final wash, the beads were pelleted by centrifuging at 14,000 rpm for 2 
minutes followed by the removal of the supernatant. The beads were re-
suspended in 20 μl 2X Sample Buffer and boiled for 5 min at 1000C. Samples 
were then centrifuged at 14,000 rpm for 30 seconds to pellet the bead and the 
supernatant was transferred into a fresh tube. Samples were stored at -200C 
and analyzed by SDS PAGE (see section 2.5.5). 
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2.5.5 SDS - Polyacrylamide gel electrophoresis (PAGE) 
Protein samples were separated on SDS-PAGE gels using an electrophoresis 
gel tank system (Biorad) using a protocol from Gallagher, 2005 [361], with all 
steps performed at RT unless otherwise stated. A 10% SDS-PAGE resolving gel 
was prepared with a 4% stacking gel on top with an inserted gel comb. Protein 
samples were prepared using 10-40 μg of protein, with the addition of 5X 
Sample Buffer and RIPA Buffer to give a final volume of 20 µl. Samples were 
denatured for 5 minutes at 1000C before cooling on ice and briefly centrifuging 
to remove condensation from the lid. Samples were loaded into the wells of the 
gel along with a molecular weight standard (Kaleidoscope, Promega). The gel 
was submerged in running buffer and samples were run at 100 volts (V) for 10 
minutes, to allow samples to reach the resolving gel, and then 180 V for further 
45 minutes or until the bromophenol blue tracking dye of the Sample Buffer 
reached the bottom of the gel. 
 
2.5.6 Coomassie Blue stain 
Coomassie blue was used to visualize protein bands on SDS-PAGE gels with all 
steps performed on a shaker at RT. The SDS-PAGE gel was washed three 
times, each for 2 minutes, in analytical grade water (Sigma) before incubating 
with 100 ml Coomassie Blue Solution for 1 hour. The gel was then de-stained by 
washing twice in 30% methanol for 1 hour and then again in 30% methanol 
overnight. Once de-stained, the gel was washed in analytical grade water and 
stored long-term in 0.1% sodium azide (BDH) at 40C to prevent contamination. 
 
2.5.7 Western blot 
Proteins were transferred from the SDS-PAGE gels to nitrocellulose membranes 
(Hybond C extra, GE Healthcare) using a tank transfer system (Biorad) using 
the protocol from Sasse & Gallagher, 2005 [362]. The gel and nitrocellulose 
membrane were sandwiched between four pieces of filter paper and two 
sponges in a cassette. The cassette was inserted into the tank and fully 
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immersed in transfer buffer. The gel was transferred at either 70 V for 2 hours or 
30 V overnight, both at 40C. The membrane was then briefly washed in 
analytical grade water and the protein loading was temporarily visualized using 
Ponceau S Stain, which was then removed using PBS. 
 
2.5.8 Antibody immunoblot and visualization 
For antibody immunoblot and visualization all steps were performed at RT on a 
shaker unless otherwise stated following the protocol from Gallagher, 2005 
[363]. The nitrocellulose membrane was blocked for 1 hr in Blocking Buffer in 
either TBS or PBS (TBS if the primary antibody was raised against a 
phosphorylated target; PBS for all others) and then incubated with the primary 
antibody (Table 5), diluted in Blocking Buffer,  for either 2 hours at RT or 
overnight at 40C. The membrane was then washed four times, 5 minutes each, 
in Wash Buffer in either TBS or PBS (TBS if the primary antibody was raised 
against a phosphorylated target; PBS for all others) to remove excess primary 
antibody. Membranes were incubated with the secondary antibody (see Table 
6), also diluted in Blocking Buffer, for 1 hour. The secondary antibody was 
conjugated to horseradish peroxidase and was raised against the host IgG of 
the primary antibody. The membrane was washed four times, for 5 minutes 
each, in Wash Buffer to remove excess secondary antibody. The membrane 
was then incubated with electrochemical luminescence (ECL) enhancer 
reagents (GE Healthcare) for 3 minutes. Excess reagent was removed and the 
membrane was placed in an x-ray cassette. Proteins on the membrane were 
visualized using light sensitive hyperfilm (GE Healthcare), which were developed 
in a Hyperprocessor (Amersham Pharmacia). 
 
Membranes were stripped immediately and a maximum of three times. 
Antibodies were removed by incubating the membrane in Stripping Buffer for 30 
minutes at 550C. Membranes were then washed three times, for 3 minutes each, 
in Wash Buffer and stored in PBS at 40C. 
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Table 5: Primary antibodies for Western blot analysis 
Antibody Host Dilution 
Phospho-Akt T308 (4056) Cell Signalling Rabbit 1:500 
Phospho-Akt S473 (9271) Cell Signalling Rabbit 1:500 
Total Akt (9272) Cell Signalling Rabbit 1:1000 
Akt1 2H10 (2967) Cell Signalling Mouse 1:1000 
Akt2 5B5 (2964) Cell Signalling Rabbit 1:500 
Akt3 (4059) Cell Signalling Rabbit 1:1000 
β-actin AC-15 (A5441) Sigma Mouse 1:2000 
Phospho-BAD S136 (sc-7999) Santa Cruz Rabbit 1:500 
FASN (ab22759) Abcam Rabbit 1:500 
Filaggrin (219-234) Zymed Rabbit 1:1000 
Phospho-FOXO1A S256 (ab38501) Abcam Rabbit 1:1000 
Phospho-GSK3β S9 (9323) Cell Signalling Rabbit 1:1000 
HA Clone HA-7 (H3663) Sigma Mouse 1:5000 
HMG CoA Reductase (07-457) Upstate Rabbit 1:500 
IRS-1 (06-248) Millipore Rabbit 1:1000 
Phospho-IRS-1 S636/639 (2388) Cell Signalling Rabbit 1:500 
IRS-2 L1326 (3089) Cell Signalling Rabbit 1:1000 
Keratin-1 AF109 (PRB-149P) Covance Rabbit 1:1000 
Keratin-14 AF64 (PRB-155P) Covance Rabbit 1:2000 
Phospho-mTOR S2448 (2971) Cell Signalling Rabbit 1:1000 
Phospho-mTOR S2481 (2974) Cell Signalling Rabbit 1:1000 
mTOR (2972) Cell Signalling Rabbit 1:500 
Phospho-NDRG1 T346 (3217) Cell Signalling Rabbit 1:1000 
Phospho-PKCα S657 (sc-12356) Santa Cruz Rabbit 1:1000 
Phospho-PKCα/β II T638/641 (9375) Cell Signalling Rabbit 1:1000 
Phospho-S6 S240/244 (2215) Cell Signalling Rabbit 1:1000 
S6 5G10 (2217) Cell Signalling Rabbit 1:1000 
Phospho-S6K T389 (9205) Cell Signalling Rabbit 1:1000 
SREBP1 H160 (sc-8984) Santa Cruz Rabbit 1:1000 
SREBP2 H164 (sc-5603) Santa Cruz Rabbit 1:1000 
Phospho-Tyr PY20 (610007) BD Transduction Labs. Mouse 1:200 
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Table 6: Secondary antibodies for Western blot analysis 
Antibody Host Dilution 
Raised 
against 
Anti-mouse (ab6789) Abcam Goat 1:5000 
Mouse 
IgG 
Anti-rabbit (111-035-144) Jackson 
Immunoresearch 
Goat 1:5000 
Rabbit 
IgG 
 
 
2.5.9 Western blot quantification and statistical analysis 
Densitometry analysis for Western blots was determined using Image J software 
for n=3 unless otherwise stated. Samples were normalised to the loading 
controls, β-actin or keratin-14, or to the total protein (see Appendix 8.8 for 
densitometry data tables). Two-tailed Student’s T-test performed using Microsoft 
Excel TTEST function. 
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2.6 Molecular biology 
2.6.1 Materials and solutions 
Tris-acetate electrophoresis (TAE) Buffer  
40 mM Tris-acetate (BDH) 
1 mM EDTA (BDH), pH 8.0 
 
Agarose-TAE gel 
TAE Buffer 
1-2% Agarose (Invitrogen) 
 
6X DNA Loading Buffer 
50 mM EDTA  
30% (v/v) Glycerol  
0.25% (w/v) Bromophenol blue  
 
2.6.2 Ribonucleic acid (RNA) extraction 
RNA was extracted from cells using Qiagen RNeasy kit (Qiagen) according to 
manufacturer’s instructions. All samples were lysed in RNeasy lysis buffer 
(RLT), with the addition of 10 µl β-mercaptoethanol per 1 ml RLT, and all steps 
were performed at RT. For RNA isolation from cells in culture, 600 µl RLT was 
added per well of a 6-well cell-culture plate and the lysate was transferred into 
an eppendorf tube. For obtaining RNA from tissue, the tissue was disrupted 
using a mortar and pestle with the addition of liquid nitrogen. The tissue was 
ground up into a powder form and transferred into an eppendorf tube. The tissue 
was then lysed in 600 µl RLT. 
 
Lysed samples were homogenized by transferring the samples onto 
Qiashredder spin columns (Qiagen) and centrifuging at 14,000 rpm for 2 
minutes. The samples were mixed with one volume of 70% (v/v) analytical grade 
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ethanol (Sigma-Aldrich) and transferred onto RNeasy mini columns. The 
samples were centrifuged at 14,000 rpm for 15 seconds to attach the RNA to the 
spin column.  The columns were then washed by the addition of 350 µl RW1 
buffer, centrifugation at 14,000 rpm for 15 seconds with the flow-through 
discarded. Deoxyribonucleic acid (DNA) digestion was performed using RNase-
free DNase kit (Qiagen) according to manufacturer’s instructions. In brief, 10 µl 
DNase 1 mixed with 70 µl RDD buffer was incubated on the columns for 15 
minutes. The columns were then washed again with 350 µl RW1 buffer and the 
flow-through discarded. The columns were washed twice more with 500 µl RPE 
buffer and the flow-through discarded. Finally the RNA was eluted by incubating 
30 µl DNA/RNA-free water on the column for 1 minute followed by centrifugation 
at 14,000 rpm for 1 minute. RNA was quantified using a nanodrop (ND1000 
spectrophotometer) and stored at -800C.  
 
2.6.3 Reverse-transcriptase-polymerase chain reaction (RT-PCR) 
Complementary DNA (cDNA) synthesis was carried out using the iScript select 
cDNA synthesis kit (Biorad), according to manufacturer’s instructions. Each 
reaction contained 4µl 5X iScript select reaction mix, 2 µl Oligo(dT) primer, 1 µl 
iScript reverse transcriptase, 1 μg RNA and x µl DNA/RNA-free water (Sigma-
Aldrich) to make a total volume of 20 µl. Reactions were performed in thin-
walled polymerase chain reaction (PCR) tubes incubated at 420C for 90 minutes 
followed by 850C for 5 minutes to stop the reaction. Samples were stored at -
200C. 
 
PCR was performed using Biotaq core kit (Bioline), according to manufacturer’s 
instructions. Reactions contained 2 µl 10X NH4 buffer, 1 μl 50 mM magnesium 
chloride (MgCl2), 0.4 μl 10 mM deoxyribonucleotide triphosphate (dNTP) mix, 
0.25 μl Taq polymerase, 0.5 μl 40 μM forward and reverse primer mix (see 
Table 7), 1 μl cDNA from the cDNA synthesis reaction and x µl DNA/RNA-free 
water to make a total volume of 20 µl. PCRs were performed in thin-walled PCR 
tubes as follows; 940C for 4 minutes, then 30 cycles (number of cycles optimized 
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for each gene, see Table 7) of 940C for 30 seconds, 600C for 1 minute and 720C 
for 1 minute followed by the final elongation step of 720C for 5 minutes. Samples 
were stored at -40C and analyzed on an agarose gel (see section 2.6.4). 
 
Table 7: PCR primers 
Gene Species Forward Reverse 
Cycle 
No. 
FASN Rat GGC ATC ATT GGG CAC TCC TT GCT GCA AGC ACA GCC TCT CT 30 
HMG CoA 
Reductase 
Rat AAC CTG CTG CCA TAA ACT GGA T ACC ACC TTG GCT GGA ATG AC 30 
IRS-1 Rat CTG ACA TTG GAG GTG GGT CT GCA AGG CAA GAG CTT ACC AC 25 
IRS-2 Rat CCA CAC ACC TGT CCT CAT TG CTT ATG AAG GCT GAC GAG GC 25 
β-actin Rat GAG CGG TTC CGA TGC CCT GAG GCC GGA CTC ATC GTA CTC CTG 20 
 
2.6.4 Agarose gel analysis 
Agarose gel analysis was performed according to Voytas et al [364]. PCR 
products were analyzed on a 1-2% agarose-TAE gel, with the percentage of 
agarose depending on the size of the PCR product (Increased agarose 
percentage gel used for smaller PCR products). For a 1% gel, 1 g agarose was 
dissolved in 100 ml TAE Buffer by heating for 2 minutes on full power in a 
microwave. The solution was then cooled to approximately 500C before addition 
of 5 µl 10 mg/ml ethidium bromide (Sigma-Aldrich). The solution was poured into 
gel cassette with an inserted gel comb and allowed to set at RT. Samples were 
prepared with the addition of 6X DNA Loading Buffer and DNA/RNA-free water 
to give a final volume of 20 µl. The gel was then submerged in TAE buffer and 
the samples were loaded along with a DNA ladder (Easy Ladder, Bioline). The 
gel was run at 100 V for 35 minutes and then the DNA was visualized under 
ultraviolet (UV) light. 
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2.6.5 RT-PCR quantification and statistical analysis 
Densitometry analysis for RT-PCR from agarose gel was determined using 
Image J software for n=3 unless otherwise stated. Samples were normalised to 
the loading control, β-actin (see Appendix 8.9 for densitometry data tables).  
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Chapter 3 – Rapamycin treatment increases PI3K/Akt signalling 
through regulation of IRS proteins in keratinocytes 
3.1 Introduction 
 
cSCC is one of the most common Caucasian skin cancers with 
immunosuppression and UV exposure being the largest risk factors associated 
with the disease [41, 42, 365]. Rates of cSCC are increased up to 250-fold in 
immunosuppressed organ transplant recipients [63-65]. Transplant patients 
treated with the immunosuppressant, rapamycin, have reduced cSCC 
occurrence compared to patients on other immunosuppressants [1, 2]. However, 
the mechanism behind rapamycin-mediated SCC reduction remains unknown. 
 
Rapamycin inhibits mTORC1 [91], a large multi-subunit protein that lies 
downstream of the PI3K/Akt pathway. In some cell types, negative feedback 
loops exist between mTORC1 signalling and the receptor accessory proteins, 
IRS-1 (Figure 3-1) and IRS-2 [238-241]. For example, mTORC1 can directly 
phosphorylate IRS-1 at S636/639, interrupting the docking of IRS-1 to PI3K and 
down-regulating the PI3K/Akt pathway in response to growth factor stimulation 
[249]. In tumours where these mTORC1-dependent negative feedback loops are 
active, rapamycin treatment leads to activation of the PI3K/Akt pathway [256, 
257]. Therefore rapamycin can result in poor clinical outcome in some tumours 
due to activation of Akt and pro-survival signalling [256, 257].  
 
Whether the mTORC1-dependent negative feedback loops are active in 
keratinocytes and what the effects of rapamycin treatment are on Akt signalling 
in epidermis remains unclear. In wild-type mouse epidermis, prolonged 
rapamycin treatment has little effect on Akt phosphorylation [171, 178]. Over-
expression of Rheb in mouse epidermis also has little effect on Akt 
phosphorylation, despite activation of mTORC1 targets [178]. However, Akt 
phosphorylation at S473 is significantly increased in human skin of patients on 
the rapamycin analogue, everolimus [254], and rapamycin increases Akt T308 
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phosphorylation in mice with epithelial deletion of PTEN [171], suggesting that 
rapamycin treatment has the potential to activate the PI3K/Akt pathway in 
epidermis under certain conditions.  
 
 
Figure 3-1: The mTORC1-dependent negative regulation of IRS-1. mTORC1 
and S6K1 negatively regulate IRS-1 at the plasma membrane leading to a 
decrease in the PI3K/Akt pathway. Rapamycin inhibits these mTORC1-
dependent negative feedback loops, resulting in activation of PI3K/Akt 
signalling. 
 
Determining whether rapamycin treatment increases the PI3K/Akt pathway in 
epidermis is important for understanding the effects of rapamycin in skin and 
may provide insights into the tumour-suppressor role of rapamycin. If the 
mTORC1-dependent regulation of IRS proteins is absent from keratinocytes 
then the lack of up-regulation of PI3K signalling may contribute to rapamycin’s 
tumour-suppressor activity in skin. In contrast, the presence of mTORC1-
dependent feedback loops acting on IRS proteins in keratinocytes may activate 
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downstream molecules that contribute to the tumour-suppressing role of 
rapamycin in skin. 
 
3.1.1 Hypothesis 
 
Rapamycin activates the PI3K/Akt pathway if the mTORC1-dependent negative 
feedback loops to IRS-1 are active in keratinocytes. If the mTORC1-dependent 
negative feedback loops to IRS-1 are not present in keratinocytes, then 
rapamycin treatment will have little effect on the PI3K/Akt pathway. 
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3.2 Aims 
 
The aim was to determine the effects of rapamycin on PI3K/Akt signalling in 
epidermis: The following questions were addressed 
1) Does rapamycin treatment lead to an increase in Akt phosphorylation? 
2) Are any changes in Akt phosphorylation due to inhibition of the mTORC1-
dependent feedback loops acting on IRS proteins? 
3) Does rapamycin treatment affect phosphorylation of Akt substrates? 
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3.3 Results 
 
3.3.1 Rapamycin increases Akt phosphorylation in keratinocytes 
I investigated the effects of rapamycin treatment on Akt phosphorylation in 
cultured rat epidermal keratinocytes (REKs). The addition of rapamycin led to a 
dose-dependent increase in Akt phosphorylation at both S473 and T308 within 1 
hour of treatment, with Akt phosphorylation increased with rapamycin 
concentrations as low as 1 nM (Figure 3-2A). These changes were associated 
with inhibition of ribosomal protein S6 phosphorylation, consistent with previous 
reports [366, 367]. Treatment with rapamycin rapidly induced Akt 
phosphorylation at both S473 and T308, with little difference in their 
phosphorylation kinetics, suggesting a common activation mechanism for 
phosphorylation of the two sites in response to rapamycin (Figure 3-2B). A 
single treatment with rapamycin elevated Akt phosphorylation for at least 24 
hours (Figure 3-2C and D). 
 
Rapamycin also induced Akt phosphorylation in human primary keratinocytes, 
validating the use of the REKs as a model for primary keratinocyte 
differentiation. Rapamycin increased Akt phosphorylation in both 
undifferentiated and differentiating neonatal human epidermal keratinocytes 
(nHEKs) for at least 48 hours (Figure 3-3A). The nHEK differentiation is 
illustrated by an increase in the late terminal differentiation marker, filaggrin 
[368], and the characteristic differentiation-dependent biphasic activation of Akt 
[369]. Rapamycin also increased Akt phosphorylation in differentiated 
keratinocytes (Figure 3-3B). 
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Figure 3-2: Rapamycin increases Akt phosphorylation in cultured rat 
epidermal keratinocytes (REKs). A) Immunoblot of Akt (S473 and T308) and 
S6 phosphorylation following 0, 1, 5 and 10 nM rapamycin treatment for 1 hour. 
B) Immunoblot of Akt (S473 and T308) and S6 phosphorylation after rapamycin 
treatment for 0, 10, 20, 30 and 60 minutes. Quantification of changes in Akt 
(S473 and T308) phosphorylation relative to total Akt determined by 
densitometry (n=1). C) Immunoblot of Akt (S473) and S6 phosphorylation 
following vehicle or rapamycin treatment for 2, 4, 6 and 8 hours. Mean 
densitometry for Akt (S473) phosphorylation relative to total Akt, + standard 
deviation (SD) (n=3). Two-tailed paired Student’s T-test, ***P<0.01, **P<0.05, 
*P<0.10. D) Immunoblot of Akt (S473) and S6 phosphorylation following either 
vehicle or rapamycin treatment for 24 hours.  
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Figure 3-3: Rapamycin increases phosphorylation of Akt in neonatal 
human epidermal keratinocytes (nHEKs). Cells seeded in 0.2 mM CaCl2 
overnight. A) Differentiation of cells initiated by changing CaCl2 concentration to 
1.2 mM. Cells treated with either vehicle or rapamycin for 0, 2, 4, 8, 24 and 48 
hours.  Immunoblot of Akt (S473) and S6 phosphorylation plus filaggrin. B) Cells 
grown in 1.2 mM CaCl2 for 48 hours before drug treatment. Immunoblot of Akt 
(S473) and S6 phosphorylation following vehicle or rapamycin treatment for 0, 2, 
4, 8 and 24 hours. 
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3.3.2 Rapamycin-induced Akt phosphorylation is due to inhibition of the 
mTORC1-dependent negative feedback loop acting on IRS-1 in 
keratinocytes and in an embryo epidermal explant culture 
 
 
In some cell types, rapamycin induces Akt phosphorylation by inhibition of the 
mTORC1-dependent negative feedback loops to IRS-1 [238-241, 259]. These 
feedback loops can regulate both IRS-1 and IRS-2, depending on cell type [242-
244]. Therefore I determined whether these feedback loops were present in 
keratinocytes and if induction of Akt by rapamycin was due to a loss of IRS 
regulation. 
 
The optimal concentration for the PI3K inhibitor, LY-294002, was initially 
determined by titration in REKs (Appendix 1-1A). LY-294002 inhibited Akt 
phosphorylation at both S473 and T308 and blocked the rapamycin-mediated 
increase in Akt S473 and T308 phosphorylation (Figure 3-4A). This 
demonstrates that rapamycin-induced Akt phosphorylation is due to signalling 
events upstream of PI3K in keratinocytes, which is compatible with rapamycin-
induced changes to IRS-1 status. 
 
I then monitored changes in IRS-1 and IRS-2 to determine whether rapamycin-
induced Akt phosphorylation was due to regulation of IRS proteins in 
keratinocytes. Rapamycin increased IRS-1 and, to a smaller extent, IRS-2 
protein levels after 4-6 hours of drug treatment and this was maintained for at 
least 8 hours (Figure 3-4B). Rapamycin increased the electro-mobility of IRS-1 
and IRS-2 (marked by *), which has been previously reported as being due to 
changes in phosphorylation of tyrosine and serine/threonine residues [245].  
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Figure 3-4: Rapamycin-induced Akt phosphorylation is accompanied by 
changes in IRS-1 and IRS-2 in REKs. A) Immunoblot of Akt (S473 and T308) 
and S6 phosphorylation after 1 hour pre-treatment with either vehicle or LY-
294002 followed by 1 hour treatment with either vehicle or rapamycin. B) 
Immunoblot of IRS-1 and IRS-2 plus Akt (S473) and S6 phosphorylation 
following vehicle or rapamycin treatment for 2, 4, 6 and 8 hours. Shift in electro-
mobility of IRS-1 and IRS-2 marked by *. 
 
An embryo epidermal explant model, previously developed and used as a skin 
experimental model by our group [4, 218], was used to determine whether 
rapamycin also induced changes in IRS-1 in epidermis. Rapamycin treatment 
significantly increased Akt phosphorylation and the total IRS-1 levels in the 
epidermal explant lysates (Figure 3-5) demonstrating that rapamycin treatment 
also regulated the IRS-1 protein in epidermis.    
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Figure 3-5: Rapamycin increases Akt phosphorylation and IRS-1 protein 
levels in epidermis. Embryo explant cultures were grown at the air-liquid 
interface for 72 hours in the presence of either vehicle or rapamycin. 
Immunoblot for Akt (S473) and S6 phosphorylation and total IRS-1 for protein 
lysates. Mean densitometry for Akt (S473) phosphorylation and total IRS-1 
relative to keratin-14, + SD (n=3). Two-tailed paired Student’s T-test, *P<0.10. 
 
Next I investigated the molecular mechanism for the increase in IRS levels in 
response to rapamycin in keratinocytes. Rapamycin had little effect on IRS-1 
and IRS-2 mRNA levels, measured by RT-PCR, over 24 hours (Figure 3-6), 
suggesting that the increases in IRS protein levels were not due to 
transcriptional regulation. 
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Figure 3-6: Rapamycin has little effect on the transcription of IRS-1 and -2 
in REKs. RT-PCR for changes in IRS-1 and IRS-2 mRNA following treatment 
with either vehicle or rapamycin for 0, 4, 8 and 24 hours. Mean densitometry for 
IRS-1 and IRS-2 mRNA normalised to actin levels, + SD (n=3). 
 
Previous reports show that IRS-1 is degraded by the 26S proteasome, which 
can be inhibited by the specific proteasome inhibitor, lactacystin [252, 370]. 
Lactacystin increased IRS-1 and also Akt phosphorylation, though less markedly 
than rapamycin (Figure 3-7A). This demonstrates that increased IRS-1 levels 
and stability have the downstream effect of increasing Akt serine 
phosphorylation in keratinocytes. 
 
To show that rapamycin increases the stability of the IRS-1 protein, I treated 
keratinocytes with rapamycin and lactacystin in the presence of the translational 
inhibitor, cycloheximide (Figure 3-7B). Cycloheximide treatment gradually 
decreased IRS-1 levels as the protein pool was degraded over time. Both 
rapamycin and lactacystin maintained IRS-1 levels in the presence of 
cycloheximide, confirming that the increase in IRS-1 in response to rapamycin 
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was due to an increase in protein stability and not by transcriptional or 
translational regulation.  
 
 
Figure 3-7: Rapamycin increases the stability of IRS-1 in REKs.          A) 
Immunoblot of IRS-1 plus Akt (S473) and S6 phosphorylation following either 
vehicle, rapamycin or lactacystin for 4 and 8 hours. B) Immunoblot of IRS-1 plus 
Akt (S473) and S6 phosphorylation after addition of cycloheximide and either 
vehicle, rapamycin or lactacystin for 0, 2, 4, 6 or 8 hours. 
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Rapamycin treatment increased the electro-mobility of IRS proteins in 
keratinocytes (Figure 3-4B), suggesting changes in IRS phosphorylation [245]. 
IRS-1 becomes phosphorylated at multiple tyrosine residues within its C-
terminus by activated receptor tyrosine kinases [246]. These phosphorylated 
tyrosine sites interact with SH2 domains of downstream substrates and lead to 
increased downstream signalling. For example, Y612 and Y632 are the major 
docking sites for PI3K [247]. Rapamycin treatment increased tyrosine 
phosphorylation of IRS-1 in keratinocytes, demonstrating that rapamycin 
promotes IRS-1 signalling (Figure 3-8A).  
 
In contrast, phosphorylation of serine residues in the C-terminal of IRS-1 can 
inhibit IRS-1 signalling in a number of ways, including disruption of the docking 
of PI3K [248]. IRS-1 is directly phosphorylated at S636/639 by mTORC1, which 
lies close to the tyrosine phosphorylation site Y632 [245, 249]. Changes in 
phosphorylation at this site could not be detected in basal keratinocytes (not 
shown); however rapamycin inhibited IRS-1 phosphorylation at S636/639 in 
response to insulin (Figure 3-8B). This demonstrates that the S636/639 site on 
IRS-1 is regulated by mTORC1 in keratinocytes, which probably contributes to 
an increase in the stability of IRS-1 in response to rapamycin and facilitates the 
phosphorylation of Y632.  
 
In summary, rapamycin inhibited the mTORC1-dependent negative feedback 
loops to IRS in keratinocytes, leading to increased Akt phosphorylation. These 
feedback loops regulated both IRS-1 and IRS-2 and were activated in response 
to insulin in keratinocytes. Rapamycin increased the stability and signalling of 
IRS-1, leading to activation of the PI3K/Akt pathway.  
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Figure 3-8: Rapamycin increases tyrosine phosphorylation and reduces 
S636/639 phosphorylation of IRS-1 in REKs. A) Immunoblot of phospho-
tyrosine of immunoprecipitated endogenous IRS-1 and immunoblot of Akt 
(S473) and S6 phosphorylation and IRS-1 for corresponding lysates following 
vehicle or rapamycin for 1 hour. B) Cells were serum-starved overnight and 
treated with vehicle or rapamycin for 1 hour followed by insulin for 15 minutes. 
Immunoblot of phospho-tyrosine of immunoprecipitated endogenous IRS-1 and 
immunoblot of IRS-1 (S636/639), Akt (S473) and S6 phosphorylation for 
corresponding lysates. 
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3.3.3 GSK3β S9, FOXO1A S256 and BAD S136 phosphorylation events are 
not primarily regulated by Akt in keratinocytes 
 
The effect of rapamycin treatment on Akt substrates was also monitored to 
establish the downstream pathways activated by rapamycin-induced Akt 
phosphorylation. Several well-known generic Akt substrates, GSK3β, FOXO1A 
and BAD [206-209], were monitored for changes in phosphorylation in response 
to rapamycin. There were few changes in phosphorylation of the Akt substrates 
tested in response to rapamycin (Figure 3-9A). Furthermore, Akt substrate 
phosphorylation was not reduced by treatment with Akt inhibitors, SH-5 and API-
2 [371], despite inhibition of Akt phosphorylation (Figure 3-9B). Optimal 
concentrations for Akt inhibitors were determined by titration in REKs (Appendix 
1-1B & C). This demonstrates that these proteins are probably not downstream 
of Akt in keratinocytes. In contrast, phosphorylation of GSK3β is inhibited by 
PI3K inhibition (Figure 3-9C).  
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Figure 3-9: Rapamycin treatment has little effect on GSK3β, FOXO1A and 
BAD phosphorylation in REKs. A) Immunoblot of GSK3β (S9), FOXO1A 
(S256), BAD (S136) and S6 phosphorylation following either vehicle or 
rapamycin for 2, 4, 6 and 8 hours. B) Immunoblot of Akt (S473), GSK3β (S9), 
FOXO1A (S256), BAD (S136) and S6 phosphorylation following either SH-5, 
API-2 or rapamycin for 2 hours. C) Immunoblot of GSK3β (S9), FOXO1A 
(S256), BAD (S136) and S6 phosphorylation after 1 hour pre-treatment with 
vehicle or LY-294002 followed by 1 hour treatment with either vehicle or 
rapamycin. 
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3.4 Discussion 
 
In this work I show that rapamycin treatment increases Akt phosphorylation by 
inhibition of the mTORC1-dependent negative feedback loops to IRS-1 and IRS-
2 in cultured keratinocytes and in the embryo explant model. Rapamycin inhibits 
phosphorylation of IRS-1 at S636/639, which correlates with an increase in IRS-
1 stability, IRS-1 tyrosine phosphorylation and downstream signalling. This 
demonstrates that inhibition of mTORC1 by rapamycin treatment results in an 
up-regulation of the PI3K/Akt pathway in cultured keratinocytes and embryo 
epidermis. 
 
This study is the first to demonstrate that the mTORC1-dependent negative 
feedback loop to IRS-1 is active in keratinocytes, which is supported by 
observations of Akt phosphorylation increasing in the skin of rapamycin-treated 
patients [254]. Activation of the PI3K/Akt pathway in response to rapamycin can 
have undesired effects in some tumours [258]. However, it is possible that 
activation of the PI3K/Akt pathway is protective in epidermis and inhibits the 
development of cSCCs. This would provide a further mechanism for rapamycin’s 
anti-tumour activity in skin. 
 
Rapamycin treatment increased IRS-1 stability in keratinocytes and inhibited 
phosphorylation of IRS-1 at S636/639, which lies close to the PI3K docking site 
at Y632 [245, 247, 249]. However, S636/639 is only one of several 
phosphorylation sites on IRS-1 regulated by mTORC1 signalling [240, 251, 372, 
373]. For example, S6K1 phosphorylates IRS-1 at S307, which inhibits the 
interaction of IRS-1 with the IR and reduces IRS-1 tyrosine phosphorylation 
[250, 251]. Therefore rapamycin probably inhibits the phosphorylation of multiple 
serine residues on IRS-1, adding to the stability and increased downstream 
signalling of IRS-1.  
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Rapamycin treatment increased the electromobility and the total levels of both 
IRS-1 and IRS-2 in cultured keratinocytes, suggesting that both proteins are 
regulated by mTORC1 signalling in epidermis. Furthermore rapamycin 
increased IRS-1 signalling in response to insulin in keratinocytes, demonstrating 
that IRS-1 lies downstream of the IR. This is supported by IRS-1 having reduced 
tyrosine phosphorylation in keratinocytes isolated from IR null mice, placing IRS-
1 downstream of the IR [255, 374]. In contrast, IRS-2 null mice have a normal 
epidermal phenotype [255], suggesting a less important role for IRS-2 in 
epidermis. However IRS-2 over-expression normalizes the IGF-1R knock-out 
phenotype, suggesting an alternative role for IRS-2 in epidermal homeostasis 
[173].  
 
Rapamycin treatment increased Akt phosphorylation at both S473 and T308, the 
two phosphorylation sites required for full activation of the kinase [191]. The 
similar phosphorylation kinetics of S473 and T308 in response to rapamycin 
(Figure 3-2B) suggests a common activation mechanism for the two 
phosphorylation sites. T308 is phosphorylated by PDK1, downstream of PI3K 
[188, 190], while S473 is phosphorylated by mTORC2, which is also 
downstream of PI3K, although the precise mechanism for mTORC2 activation is 
unknown [191, 261]. Therefore increased phosphorylation at both S473 and 
T308 can be explained by rapamycin increasing PI3K activity by inhibition the 
mTORC1-dependent negative feedback loops to IRS-1. 
 
The increase in both S473 and T308 phosphorylation in response to rapamycin 
strongly suggests an increase in Akt activity [191]. Rapamycin treatment had 
little effect on the phosphorylation of the well-known Akt substrates GSK3β, 
FOXO1A and BAD [206-209]. However, Akt inhibition also had little effect on the 
phosphorylation of these substrates, suggesting that Akt has cell-type specific 
down-stream substrates in keratinocytes. Therefore further studies are required 
in order to determine the specific Akt substrates in epidermis.   
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Activation of Akt in response to rapamycin could have different outcomes in 
epidermis depending on which of the two active Akt isoforms are 
phosphorylated. This is due to the isoforms having opposing roles in epidermis. 
Akt1 regulates terminal differentiation of keratinocytes and is down-regulated in 
cSCC, suggesting a tumour-suppressor role for Akt1 in epidermis [4, 218]. In 
contrast, Akt2 is induced developmentally and is up-regulated in cSCC [4, 218]. 
The most likely Akt isoform activated in response to rapamycin in epidermis is 
Akt1 due to its suggested tumour-suppressor role in epidermis [4]. Therefore, it 
is possible that rapamycin promotes Akt1 activation, which is sufficient to reduce 
the development of cSCCs. 
 
In conclusion, rapamycin treatment increases Akt phosphorylation, via inhibition 
of the mTORC1-dependent negative feedback loops to IRS-1 in keratinocytes 
(Figure 3-10). The activation of the PI3K/Akt pathway in response to rapamycin 
treatment could have different outcomes in epidermis depending on which of the 
two Akt isoforms are phosphorylated. Therefore it is important to determine 
which of the Akt isoforms are affected by rapamycin in keratinocytes. 
 
Figure 3-10: Rapamycin increases Akt phosphorylation by inhibition of the 
mTORC1-dependent negative feedback loop to IRS-1. Rapamycin inhibits 
mTORC1, preventing phosphorylation of IRS-1 at S636/639 and increasing IRS-
1 stability, leading to increased IRS-1 signalling and Akt phosphorylation.   
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Chapter 4 – Rapamycin treatment can selectively promote Akt1 
phosphorylation in epidermis 
4.1 Introduction 
 
There are two active Akt isoforms in epidermis, Akt1 and Akt2 [215, 217]. Akt1, 
the predominant isoform in adult skin, regulates terminal differentiation and the 
formation of the cornified layer in keratinocytes and is expressed in the granular 
layers (Figure 1-11) [218]. In contrast, Akt2 is expressed developmentally in the 
para-basal layers of the epidermis and is down-regulated in adult skin (Figure 1-
11) [218].  Akt3 is undetectable in epidermis but is present in cultured 
keratinocytes [217, 218]. 
 
CSCC is associated with changes in Akt. Akt2 is up-regulated in SCC, with Akt2 
phosphorylation probably correlating with tumour malignancy, suggesting that 
Akt2 activation may be important for tumour progression in epidermis (Figure 4-
1) [4]. In contrast, Akt1 is down-regulated in cSCC, suggesting a tumour-
suppressor role for Akt1 in epidermis (Figure 4-1) [4].  
 
In the previous chapter I demonstrated that rapamycin treatment activates the 
PI3K/Akt pathway in cultured keratinocytes through inhibition of the mTORC1-
dependent feedback loops to IRS proteins. This raises the question; which 
epidermal Akt isoforms are affected by rapamycin and can this be linked to 
rapamycin’s tumour suppressive activity in skin?  
 
Activation of Akt could have different outcomes in epidermis depending on which 
of the two Akt isoforms are phosphorylated. The most likely Akt isoform 
activated in response to rapamycin in epidermis is Akt1 due to its suggested 
tumour-suppressor role in epidermis [4]. It is possible that rapamycin promotes 
Akt1 activation, which is sufficient to reduce the development of cSCCs. 
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Figure 4-1: Akt1 expression is down-regulated and Akt2 is highly 
expressed and phosphorylated and in cSCC. Immunostaining for Akt (S473) 
phosphorylation and total Akt1 and Akt2 and H&E staining in UV-induced cSCC 
in transgenic mice with the Complete Early Region of Human Papillomavirus 8 
(HPV8–CER). The HPV8-CER transgenic mice were obtained from Dr. Herbert 
Pfister at the Institute of Virology, University of Cologne. Transgenic mice were 
generated, expressing HPV8-CER under the control of the human K14 
promoter, which targets transcription to the basal epithelial layer [375]. Mice 
received a single dose of 1 MED for UVA and 2 MED for UVB on a shaved 4 
cm2 area on the dorsam. The MED was determined at 0.5 J cm−2 for UVB and 
10 J cm−2 for UVA. Mice were killed at 3 weeks and the dorsal skin collected. 
Bar=50µm (Sully et al unpublished). 
 
4.1.1 Hypothesis 
 
Rapamycin selectively increases Akt1 phosphorylation, but not Akt2, in 
epidermis, which leads to protection from cSCC development due to Akt1’s 
tumour-suppressing role in epidermis.  
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4.2 Aims 
 
The aim was to determine the effects of rapamycin on the active Akt isoforms in 
epidermis: The following questions were addressed 
1) Which of the epidermal Akt isoforms are affected by rapamycin treatment? 
2) What is the effect of rapamycin treatment on phosphorylation of the Akt 
isoforms in response to UV radiation? 
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4.3 Results 
4.3.1 Rapamycin selectively increases Akt1 phosphorylation in 
keratinocytes and in epidermal explant cultures  
There were no isoform specific phospho-Akt S473 antibodies available. 
Therefore, phosphorylated Akt was immunoprecipitated from vehicle and 
rapamycin-treated keratinocytes and changes in the three Akt isoforms were 
detected by Western blot. Rapamycin increased the amount of 
immunoprecipitated phospho-Akt1, but had little effect on Akt2 and Akt3 (Figure 
4-2). This demonstrates that rapamycin selectively increases Akt1 
phosphorylation, but that changes in Akt2 and Akt3 phosphorylation are 
insensitive to rapamycin treatment in keratinocytes. 
 
Figure 4-2: Rapamycin treatment selectively increases Akt1 
phosphorylation in REKs. Cells were treated with either vehicle or rapamycin 
for 2 hours. Immunoblot for phospho-Akt (S473), Akt1, Akt2 & Akt3 from 
immunoprecipitated endogenous phospho-Akt (S473), left hand side. Mean 
densitometry, + SD (n=3), shown for each isoform relative to vehicle control. 
Immunoblot for corresponding lysates shown in right hand blot. 
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The epidermal Akt isoform responsive to rapamycin was also investigated using 
HA-tagged transfected Akt1 and 2 constructs (Appendix 1-2). Only HA-
immunoprecipitated Akt1 showed enhanced S473 phosphorylation in response 
to rapamycin, while immunoprecipitated HA-Akt2 levels remained constant. This 
finding confirms that rapamycin selectively increases Akt1 phosphorylation in 
keratinocytes. 
 
Akt isoform phosphorylation in response to rapamycin was also monitored using 
the mouse embryo epidermal explant model treated with rapamycin from E15.5 
to E18.5, a period where both Akt isoforms are active in epidermis and can be 
spatially separated due to their differing expression in differentiating 
keratinocytes [218]. Rapamycin treatment had undetectable effect on 
keratinocyte apoptosis and cellular stress (Appendix 1-3), suggesting little 
toxicity at the concentrations used. Rapamycin reduced S6 phosphorylation in 
the cytoplasm of the keratinocytes demonstrating inhibition of mTORC1 activity 
(Figure 4-3A). Rapamycin treated explants had significantly increased phospho-
Akt1 levels compared to the vehicle control, with changes in Akt1 
phosphorylation occurring in a dose-dependent manner (Figure 4-3A & B). In 
contrast, rapamycin slightly reduced phospho-Akt2 levels, suggesting that the 
rapamycin-induced Akt phosphorylation was specific to Akt1. 
 
In summary, rapamycin selectively increases Akt1 phosphorylation, but has no 
significant effect on the phosphorylation of Akt2 in both cultured keratinocytes 
and in the mouse emrbyo explant model. 
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Figure 4-3: Rapamycin increases Akt1 phosphorylation in the epidermis. 
Mouse embryo explant cultures were grown at the air-liquid interface for 72 
hours in the presence of either vehicle or rapamycin. A) Immunofluorescence for 
Akt (S473) & S6 phosphorylation. Bar=50µm. B) Mean Akt (S473) 
phosphorylation fluorescence, + SD, taken from n=3, with x3 fields taken per 
sample. Rapamycin significantly affects Akt1 phosphorylation, ANOVA P < 
0.005. 
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4.3.2 Rapamycin has no significant effect on total Akt1 and Akt2 levels in 
keratinocytes and in epidermal explant cultures 
 
Not only is Akt1 phosphorylation down-regulated in response to cSCC, but total 
levels of Akt1 are also reduced [4]. Akt2 expression is increased in cSCC [4]. 
Therefore, it was important to determine whether rapamycin was affecting the 
total protein levels of the two Akt isoforms. 
 
Both acute and prolonged rapamycin treatment had no significant effect on total 
Akt isoform levels in cultured keratinocytes (Figure 4-4A-C). Similarly, rapamycin 
had undetectable effects on both Akt1 and Akt2 protein levels in the mouse 
embryo explant model (Figure 4-5), demonstrating that rapamycin has little 
effect on the total levels of the epidermal Akt isoforms. 
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Figure 4-4: Rapamycin has no significant effect on total Akt levels in 
cultured keratinocytes. Immunoblot of S6 phosphorylation and total Akt1, Akt2 
and Akt3 following either vehicle or rapamycin for: A) 0, 2, 4, 8 or 24 hours in 
REKs. B) 24, 48 and 72 hours in REKs. C) 0, 24, 48 or 72 hours in nHEKs. 
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Figure 4-5: Rapamycin has little effect on total Akt levels in epidermis. 
Mouse embryo explants were grown at the air-liquid interface for 72 hours in the 
presence of either vehicle or rapamycin (n=3). Immunohistochemistry for Akt1 & 
Akt2. Bar=50µm. 
 
4.3.3 Rapamycin treatment does not protect against the UV-induced down-
regulation of Akt1 phosphorylation 
 
UV radiation is one of the largest risk factors associated with cSCC [365]. 
Therefore it is important to determine the effects of rapamycin on 
phosphorylation of the Akt isoforms in response to UV radiation. In adult mouse 
skin in vivo UV treatment down-regulates Akt1 expression and up-regulates Akt2 
phosphorylation within two days of UV exposure (Figure 1-13) (Sully et al 2012 
[235]).  
 
In the mouse embryo explant model, UV radiation significantly increased Akt2 
phosphorylation and significantly reduced Akt1 phosphorylation 24 hours after 
UV exposure (Figure 4-6A & B), similar to the results seen in vivo (Sully et al 
2012 [235]). This demonstrates that the embryo explant culture system models 
adult epidermal response to UV.  
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Rapamycin increased Akt1 phosphorylation, but had little effect on Akt2 
phosphorylation as reported previously. Rapamycin treatment did not protect 
against the down-regulation of Akt1 phosphorylation in response to UV in this 
model as Akt1 phosphorylation was reduced by UV in the presence of 
rapamycin. Surprisingly, rapamycin treatment inhibited the UV-induced increase 
in Akt2 phosphorylation. Therefore rapamycin treatment does not protect against 
UV-induced changes in Akt1 phosphorylation in this model, but may inhibit the 
UV-induced up-regulation of Akt2 phosphorylation.  
 
Figure 4-6: Rapamycin treatment does not protect against the UV-induced 
reduction of Akt1 phosphorylation in epidermis. Mouse embryo explants 
were grown at the air-liquid interface for 72 hours in the presence of either 
vehicle or rapamycin followed by a further 24 hours in culture after 0 or 6 
mJ/cm2 UV radiation. A) Immunofluorescence for Akt (S473) phosphorylation. 
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Bar=50µm. B) Mean Akt (S473) phosphorylation fluorescence, + SD, taken from 
vehicle n=3, 1 and 5 µM rapamycin n=2, with x3 fields taken per sample. Two-
tailed paired Student’s T-test, *P<0.10. 
 
Rapamycin did not protect against the changes in Akt1 and Akt2 expression in 
response to UV radiation in the mouse embryo explant model. Rapamycin 
treatment did not prevent the down-regulation of total Akt1 in response to UV 
(Figure 4-7). Additionally, rapamycin treatment had little effect on the up-
regulation of total Akt2 in response to UV (Figure 4-7). 
 
 
 
Figure 4-7: Rapamycin treatment does not protect against changes in Akt1 
and Akt2 expression in response to UV in epidermis. Mouse embryo 
explants were grown at the air-liquid interface for 72 hours in the presence of 
either vehicle or rapamycin followed by a further 24 hours in culture after 0 or 6 
 136 
mJ/cm2 UV radiation. Vehicle n=3, 1 and 5 µM rapamycin n=2. Immunostaining 
for total Akt1 and Akt2. Bar=50µm. 
 
The UV-induced up-regulation of Akt2 S473 phosphorylation and down-
regulation of Akt1 S473 phosphorylation suggest changes in activity of the 
kinase responsible for phosphorylating Akt at S473, mTORC2. However, UV 
radiation had undetectable effects on another mTORC2 substrate, PKCα, in the 
same skin model (Appendix 1-4A & B). This suggests that UV radiation has little 
effect on mTORC2 signalling in this model and that the changes in Akt 
phosphorylation in response to UV radiation may be due to changes in total 
protein levels (Figure 4-1) and not due to up-regulation of up-stream signalling 
pathways. 
 
In summary, despite rapamycin treatment selectively increasing Akt1 
phosphorylation, rapamycin does not protect against the down-regulation of Akt1 
in response to UV in epidermis. Surprisingly, rapamycin treatment may inhibit 
the up-regulation of Akt2 phosphorylation in response to UV, despite having no 
effect on Akt2 phosphorylation under normal conditions.  
 
4.3.4 Rapamycin treatment promotes Akt1 phosphorylation in epidermal 
explant cultures recovering from UV exposure 
 
An alternative possibility for rapamycin’s tumour suppressing role in epidermis 
through Akt1 signalling is that rapamycin affects phosphorylation and activation 
of Akt1 in epidermis recovering from UV.  Akt1 levels begin to be restored three 
days post acute UV radiation and are subsequently phosphorylated during days 
4 and 5 (see Figure 1-13 in Introduction) (Sully et al 2012 [235]).  
 
Therefore, we monitored UV-radiated explant skin cultures for effects of 
rapamycin on Akt1 phosphorylation approximately three days (66 hours) after an 
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acute UV dose when Akt1 levels are recovering but not yet substantially 
phosphorylated. Rapamycin increased epidermal Akt1 phosphorylation during 
recovery from UV (Figure 4-8). Therefore rapamycin treatment could promote 
recovery of Akt1 phosphorylation in skin following UV radiation. The rapamycin-
induced increase in Akt1 recovery could potentially be anti-tumourigenic if Akt1 
has a tumour-suppressing role in skin. 
 
 Figure 4-8: Rapamycin promotes epidermal Akt1 phosphorylation during 
recovery from UV exposure. Mouse embryo explants were grown at the air-
liquid interface for 72 hours in the presence of either vehicle or 5 µM rapamycin 
followed by a further 66 hours in culture after 0 or 6 mJ/cm2 UV radiation. 
Immunofluorescence for Akt (S473) phosphorylation (green) and total Akt1 (red) 
levels. Bar=50µm.  
 
4.3.5 Rapamycin treatment has no detectable effect on Akt 
phosphorylation in adult mouse epidermis 
 
The mouse embryo explant experiments provided a model where changes in 
Akt1 and Akt2 could be monitored in response to rapamycin due to both 
isoforms being phosphorylated and their spatial separation. However, it was 
important to determine the effect of rapamycin on Akt in adult skin where Akt1 is 
the predominantly phosphorylated isoform.  
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Changes in Akt isoform phosphorylation in response to rapamycin were 
monitored in the adult mouse explant model (Figure 4-9). Rapamycin reduced 
S6 phosphorylation in the cytoplasm of the keratinocytes in adult mouse 
epidermis demonstrating partial inhibition of mTORC1 activity. In contrast to the 
embryo explant model, rapamycin had little effect on Akt1 phosphorylation in 
adult mouse epidermis in vitro. Additionally, rapamycin had little effect on the 
total levels of both Akt1 and Akt2.  
 
 
Figure 4-9: Rapamycin has no detectable effect on Akt in mouse adult 
epidermal explants. Dorsal ear skin from adult C57 black mice was grown at 
the air-liquid interface for 24 hours in the presence of either vehicle or rapamycin 
(n=3). Immunostaining for Akt (S473) and S6 phosphorylation plus Akt1 and 
Akt2. Bar=50µm. 
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Prolonged rapamycin treatment also had no significant effect on Akt 
phosphorylation in mouse skin in vivo (Figure 4-10A). Adult mice were treated 
over a 10 day period with rapamycin at doses experimentally related to clinical 
rapamycin treatments [357]. Rapamycin treatment reduced S6 phosphorylation 
in epidermis, with some phosphorylation retained in the uppermost layers, and 
had little effect on total Akt1 levels, similar to the results seen in the mouse 
explant models. (Figure 4-10A & B). However, rapamycin treated mice had 
comparable epidermal Akt phosphorylation levels to the non-treated group, 
suggesting differences in the effects of rapamycin treatment on Akt 
phosphorylation in the embryo explant model and unstressed adult epidermis.  
 
Interestingly, regional up-regulation of S6 phosphorylation was observed in the 
upper layers of the epidermis in some of the rapamycin treated mice (Appendix 
1-5), despite down-regulation of S6 phosphorylation in other areas. Furthermore, 
the up-regulation of S6 phosphorylation correlated with increased keratin-6 
expression, suggesting that mTORC1 signalling is up-regulated in response to 
epidermal stress. Therefore it is important to study rapamycin activity in a whole 
animal or whole-patient context due to stress-activated mTORC1 signalling not 
being blocked at this dose of rapamycin. 
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Figure 4-10: Rapamycin treatment has no significant effect on Akt in 
mouse epidermis in vivo. C57 black mice, obtained from Dr. Matthew 
Hardman, University of Manchester, were treated with 8mg/kg rapamycin 
administered by IP injection over a 10 day period. A) Immunofluorescence for 
Akt (S473) and S6 phosphorylation plus total Akt1 and Akt2. Bar=50µm. B) 
Mean S6 phosphorylation fluorescence, + SD, with x3 fields taken per sample 
(Vehicle n=4, rapamycin treated n=5).  
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4.3.6 Differences between the co-localisation of Akt1 and mTORC1 activity 
in adult and E.18.5 skin  
 
The effects of rapamycin treatment on Akt1 phosphorylation in the embryo 
mouse explant model differs from the adult mouse skin models. This suggests 
that Akt1 may be regulated differently in adult skin.  In the embryo explant model 
Akt1 is regulated indirectly by mTORC1 via the mTORC-1-dependent feedback 
loops acting on IRS-1 [238-241]. However, it is possible that these mTORC1-
dependent feedback loops to IRS are not active in adult epidermis, with Akt1 
phosphorylation independent from mTORC1 activity.  
 
In order to understand whether mTORC1 regulated Akt1 in adult skin, Akt1 and 
Akt2 were co-localised with phosphorylated S6 to determine whether mTORC1 
was active in the same layers as Akt1 was expressed. Akt1 and phosphorylated 
S6 were present in the same layers in mouse epidermis at E18.5, the end-point 
of the embryo explant model, suggesting that mTORC1 is able to regulate Akt1 
(Figure 4-11A). This supports rapamycin treatment increasing Akt1 
phosphorylation, due to inhibition of the mTORC1-dependent feedback loops to 
IRS-1. Conversely, Akt1 does not co-localise with phosphorylated S6 in adult 
skin (Figure 4-11A). This suggests that mTORC1 is not predominantly active in 
the same layers where Akt1 is expressed and therefore mTORC1 may not be 
able to regulate Akt1 in adult skin. Interestingly, Akt2 co-localises with 
phosphorylated S6 in both E18.5 and adult skin (Figure 4-11B) suggesting that 
Akt2 could potentially be regulated by mTORC1 activity, however, this is not the 
case in the mouse embryo explant model (Figure 4-3). 
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Figure 4-11: Differences in co-localisation of Akt1 and Akt2 with 
phosphorylated S6 in E18.5 and adult epidermis. A) Akt1 (red) and 
phosphorylated S6 (green) in E18.5 CD1 mouse, adult CD1 mouse and adult 
human skin. Bar=50µm. B) Akt2 (green) and phosphorylated S6 (red) in E18.5 
mouse, adult mouse and adult human skin. Bar=50µm. 
 
 
4.3.7 mTORC1 is active in the same epidermal layers as Akt1 in 
hyperproliferative adult epidermis  
 
The differences in the co-localisation of Akt1 with mTORC1 activity questions 
whether the embryo explant model reflects normal adult skin, or adult human 
skin. The embryo explants are cultured from E15.5 to E18.5, a period in late 
epidermal development, and are thought to resemble developed new-born type 
skin at the end-point of the experiment. However, this model may more 
accurately resemble hyperproliferative epidermis, with an increased number of 
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epidermal cell layers being present due to keratinocyte proliferation, resulting in 
Akt1 expression and mTORC1 signalling occurring in the same cellular layers. 
This raises the question whether Akt1 can be regulated by mTORC1 signalling 
in hyperproliferative adult epidermis? 
 
In order to understand whether mTORC1 regulated Akt1 in hyperproliferative 
adult skin, Akt1 was co-localised with phosphorylated S6 in UV exposed 
hyperproliferative mouse epidermis in vivo. In untreated adult mouse epidermis 
Akt1 did not co-localise with phosphorylated S6 (Figure 4-12; day 0), similar to 
previous results (Figure 4-11). In hyperproliferative epidermis recovering from 
UV exposure Akt1 was predominantly expressed in the same epidermal layers 
as where phosphorylated S6 was present (Figure 4-12; days 2, 4 and 5). This 
suggests that Akt1 can be regulated by mTORC1 activity in adult 
hyperproliferative epidermis.  
 
In summary, Akt1 is regulated by mTORC1 activity in embryo epidermis, but is 
independent from mTORC1 in unstressed adult epidermis probably due to 
mTORC1 being predominantly active in different epidermal layers to Akt1 
expression. In hyperproliferative adult epidermis mTORC1 activity and Akt1 and 
present in the same epidermal layers suggesting that mTORC1 also regulates 
Akt1 in hyperproliferative adult epidermis. Therefore rapamycin may promote 
Akt1 phosphorylation in hyperproliferative adult epidermis following UV 
exposure.  
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Figure 4-12: Phosphorylated S6 and Akt1 co-localise in hyperproliferative 
UV-exposed adult mouse epidermis in vivo. A) Immunofluorescence for 
phosphorylated Akt (S473) (left hand panel) and co-localisation of Akt1 (red) 
with phosphorylated S6 (green) in adult mouse epidermis, 0-5 days after UV 
radiation. Female Skh:hr-1 mice 8-10 weeks old, obtained from Dr. Vivienne 
Reeve at the Veterinary Science breeding colony, University Sydney, were 
irradiated with a single exposure of 3 × the MEdD of SSUV radiation from a 
fluorescent UVA and UVB tube source on the dorsum, and mid-dorsal skin 
samples were taken before and at 1-5 days after.  Bar=50µm. 
 145 
4.4 Discussion 
 
In this work I show that rapamycin selectively increases Akt1 phosphorylation, 
but has little effect on Akt2 in cultured keratinocytes and in the mouse embryo 
explant model. Rapamycin does not protect against the UV-induced down-
regulation of epidermal Akt1, but promotes the recovery of Akt1 phosphorylation 
following UV exposure in skin culture. These findings show that rapamycin is 
opposing the effects of UV radiation, the most significant epidermal carcinogen, 
on Akt1 activity and suggest another mechanism for rapamycin’s anti-tumour 
activity in epidermis.  
 
Rapamycin treatment selectively increased Akt1 phosphorylation and slightly 
reduced the phosphorylation status of the Akt2 isoform in cultured keratinocytes 
and the mouse embryo explants. The mechanism behind selective 
phosphorylation of epidermal Akt1 by rapamycin-mediated mTOR inhibition is 
unknown. Possible mechanisms for selectivity include restricted Akt isoform 
expression and differential regulation by extracellular stimuli (reviewed by [376]). 
 
The selectivity of rapamycin is not due to restricted expression patterns of the 
Akt isoforms as mTORC1 activity, accounted for by phosphorylation of its 
substrate S6, overlaps with both Akt1 and Akt2 expression in embryo epidermis 
(Figure 4-11). The presence of Akt2 in the same cell layers as active mTORC1 
means that rapamycin can potentially phosphorylate both isoforms. However 
this is not the case as rapamycin selectively phosphorylates Akt1.  
 
Another possibility is that the Akt isoforms have different upstream regulation. In 
embryo epidermis we can predict that Akt1 is downstream of IRS-1 and 
therefore regulated by the mTORC1-dependent feedback loops acting on IRS-1 
and that Akt2 is regulated by alternative stimuli and is therefore independent 
from mTORC1 signalling.  
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Rapamycin treatment has little effect on Akt1 phosphorylation in unstressed 
adult mouse skin. This is supported by a lack of increase in Akt phosphorylation 
in response to rapamycin in other mouse models [171, 178] and suggests a 
difference in Akt1 regulation by mTORC1 activity in adult and E18.5 epidermis, 
the end-point of the embryo explant experiment. In E18.5 epidermis mTORC1 is 
active in the same cell layers as where Akt1 is expressed (Figure 4-11A), 
resulting in Akt1 being regulated by mTORC1 via the mTORC1-dependent 
negative feedback loops acting on IRS [238-241]. In unstressed adult epidermis, 
Akt1 expression is separated from the cell layers where mTORC1 is 
predominantly active making Akt1 independent of mTORC1 activity (Figure 4-
11A). This provides an explanation for why rapamycin treatment does not up-
regulate Akt1 in adult skin in these models. These differences in Akt1 regulation 
by mTORC1 must therefore be considered when investigating the effects of 
rapamycin in epidermis as data in cultured keratinocytes may not translate into 
in vivo murine models. 
 
Akt1 also co-localises with mTORC1 activity in hyperproliferative adult mouse 
epidermis suggesting that mTORC1 can regulate Akt1 in adult epidermis under 
certain conditions. Therefore rapamycin has the potential to increase Akt1 
phosphorylation in adult epidermis. Patients with advanced solid tumours treated 
with everolimus had a significant overall increase in Akt S473 phosphorylation in 
skin, strongly suggesting that the mTORC1-dependent negative feedback loops 
acting on PI3K/Akt signalling are active in adult epidermis [254]. This is not due 
to changes in Akt expression or differences in everolimus plasma trough 
concentrations and with almost complete inhibition of S6 phosphorylation in 
epidermis of all patients [254]. Therefore it is important to look at the effects of 
rapamycin on Akt1 phosphorylation in human patient skin samples to confirm 
whether the mTORC1-dependent negative feedback loops, acting on IRS 
proteins, are active in human skin.  
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Rapamycin treatment did not protect against the UV-induced down-regulation of 
Akt1 phosphorylation in epidermis. This could be due to UV radiation decreasing 
upstream signalling, independent of mTORC1 regulation, resulting in a reduction 
of Akt1 phosphorylation. Alternatively, the decrease in phosphorylated Akt1 may 
be due to the UV-induced reduction in total Akt1 levels leaving little Akt1 protein 
available for phosphorylation in response to rapamycin. Either way, the lack of 
protection against the UV-induced down-regulation of Akt1 in response to 
rapamycin suggests that rapamycin’s tumour-suppressing role in skin is not due 
to maintaining Akt1 phosphorylation following UV radiation. 
 
In skin culture rapamycin treatment promotes the recovery of Akt1 
phosphorylation in response to UV radiation. UVB radiation reduces epidermal 
barrier function [343, 345, 346] and Akt1 is linked with maintaining epidermal 
barrier integrity [218]. I propose that UV-mediated Akt1 downregulation 
compromises epidermal barrier activity. Mild epidermal barrier defects have 
previously been linked to skin carcinogenesis through a mechanism involving 
interactions between the barrier-defective epidermis and its underlying stroma 
[377]. In addition, the barrier is the primary defense against further carcinogen 
(e.g. further UV) entry. Rapamycin may accelerate barrier recovery following UV 
exposure by restoring Akt1 phosphorylation and protect against further UV-
damage. Essential future work is to find whether UV-mediated tumourigenesis is 
affected in mouse models with reduced Akt1. 
 
Rapamycin treatment may also inhibit the UV-induced increase in Akt2 
phosphorylation in epidermis, suggesting an alternative mechanism for 
rapamycin’s tumour-suppressing role in skin. The variation in Akt2 
phosphorylation in the embryo explant experiment was relatively high (Figure 4-
6B) and therefore further studies are required to confirm that rapamycin 
treatment can inhibit the up-regulation of Akt2 phosphorylation in response to 
UV radiation. The mechanism for rapamycin inhibiting Akt2 phosphorylation in 
response to UV is unclear, although mTORC1 does have the potential to 
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regulate Akt2 phosphorylation as mTORC1 is active in the same cell layers as 
Akt2 is expressed in both adult and embryo epidermis (Figure 4-11B). Akt2 
activation is probably linked to tumour progression in epidermis as Akt2 is up-
regulated in response to UV and in cSCC [4, 237]. Therefore rapamycin 
treatment may also inhibit cSCC development through inhibition of Akt2 
phosphorylation in response to UV radiation.  
 
An up-regulation of Akt2 phosphorylation at S473 in response to UV radiation 
would require increased activity of the upstream kinases responsible, including 
mTORC2 [191]. Prolonged rapamycin treatment has been shown to inhibit 
mTORC2 activity in some cell types [5, 101]. Therefore, it is possible that 
prolonged rapamycin treatment inhibits mTORC2 activity, preventing the 
increase in Akt2 phosphorylation in response to UV radiation. Therefore it is 
important to determine the effects of rapamycin on mTORC2 activity in 
epidermis to establish whether rapamycin inhibits the UV-induced Akt2 
phosphorylation via mTORC2.  
 
 
In conclusion, rapamycin treatment can selectively activate Akt1 in epidermis, 
but has little effect on Akt2. Rapamycin may inhibit the up-regulation of Akt2 in 
response to UV radiation, but does not protect against the down-regulation of 
Akt1 in these experiments. However, rapamycin treatment increases recovery of 
Akt1 phosphorylation in epidermis following UV exposure. Increased Akt1 
phosphorylation may promote epidermal barrier integrity and provide a 
mechanism for rapamycin’s tumour-suppressive activity in skin.  
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Chapter 5 – Rapamycin treatment can increase mTORC2 
activity in epidermis 
5.1 Introduction 
 
mTORC2 is insensitive to acute rapamycin treatment, with the FKBP12-
rapamycin complex unable to bind to mTOR associated with rictor [92]. 
However, prolonged rapamycin treatment inhibits the assembly of mTORC2 in 
some cell types [5, 101]. It is unknown whether rapamycin inhibits mTORC2 in 
keratinocytes. 
 
mTORC2 promotes phosphorylation of Akt, PKCα/β/γ/ε and SGK1, with Akt 
being the best characterised substrate [92, 105, 191, 266, 267]. SGK1 is 
expressed in epidermis and may regulate epithelial sodium channel (ENaC) 
expression [269, 271, 272], which affects epidermal barrier activity [292, 293]. 
PKCε and PKCα are the only PKC isoforms regulated by mTORC2 that are 
expressed in epidermis [268, 294, 295]. PKCε is expressed in the basal layer 
and acts as a tumour promoter [296, 298, 299] and PKCα, expressed in the 
suprabasal layers, has a tumour-suppressor type role [307]. The two active Akt 
isoforms have opposing roles, with Akt2 up-regulated and Akt1 down-regulated 
in cSCC [4]. This raises the question; are both Akt isoforms under the control of 
mTORC2 in epidermis? 
 
mTORC2 activity has been linked with cancer, with mTORC2 activity important 
for malignant transformation in some settings [304-306]. This has led to the 
development of ATP-competitive mTOR inhibitors, which inhibit both mTORC1 
and mTORC2 [313-316]. The introduction of ATP-competitive mTOR inhibitors 
raises the question; would inhibition of mTORC1 and mTORC2 have the same 
effect as rapamycin treatment in epidermis and reduce cSCC occurrence? 
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5.1.1 Hypothesis 
 
Prolonged rapamycin treatment does not inhibit mTORC2 activity in epidermis. 
mTORC2 activity is important in rapamycin’s tumour suppressing effect in skin 
as it phosphorylates Akt1 and promotes Akt1’s tumour suppressing role in 
epidermis.  
 
The ATP-competitive mTOR inhibitors inhibit phosphorylation of both mTORC1 
and mTORC2 substrates in epidermis. The reduction in phosphorylation of Akt1 
and Akt2 in epidermis is predicted to be both tumour-promoting and tumour-
suppressing. Therefore, the effects of ATP-competitive mTOR inhibitors on 
epidermal tumourigenesis are unclear. 
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5.2 Aims 
 
The aim was to establish the effects of prolonged rapamycin treatment on 
mTORC2 activity and to gain insight into the role of mTORC2 in epidermis using 
ATP-competitive mTOR inhibitors. The following questions were addressed 
1) What are the effects of prolonged rapamycin treatment on mTORC2 substrate 
phosphorylation? 
2) Do ATP-competitive mTOR inhibitors have similar effects on mTORC2 activity 
and Akt phosphorylation as rapamycin treatment?  
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5.3 Results 
5.3.1 Rapamycin treatment increases phosphorylation of mTORC2 
substrates in keratinocytes 
 
The ATP-competitive mTOR inhibitor, Torin-1, that targets both mTOR 
complexes, was used to determine whether SGK1, Akt and PKCα (one of two 
isoforms regulated by mTORC2 and expressed in epidermis [268, 294, 295]) 
were downstream of mTOR in cultured keratinocytes [140, 313]. Torin-1 is highly 
selective for mTOR over related kinases and a screen of 353 diverse kinases 
identified no significant off-target effects [313]. Acute treatment with Torin-1 
inhibited phosphorylation of mTORC1 substrate, S6, and phosphorylation within 
the HM of mTORC2 substrates, Akt and PKCα and also phosphorylation of 
NDRG1 (which is a biomarker for SGK1 activity), at concentrations as low as 10 
nM (Figure 5-1A & B). Torin-1 had little effect on PKCα phosphorylation within 
the control TM site, as predicted, due to this phosphorylation event being 
independent from growth factor signalling (Appendix 1-6) [266]. 
 
However, PKCα phosphorylation within the HM was insensitive to Torin-1 in 
keratinocytes cultured in high CaCl2 concentrations (Figure 5-1B). Therefore 
inhibition of mTORC2 does not completely abolish PKCα phosphorylation within 
the HM in the presence of calcium. Inactivation of mTORC2 also fails to fully 
inhibit PKCα in other cell types [268]. This may be due to calcium-dependent 
autophosphorylation of PCKα at its HM domain, as demonstrated for other 
conventional PKCs [378, 379]. Alternatively, PKC may be phosphorylated within 
the HM by another kinase activated by calcium, yet to be identified. 
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Figure 5-1: Torin-1 inhibits mTORC1 and mTORC2 substrate 
phosphorylation in keratinocytes. Cells were treated with 0, 1, 10 or 100 nM 
of Torin-1 for 1 hour. A) Immunoblot of Akt (S473), NDRG1 (T346), PKCα 
(S657) and S6 phosphorylation in REKs. B) nHEKs seeded in 0.2 mM CaCl2 
overnight followed by either 0.2 or 1.2 mM CaCl2 for a further 24 hours before 
drug treatment. Immunoblot of Akt (S473), NDRG1 (T346), PKCα (S657) and S6 
phosphorylation in nHEKs. 
 
Over prolonged periods, low concentrations of Torin-1 increased Akt T308 
phosphorylation and failed to inhibit S473 phosphorylation (Figure 5-2A; note 
that S473 is an mTORC2 substrate but T308 is not). This is consistent with the 
regulatory feedback loop between mTORC1 and IRS-1 being active in 
keratinocytes, with prolonged mTORC1 inhibition leading to PI3K 
hyperactivation and increased phosphorylation of Akt at T308, similar to 
rapamycin treatment (see Chapter 3) [238-241].  
Furthermore, higher concentrations of Torin-1 were required to inhibit Akt S473 
phosphorylation, but not NDRG1 phosphorylation, over prolonged periods of 
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drug treatment (Figure 5-2B). This is probably due to PI3K hyperactivation 
following prolonged mTORC1 inhibition leading to mTORC2 acitvation and 
phosphorylation of some mTORC2 substrates, as reported previously [260, 261, 
380]. Therefore, these data suggest that in keratinocytes prolonged mTORC1 
inhibition can effectively activate mTORC2, via activation of PI3K, as reported in 
some other cell-types [380]. Higher concentrations of Torin-1 are required at 
longer timepoints to fully inhibit mTORC2 signalling and overcome the increase 
in PI3K activity [380]. 
 
 
Figure 5-2: Higher concentrations of Torin-1 are required to inhibit Akt 
phosphorylation over prolonged periods in REKs. A) Immunoblot of Akt 
(S473 and T308) and S6 phosphorylation following either vehicle or 100 nM 
Torin-1 for 2, 4, 8 or 24 hours. B) Immunoblot of Akt (S473), NDRG1 (T346) and 
S6K (T389) and S6 phosphorylation following 0, 100, 250 or 500 nM Torin-1 for 
24 hours.  
 
Prolonged rapamycin treatment (24 hour) has been reported to inhibit mTORC2 
in some cell types [5, 101]. To address whether rapamycin inhibited mTORC2 in 
keratinocytes, I monitored changes in phosphorylation of mTORC2 substrates in 
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response to 24 hour rapamycin treatment in cultured REKs. Rapamycin did not 
inhibit phosphorylation of the mTORC2 substrates in REKs (Figure 5-3A). 
Surprisingly, rapamycin treatment increased phosphorylation of Akt, PKCα and 
NDRG1, suggesting an increase in mTORC2 activity. This finding is consistent 
with the proposal that sustained mTORC1 inhibition in keratinocytes causes 
hyperactivation of PI3K signalling and activation of mTORC2 (see previous 
section). 
 
mTORC2 substrate phosphorylation was also monitored in undifferentiated and 
differentiating nHEKs to confirm the finding in REKs. Prolonged (24 hour) 
rapamycin treatment increased phosphorylation of Akt and PKCα in 
undifferentiated keratinocytes (low calcium - Figure 5-3B), similar to the result 
seen in the REKs. In differentiated nHEKs (high calcium – Figure 5-3B) PKCα 
phosphorylation was independent from rapamycin treatment, as had been found 
with Torin-1 (Figure 5-1B). However, prolonged (24 hour) rapamycin treatment 
inhibited phosphorylation of NDRG1 in both undifferentiated and differentiated 
nHEKs, suggesting that the regulation of NDRG1 in response to rapamycin is 
cell-type specific. 
 
There was little change in PKCα phosphorylation at the control TM site, which is 
growth-factor insensitive, in response to rapamycin (Appendix 1-6), similar to the 
result seen with Torin-1 treatment. 
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Figure 5-3: Rapamycin treatment increases phosphorylation of some 
mTORC2 substrates in keratinocytes. A) Immunoblot of Akt (S473), NDRG1 
(T346), PKCα (S657) and S6 phosphorylation following vehicle or rapamycin for 
24 hours in REKs. B) nHEKs were seeded in 0.2 mM CaCl2 overnight and then 
either grown in 0.2 or 1.2 mM CaCl2 for 24 hours in the presence of vehicle or 
rapamycin. Immunoblot of Akt (S473), NDRG1 (T346), PKCα (S657) and S6 
phosphorylation. 
 
In summary, the ATP-competitive mTOR inhibitor Torin-1 inhibits 
phosphorylation of mTORC1 and mTORC2 substrates in keratinocytes (Figure 
5-4).  However, prolonged inhibition of mTORC1 with Torin-1 in keratinocytes 
can effectively activate mTORC2, most likely via activation of PI3K (Figure 5-2 
and 5-4).  In agreement, sustained mTORC1 inhibition by rapamycin increased 
mTORC2 substrate phosphorylation, showing that rapamycin may increase 
mTORC2 activity in cultured keratinocytes (Figure 5-4).  
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Figure 5-4: Prolonged inhibition of mTORC1 in keratinocytes can activate 
mTORC2. A) Acute Torin-1 treatment inhibits mTORC1 and mTORC2, leading 
to reduced Akt S473 phosphorylation. B) Prolonged Torin-1 treatment inhibits 
mTORC1-dependent regulation of IRS-1 leading to hyperactivation of PI3K. 
PI3K activates PDK1 leading to increased Akt T308 phosphorylation. PI3K also 
activates mTORC2, reducing the effect of Torin-1 on Akt S473 phosphorylation. 
C) Rapamycin treatment inhibits mTORC1-dependent regulation of IRS-1 
leading to hyperactivation of PI3K. Activated PI3K increases Akt T308 
phosphorylation via activation of PDK1, and S473, via activation of mTORC2. 
 
5.3.2 Rapamycin treatment increases mTORC2 substrate phosphorylation 
in mouse embryo explants 
 
The effects of rapamycin and ATP-competitive mTOR inhibitors on mTORC2 
substrates were investigated in the mouse embryo explant model in order to 
confirm the findings seen in cultured keratinocytes. Torin-1 had little effect on 
keratinocyte apoptosis and cellular stress (Appendix 1-6), suggesting little 
toxicity at the concentrations used. Torin-1 inhibited both S6 and PKCα 
phosphorylation demonstrating successful inhibition of the substrates for both 
mTOR complexes in epidermis (Figure 5-5A & B). The phospho-NDRG1 
antibody could not detect protein by immunohistochemistry. Similar results for 
S6 and PKCα phosphorylation were also seen with an alternative ATP-
competitive mTOR inhibitor, KU-0063794 (Appendix 1-7) [315]. 
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Figure 5-5: Torin-1 inhibits mTORC1 and mTORC2 substrate 
phosphorylation in epidermis. Mouse embryo explants were grown at the air-
liquid interface for 72 hours in the presence of vehicle or Torin-1. A) 
Immunofluorescence for PKCα (S657) and S6 phosphorylation. Bar=50µm. B) 
Mean PKCα (S657) phosphorylation fluorescence, + SD (n=1) with x4 fields 
taken per sample. Two-tailed paired Student’s T-test, *P<0.10. 
 
In contrast to Torin-1, rapamycin treatment increased Akt1 and PKCα 
phosphorylation in the embryo explant model (Figure 5-6 & B), suggesting an 
increase in mTORC2 activity, similar to the result seen in cultured keratinocytes 
(Figure 5-3). Rapamycin inhibited S6 phosphorylation, demonstrating successful 
inhibition of mTORC1 in this model (Figure 5-6A).  
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Figure 5-6: Rapamycin increases mTORC2 substrate phosphorylation in 
epidermis. Mouse embryo explants were grown at the air-liquid interface for 72 
hours in the presence of vehicle or rapamycin. A) Immunofluorescence for Akt 
(S473), PKCα (S657) and S6 phosphorylation. Bar=50µm. B) Mean PKCα 
(S657) phosphorylation fluorescence, + SD (n=3) with x3 fields taken per 
sample. Rapamycin treatment significantly affects PKCα (S657) 
phosphorylation, ANOVA P<0.063. 
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5.3.3 ATP-competitive mTOR inhibitors at high concentrations reduce Akt1 
phosphorylation in foetal explants 
 
In the previous chapter I demonstrated that rapamycin treatment increased Akt1 
phosphorylation in an organ culture model, suggesting a mechanism for 
rapamycin’s tumour suppressing role in epidermis. Therefore, it was important to 
determine the effect of mTORC1 and mTORC2 inhibition by ATP-competitive 
inhibitors on Akt phosphorylation in epidermis.  
 
At low concentrations, Torin-1 increased phosphorylation of both Akt1 and Akt2 
at S473 in the mouse embryo explant model (Figure 5-7A & B), supporting the 
findings in cultured keratinocytes (Figure 5-2) and in previous studies [380], that 
low concentrations of Torin-1 result in an up-regulation of mTORC2 activity, 
probably due to PI3K hyper-activation. However the effects of low 
concentrations of Torin-1 on epidermal Akt phosphorylation differ from 
rapamycin treatment as Torin-1 increased the phosphorylation of both Akt 
isoforms, whereas rapamycin selectively up-regulated Akt1. The up-regulation of 
Akt1 phosphorylation by Torin-1 was less significant than rapamycin, probably 
because Torin-1 partially inhibited mTORC2 activity and prevented maximum 
phosphorylation of Akt S473 [191]. 
 
Higher concentrations of Torin-1 significantly reduced Akt1 phosphorylation in 
the upper layers of the epidermis (Figure 5-7A & B), demonstrating successful 
inhibition of mTORC2 activity. However, Torin-1 had little effect on 
phosphorylation of the Akt2 isoform compared to the untreated control (Figure 5-
7A & B). This demonstrates that Akt1 is a substrate of mTORC2 in epidermis 
and suggests a more complex regulation for Akt2. Treatment with the alternative 
ATP-competitive mTOR inhibitor, KU-0063794, inhibited both Akt1 and Akt2 
S473 phosphorylation in the mouse embryo explant model (Appendix 1-7). 
However, the high concentrations of KU0063794 used may inhibit other 
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members of the PI3K-related kinases [315]. This includes DNA-PK, which is also 
able to phosphorylate Akt at S473 [381, 382], and may contribute to the down-
regulation of Akt2 phosphorylation in response to KU-0063974. This inhibitor 
also had little effect on keratinocyte apoptosis (Appendix 1-7), suggesting little 
toxicity at the concentrations used. 
 
 
Figure 5-7: High concentrations of Torin-1 inhibit Akt1 phosphorylation in 
epidermis. Mouse embryo explants were grown at the air-liquid interface for 72 
hours in the presence of vehicle or Torin-1. A) Immunofluorescence for Akt 
(S473) phosphorylation. Bar=50µm. B) Mean Akt (S473) phosphorylation 
fluorescence, + SD (n=1) with x4 fields taken per sample. Two-tailed paired 
Student’s T-test, *** P<0.01. 
 
ATP-competitive mTOR inhibitors also affected total Akt1 levels, but had little 
effect on Akt2. High concentrations of Torin-1 reduced total Akt1 levels in the 
granular layer of epidermis (Figure 5-8A & B). Similarly, KU-0063794 also 
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reduced total Akt1 levels (Appendix 1-7). This reduction in Akt1 is probably due 
to the prolonged inhibition of phosphorylation within the TM of Akt1, leading to 
protein ubiquitination and subsequent degradation [266, 268, 383].  
 
Figure 5-8: Torin-1 reduces total Akt1 in epidermis. Mouse embryo explants 
were grown at the air-liquid interface for 72 hours in the presence of vehicle or 
Torin-1. A) Immunohistochemistry for Akt1 and Akt2. Bar=50µm. B) Mean Akt1 
staining, + SD (n=1) with x4 fields taken per sample. Two-tailed paired Student’s 
T-test, ***P<0.01. 
 
UV exposure is associated with changes in epidermal Akt phosphorylation (Sully 
et al 2012 [235]). Therefore it was important to determine the effects of ATP-
competitive mTOR inhibitors on Akt phosphorylation in response to UV radiation. 
Unfortunately, changes in Akt phosphorylation and total Akt1 levels in the 
presence of KU-0063794 could not be determined in response to UV radiation 
due to the large down-regulation of Akt with the drug treatment (Appendix 1-9). 
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In summary, rapamycin treatment increased phosphorylation of mTORC2 
substrates, PKCα and Akt1, in the upper layers of the epidermis, suggesting that 
rapamycin increases mTORC2 activity. ATP-competitive mTOR inhibitors 
reduced phosphorylation of mTORC1 substrate, S6, and mTORC2 substrates, 
PKCα and Akt, although higher concentrations were required over prolonged 
periods to fully inhibit mTORC2 activity.  
 
 
5.3.4 mTOR S2481 phosphorylation correlates with mTORC2 activity and 
phospho-mTOR S2448 correlates with mTORC1 
 
mTOR is phosphorylated on several residues including S2481 and S2448. In 
some cell-lines, mTORC1 has been shown to be predominantly phosphorylated 
on S2448, which is regulated by S6K1 [384, 385], and mTORC2 predominantly 
phosphorylated on the rapamycin-insensitive site S2481 (Figure 5-9) [386, 387]. 
S2481 is reported as a biomarker for mTORC2 activity [387], however, S2481 
has also been reported as an autophosphorylation site responsible for intrinsic 
mTOR catalytic activity in both complexes [388]. Therefore the functional 
significance of mTOR phosphorylated at these sites remains poorly understood.  
 
 
Figure 5-9: mTOR protein domain structure demonstrating mTOR 
phosphorylation at S2481 and S2448. Human mTOR protein with Huntington, 
elongation factor 3, PR65/A, TOR (HEAT) repeats at the amino terminus, a C-
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terminus kinase domain, a FRB domain, a FAT (FRAP) domain and a FRAP 
ATM TRRAP carboxy terminus (FATC). Residues S2448 and S2481 are both 
located near to the kinase domain. S2448 phosphorylation is reported as being 
rapamycin sensitive and predominantly phosphorylated on mTORC1 [387], 
whilst S2481 is reported as being rapamycin insensitive and a read-out for 
mTORC2 activity in some cell types [386, 387]. 
 
I monitored changes in mTOR phosphorylation during mouse late development 
in comparison to phosphorylation of their substrates to determine the roles of 
S2481 and S2448 phosphorylation in epidermis. In some cell lines, 
phosphorylation of mTOR at S2481 is predicted as a biomarker for mTORC2 
activity and mTORC1 reported as being predominantly phosphorylated on 
S2448 [387]. Little is known about the functional role of mTOR phosphorylation 
in keratinocytes. 
 
mTOR phosphorylation at S2448 correlated with phosphorylation of S6, present 
in the cytoplasm of keratinocytes in the supra-basal and granular layers of the 
epidermis, from E15 upwards (Figure 5-10). S2481 phosphorylation correlated 
with Akt1 & PKCα phosphorylation in the granular layers, but could not be 
detected in the para-basal layer with phosphorylated Akt2 (Figure 5-10). This 
suggests that S2448 is marking mTORC1 activity in the suprabasal and granular 
layers during late stage epidermal development. In contrast, mTORC2 appears 
to be predominantly phosphorylated on S2481 with highest activity in the 
granular layers of the epidermis.  
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Figure 5-10: mTOR S2481 phosphorylation correlates with mTORC2 
substrate phosphorylation, while mTOR S2448 phosphorylation correlates 
with mTORC1 substrate phosphorylation during late development in 
mouse epidermis. Immunofluorescence for Akt (S473), PKCα (S657), mTOR 
(S2481 & S2448) and S6 phosphorylation in CD1 mouse epidermis during 
development from E15.5 to E18.5. Bar=50µm. 
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5.3.5 Rapamycin treatment increases mTOR S2481 phosphorylation, the 
predicted mTORC2 biomarker, in mouse embryo epidermis in vitro  
 
I examined the effects of rapamycin and the ATP-competitive inhibitors on 
mTOR phosphorylation using the mouse embryo explant model to further 
determine whether changes in mTOR complex activity correlated with 
phosphorylation at S2448 and S2481. Rapamycin treatment only slightly 
reduced mTOR phosphorylation at S2448, the predicted mTORC1 biomarker, in 
the cytoplasm of keratinocytes in the suprabasal layers of the epidermis (Figure 
5-11A & B). This demonstrates that S2448 phosphorylation is rapamycin 
insensitive and not a read-out for mTORC1 activity. In contrast, Torin-1 dose-
dependently reduced mTOR phosphorylation at S2448 in mouse embryo 
epidermis (Figure 5-11A & B), demonstrating a difference between rapamycin 
treatment and the ATP-competitive mTOR inhibitor, Torin-1.  
 
In contrast, mTOR S2481 phosphorylation positively correlated with changes in 
mTORC2 activity, demonstrating S2481 as an mTORC2 biomarker in the 
embryo explant model. Rapamycin significantly increased the amount of mTOR 
phosphorylated at S2481 in the granular layers of the epidermis (Figure 5-12A & 
B), correlating with increases in Akt1 S473 and PKCα S657 phosphorylation 
(Figure 5-6). Torin-1 dose-dependently reduced mTOR phosphorylation at 
S2481 (Figure 5-12A & B), correlating with reduced Akt1 S473 and PKCα S657 
phosphorylation (Figure 5-5). A similar reduction in mTOR S2481 
phosphorylation was also seen with KU0063794 (Appendix 1-7). 
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Figure 5-11: mTOR S2448 phosphorylation is rapamycin insensitive and 
not a true biomarker for mTORC1 activity in epidermis. Mouse embryo 
explants were grown at the air-liquid interface for 72 hours in the presence of 
vehicle, rapamycin or Torin-1. A) Immunofluorescence for mTOR (S2448). 
Bar=50µm. B) Mean mTOR (S2448) phosphorylation fluorescence for; 
rapamycin + SD (n=3) with x3 fields taken per sample; Torin-1 + SD (n=1) with 
x3 fields taken per sample, Torin-1 significantly effects PKCα (S657) 
phosphorylation, ANOVA P<0.012. 
 
 169 
 
Figure 5-12: Rapamycin increases, while the ATP-competitive mTOR 
inhibitor decreases, mTOR S2481 phosphorylation, the potential mTORC2 
biomarker, in epidermis. Mouse embryo explants were grown at the air-liquid 
interface for 72 hours in the presence of vehicle, rapamycin or Torin-1. A) 
Immunofluorescence for mTOR (S2481) phosphorylation. Different exposures 
used for rapamycin and Torin-1 treated samples to demonstrate different 
responses to drug treatment. Bar=50µm. B) Mean mTOR (S2481) 
phosphorylation fluorescence for; rapamycin + SD (n=3) with x3 fields taken per 
sample, rapamycin significantly affects mTOR (S2481) phosphorylation, ANOVA 
P<0.002; Torin-1 + SD (n=1) with x4 fields taken per sample, Torin-1 
significantly affects mTOR S2481 phosphorylation, ANOVA P<0.090. 
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Similarly, Torin-1 treatment inhibited mTOR phosphorylation at both S2448 and 
S2481 in cultured keratinocytes (Figure 5-13A & B). However, rapamycin 
treatment failed to up-regulate mTOR S2481 phosphorylation in either rat or 
human cultured keratinocytes (Figure 5-13A & B). Therefore mTOR S2481 
phosphorylation is not a consistent biomarker of mTORC2 activity and cannot be 
used as an mTORC2 biomarker in cultured rat keratinocytes despite acting as 
an mTORC2 biomarker in mouse epidermis.  
 
 
Figure 5-13: Rapamycin does not increase mTOR S2481 phosphorylation 
in cultured keratinocytes. A) Immunoblot of mTOR (S2448 & S2481), Akt 
(S473) and S6K (T389) phosphorylation in REKs treated with vehicle (C), 
rapamycin (R) or 500 nM Torin-1 (T) for either 1 or 24 hours (n=2). B) 
Immunoblot of mTOR (S2448 & S2481), S6K (T389) and Akt (S473) 
phosphorylation in nHEKs treated with either vehicle, rapamycin or 500 nM 
Torin-1 for 24 hours (n=2).  
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5.4 Discussion 
 
The regulation and function of mTORC2 in epidermis is not fully understood. In 
this work I demonstrate that mTORC2 is active in the granular layers of the 
epidermis and promotes Akt1 and PKCα phosphorylation. Prolonged rapamycin 
treatment increases mTORC2 substrate phosphorylation in mouse embryo 
explants, strongly suggesting an increase in mTORC2 activity, which correlates 
with increased phosphorylation of mTOR at S2481, the putative mTORC2 
biomarker [387].  
 
In contrast to rapamycin, the ATP-competitive mTOR inhibitors at high 
concentrations inhibited mTORC2 signalling, reducing mTOR, PKCα and Akt1 
phosphorylation, and also reducing total Akt1 levels. This demonstrates 
differences between the allosteric mechanism of rapamycin and ATP-
competitive mTOR inhibitors on mTORC2 signalling in epidermis and raises 
concerns over whether ATP-competitive mTOR inhibitors would reduce cSCC 
occurrence in the same way as rapamycin.  
 
This study is the first to demonstrate that rapamycin treatment increases 
mTORC2 activity in keratinocytes. Rapamycin treatment increased 
phosphorylation of the mTORC2 substrates, Akt, PKCα and NDRG1 (the latter 
in some cell-lines) and also phosphorylation of mTOR at S2481, the site which 
correlates with mTORC2 activity and is therefore predicted to be predominantly 
phosphorylated on mTORC2 [387]. Rapamycin treatment may also increase 
phosphorylation of PKCε, as this PKC isoform is also expressed in epidermis 
and regulated by mTORC2 [268, 294, 295]. An increase in mTORC2 activity in 
response to rapamycin may be explained by the following mechanisms: 
 
1) mTOR could be a limiting factor in the formation of the complexes and 
therefore the loss of mTORC1 integrity by rapamycin treatment could lead to an 
increase in mTORC2 activity due to a more stable mTOR-rictor interaction. This 
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could be examined by comparing the amount of mTOR co-immunoprecipitated 
with rictor and raptor in response to prolonged rapamycin treatment. 
 
2) Rapamycin inhibits the mTORC1-dependent negative regulation on IRS-1 
leading to activation mTORC2 via PI3K [238-241, 259]. This is a likely 
mechanism as I have already shown this feedback loop to be active in embryo 
epidermis. Furthermore prolonged treatment with low concentrations of Torin-1 
also increased Akt phosphorylation at T308 in cultured keratinocytes (Figure 5-
2A), supporting an increase in PI3K signalling in response to mTORC1 
inhibition.  
 
The hypothesis that mTORC2 is activated via PI3K in response to rapamycin 
could be investigated by monitoring mTORC2 substrate phosphorylation in 
response to rapamycin in the presence of a PI3K inhibitor (e.g. LY294002). 
However, in the case of Akt, a myristylation signal would have to be attached to 
eliminate the membrane translocation effect of PI3K inhibition and the TM T308 
site would have to be mutated, due to its contribution to kinase activation [260]. 
An alternative method to test this hypothesis would be to perform an in vitro 
mTORC2 kinase assay in the presence of constitutively active PI3K. 
 
3) Rapamycin activates mTORC2 via alternative feedback loops. For example, 
S6K negatively regulates mTORC2-dependent phosphorylation of Akt on S473 
by phosphorylation of rictor at T1135 [264, 265]. 
 
The functional significance of mTOR phosphorylation at S2448 is poorly 
understood [386-388]. In this study, mTOR S2448 phosphorylation was inhibited 
by ATP-competitive mTOR inhibitiors but it was insensitive to rapamycin 
treatment. Therefore S2448 phosphorylation is not a biomarker for mTORC1 
activity in epidermis. This is in conflict with S6K being the kinase responsible for 
phosphorylation of mTOR at S2448 [384, 385], as S6K is potently inhibited by 
rapamycin treatment. It is possible that S2448 phosphorylation is an 
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autophosphorylation site that can only be phosphorylated when mTOR is in an 
ATP-bound state and therefore not possible in the presence of bound ATP-
competitive drugs.  
 
mTOR S2481 phosphorylation correlated with changes in phosphorylation of 
mTORC2 substrates in developing epidermis suggesting that S2481 was a 
biomarker for epidermal mTORC2 activity. Furthermore, S2481 phosphorylation 
was inhibited by ATP-competitive mTOR inhibitors and increased by rapamycin 
treatment in the embryo explant model. However, rapamycin failed to increase 
mTOR S2481 phosphorylation in cultured keratinocytes. Further studies are 
required to confirm S2481 phosphorylation as a biomarker for mTORC2 activity. 
This can be achieved by isolating the two mTOR complexes from cultured cell 
lysates by immunoprecipitating rictor and raptor and demonstrating that 
mTORC2 is predominantly phosphorylated at S2481, with increased S2481 
phosphorylation with mTORC2 activity. 
 
The ATP-competitive inhibitor Torin-1 at lower concentrations resulted in 
increased mTORC2 activity, probably due to hyper-activation of PI3K following 
prolonged mTORC1 inhibition [380]. This increase in mTORC2 activity up-
regulated both Akt1, the isoform predicted to have a tumour-suppressing role in 
epidermis due to its down-regulation in cSCC [4], and Akt2, the isoform 
predicted to have a tumour promoting role in epidermis due to its up-regulation 
in cSCC [4]. Therefore ATP-competitive mTOR inhibitors have the potential to 
be pro-carcinogenic in epidermis. 
  
High concentrations of the ATP-competitive mTOR inhibitor, Torin-1, selectively 
reduced Akt1 phosphorylation, but had little effect on Akt2, in the embryo 
explant model, suggesting that mTORC2 preferentially regulates the Akt1 
isoform. mTORC2 also preferentially activates Akt1 in an ovarian cancer cell line 
[389] and in rat skeletal muscle [390]. This demonstrates that Akt1 is 
downstream of mTORC2 in epidermis and suggests more complex regulation for 
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Akt2. Alternative kinases that may also regulate Akt2 phosphorylation at S473 
include PKC-βI [391], PKC-βII [392], DNA-PK [381, 382], IκB kinase ε (IKKε) 
and its homolog TANK-binding kinase 1 (TBK1) [393]. 
 
In conclusion, rapamycin treatment increases mTORC2 activity in keratinocytes, 
probably via activation of PI3K by inhibition of the mTORC1-dependent negative 
regulation of IRS-1. The impact of increased mTORC2 signalling in the upper 
layers of the epidermis is unknown due to a lack of understanding of mTORC2 
function in keratinocytes. The ATP-competitive inhibitor, Torin-1, at low 
concentrations also activates PI3K/Akt signalling in epidermis. However, at 
higher concentrations Torin-1 has the opposite effect to rapamycin in epidermis, 
reducing mTORC2 signalling and mTOR phosphorylation. Comparisons 
between the two classes of inhibitors have provided some understanding into 
the role of mTORC2 in epidermis, including phosphorylation of Akt1 and PKCα 
in the upper layers of the epidermis. However more research is required into 
mTORC2 signalling before ATP-competitive mTOR inhibitors can be considered 
for the treatment of cSCC.  
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Chapter 6 - Rapamycin can increase lipid levels in epidermis 
6.1 Introduction 
 
Chronic UV radiation is one of the major risk factors associated with cSCC [41, 
42]. The penetration of UV radiation into the epidermis and dermis is reduced by 
the physical barrier of the cornified layer and by synthesis of melanin. Melanin 
serves as a physical barrier that scatters UV radiation and also as an absorbent 
filter that reduces the penetration of UV through the epidermis [445] (reviewd by 
[446]). The epidermal lipids and terminal differentiation proteins of the cornified 
layer are important for maintaining epidermal barrier function and reducing UV 
penetration [6]. 
 
UVB radiation induces oxidative changes in some epidermal lipid species and 
leads to increased epidermal lipid fluidity, lamellar granule disorder and reduced 
epidermal barrier function [341-346]. This reduction in barrier function in 
response to UV radiation results in increased lipid biosynthesis of all three 
epidermal lipid classes to enhance barrier regeneration [347, 348].  
 
Previously I demonstrated that rapamycin treatment increased mTORC2 activity 
in cultured keratinocytes and in organ culture, with an increase in 
phosphorylation of Akt1 and PKCα. This raises the question; can these changes 
in mTORC2 signalling be linked to rapamycin’s tumour-suppressing activity in 
epidermis? 
 
Akt1 and PKCα are active in the upper layers of the epidermis and are involved 
in terminal differentiation of keratinocytes [218, 297, 298, 300-302]. NDRG1 also 
has a positive role in differentiation in some cell-types, although this is unknown 
for keratinocytes [278, 279, 281, 394]. Therefore mTORC2 signalling may be 
important for keratinocyte differentiation. Rapamycin may promote keratinocyte 
differentiation via activation of the mTORC2, which may be sufficient to inhibit 
the development of cSCCs.  
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In support of this, PKCα deletion enhances epidermal tumour formation in mice, 
suggesting a tumour-suppressor role for PKCα in skin [307]. Akt1 is also thought 
to have a tumour suppressor role in epidermis [4] and both Akt1 and NDRG1 
inhibit metastasis in some other tumour types [280, 281, 395, 396]. This 
suggests that mTORC2 signalling may have a tumour-suppressing role in 
epidermis. 
 
mTORC2 signalling is also connected to lipid biosynthesis, with mTORC2 
activity positively regulating ceramide synthesis via ypk1 (the yeast homolog of 
SGK) in yeast [284]. Ceramides are the dominant lipid species by weight in the 
epidermis and are important in the formation of the cornified layer and 
maintaining barrier function [318, 397]. Topical treatment of ceramides can 
improve the epidermal barrier properties, providing the appropriate mixture of 
other lipid species are also included [398-400]. mTORC2 signalling may also 
improve epidermal barrier function via SGK1 by increasing expression of 
epithelial sodium channels (ENaCs) in keratinocytes [270-272, 293]. Therefore 
rapamycin treatment may increase epidermal barrier function via activation of 
mTORC2. This rapamycin-induced increase in barrier function may overcome 
the UV-induced lipid changes and maintain epidermal barrier function. 
 
Biosynthesis of other lipids species in the cornified layer, fatty acids and 
cholesterol, are regulated by the SREBP transcription factors [155, 401]. 
Inhibition of mTORC1 by rapamycin treatment inhibits SREBP and results in a 
reduction in the expression of several SREBP target genes, including FASN and 
HMG CoA reductase [148, 167, 168]. Therefore rapamycin may reduce the 
biosynthesis of cholesterol and fatty acids in epidermis via inhibition of SREBP 
and disrupt epidermal lipid and barrier homeostasis. Therefore it is important to 
determine the effects of rapamycin on epidermal lipid biosynthesis and barrier 
function. 
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Up-regulation of FASN, a key enzyme involved in fatty acid synthesis [401], is a 
common molecular change in cancer (reviewed by [402-404]), with FASN 
expression a potential prognostic marker for selected tumours [405-411]. It is not 
yet known whether FASN is up-regulated in cSCC, however it is possible that 
rapamycin treatment inhibits the up-regulation of FASN via SREBP1 in 
epidermis, providing an alternative mechanism for rapamycin’s tumour-
suppressing activity in epidermis. 
 
6.1.1 Hypothesis 
 
Rapamycin increases barrier function in epidermis either through increased 
terminal differentiation and / or increased lipid synthesis. This increase in barrier 
function protects basal keratinocytes against UV-induced DNA damage and 
reduces the development of cSCCs. 
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6.2 Aims 
 
The aim was to establish the effects of rapamycin treatment on the epidermal 
barrier. The following questions were addressed:  
1) What is the effect of rapamycin on expression of terminal differentiation 
proteins? 
2) What is the effect of rapamycin on lipid biosynthesis in epidermis? 
3) What is the effect of rapamycin on epidermal lipids in response to UV 
radiation? 
4) Does rapamycin increase epidermal barrier function and protect against DNA 
damage in response to UV radiation? 
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6.3 Results 
6.3.1 mTORC2 activity correlates with expression of terminal 
differentiation markers in epidermis 
To determine whether rapamycin affects terminal differentiation of keratinocytes, 
I monitored changes in expression of differentiation markers in the mouse 
embryo explant model in response to rapamycin. Rapamycin treatment slightly 
increased the expression of the terminal differentiation markers, filaggrin and 
loricrin, but had little effect on differentiation markers in the spinous and basal 
layers (Figure 6-1).   
 
Figure 6-1: Rapamycin treatment slightly increases expression of terminal 
differentiation markers in epidermis. Mouse embryo explants were grown at 
the air-liquid interface for 72 hours in the presence of either vehicle or 
rapamycin. A) Immunofluorescence for epidermal markers filaggrin, loricrin, 
keratin-1 and keratin-14 plus H&E staining. Bar=50µm. B) Mean filaggrin 
fluorescence, + SD (n=3) with x3 fields taken per sample.  
 181 
Inhibition of mTORC1 and mTORC2, by Torin-1, restricted the expression of 
filaggrin and loricrin to the upper-most layers of the epidermis, resulting in a 
slight reduction in overall expression (Figure 6-2A & B). A similar reduction in 
filaggrin and loricrin expression was also seen with the alternative ATP-
competitive mTOR inhibitor, KU-0063794 (Appendix 1-8). The restriction of 
expression may not be a direct effect of mTOR inhibition and could be due to 
indirect changes in epidermal differentiation homeostasis. 
 
 
Figure 6-2: Torin-1 treatment slightly reduces expression of terminal 
differentiation markers, filaggrin and loricrin, in epidermis. Mouse embryo 
explants were grown at the air-liquid interface for 72 hours in the presence of 
either vehicle or Torin-1. A) Immunofluorescence for epidermal markers 
filaggrin, loricrin, keratin-1 and keratin-14 plus H&E staining. Bar=50µm. B) 
Mean filaggrin and loricrin fluorescence, + SD (n=1) with x4 fields taken per 
sample.  
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However, rapamycin treatment had no detectable effect on the expression of 
differentiation markers in vivo (Figure 6-3), demonstrating that mTORC1 does 
not have a major role in keratinocyte differentiation, consistent with previous 
reports of rapamycin treated skin-cultures [173]. 
  
In conclusion, changes in mTORC2 activity correlate with subtle changes in 
epidermal terminal differentiation marker expression. Rapamycin promotes 
mTORC2 activity in embryo explants and slightly increases filaggrin and loricrin 
expression. In contrast, the two ATP-competitive mTOR inhibitors, which inhibit 
mTORC2 activity, reduce terminal differentiation marker expression. Therefore 
mTORC2 signalling may slightly enhance terminal differentiation. 
 
 
Figure 6-3: Rapamycin treatment has no detectable effect on epidermal 
markers in vivo. C57 black mice were treated with 8mg/kg rapamycin 
administered by IP injection over a 10 day period. Immunofluorescence for 
epidermal markers loricrin, keratin-1 and keratin-14 plus H&E staining (Vehicle 
n=4, rapamycin n=5). Bar=50µm. 
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Additionally rapamycin treatment resulted in no significant changes in 
keratinocyte proliferation (Figure 6-4), suggesting that mTORC1 does not have a 
major role in keratinocyte proliferation.  
 
Figure 6-4: Rapamycin has no significant effect on keratinocyte 
proliferation in epidermis. Mouse embryo explants were grown at the air-liquid 
interface for 72 hours in the presence of either vehicle or rapamycin. A) 
Immunofluorescence for proliferation marker Ki-67. Bar=50µm.  B) Mean 
average for Ki-67 positive nuclei of cells, + SD (n=3) with x3 x40 fields per 
sample.  
 
 
6.3.2 Rapamycin treatment increases lipids in epidermis 
 
Epidermal lipid biosynthesis is essential for barrier functions of the skin [13]. I 
looked at changes in lipid biosynthesis in the mouse embryo explant model in 
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response to rapamycin using the fluorescent probe, Nile red, to determine the 
effect of rapamycin on lipid synthesis. Rapamycin significantly increased lipids in 
the upper layers of the epidermis (Figure 6-5A & B).  
In contrast, mTORC1 and mTORC2 inhibition with high concentrations of Torin-
1 significantly reduced lipids in the upper layers of mouse embryo epidermis 
(Figure 6-5C & D). These changes in epidermal lipid levels correlate with 
mTORC2 activity, suggesting that mTORC2 activity has a positive role in lipid 
synthesis in epidermis and also demonstrates a further difference between the 
effects of rapamycin and ATP-competitive mTOR inhibitors in skin. 
 
 
Figure 6-5: Rapamycin increases and Torin-1 decreases lipids in 
epidermis. Mouse embryo explants were grown at the air-liquid interface for 72 
hours A) Immunofluorescence for Nile red lipid analysis for epidermis grown in 
the presence of either vehicle or rapamycin. Bar=50µm. B) Mean Nile red 
fluorescence for (A), + SD (n=3) with x3 fields taken per sample. Two tailed 
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paired student’s T-test, ***P<0.01. C) Immunofluorescence for Nile red lipid 
analysis for epidermis grown in the presence of either vehicle or Torin-1. 
Bar=50µm. B) Mean Nile red fluorescence for (C), + SD (n=1) with x4 fields 
taken per sample. Two tailed paired Student’s T-test, ***P<0.01.  
 
6.3.3 Rapamycin reduces SREBP1, but not FASN, in epidermis  
The Nile red fluorescent probe demonstrated that rapamycin treatment 
increased lipids in the epidermis, however it did not specify which lipid species 
were affected. The major lipid classes in the cornified layer are free fatty acids, 
cholesterol and ceramides [412]. I initially determined whether rapamycin 
treatment affected the regulation of fatty acid biosynthesis in epidermis by 
monitoring the transcription factor SREBP1, which regulates key enzymes 
involved in fatty acid synthesis, including FASN [401].  
In keratinocytes, both rapamycin and the ATP-competitive mTOR inhibitor, 
Torin-1, reduced the levels of the full-length inactive precursor of SREBP1 (FL-
SREBP1) (Figure 6-6A & B), with FL-SREBP1 more sensitive to Torin-1 than 
rapamycin, as reported previously in other cell types [148]. Although FL-
SREBP1 levels were reduced, there was little change in the nuclear active form 
of SREBP1 (nSREBP1) and FASN (Figure 6-6A, B & C). This suggests that 
mTORC1 regulates FL-SREBP1 in keratinocytes, but that SREBP1 activation 
and FASN expression is independent from mTORC1 activity.   
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Figure 6-6: Rapamycin & Torin-1 inhibit SREBP-1, but not FASN, in REKs. 
A) Immunoblot for Akt (S473) & S6 phosphorylation plus full-length SREBP1 
(FL-SREBP1), nuclear SREBP1 (nSREBP1) and FASN after vehicle or 
rapamycin treatment for 0, 2, 4, 8 & 24 hours (n=2). B)  Immunoblot for Akt 
(S473) & S6 phosphorylation plus SREBP1 and FASN after vehicle or Torin-1 
(100 nM) treatment for 0, 2, 4, 8 & 24 hours (n=2). C) RT-PCR for mean FASN 
mRNA levels, + SD (n=3) after vehicle or rapamycin treatment for 4, 8, and 24 
hours.  
In support of this, rapamycin and Torin-1 treatment also inhibited SREBP1 in the 
granular layers of the epidermal mouse explants (Figure 6-7A). In embryo 
explants basal expression was detected in addition to granular layer SREBP 
expression previously reported [326]. mTOR inhibiton, particulary with 
rapamycin treatment, did not fully inhibit basal SREBP1 levels (Figure 6-7A). 
The SREBP1 expression in the lower layers may be responsible for masking the 
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effects of rapamycin treatment on SREBP1 levels by Western blot analysis 
(Figure 6-6A & B).  
Rapamycin and Torin-1 had little effect on granular FASN levels, despite 
reducing SREBP1 levels in the upper layers (Figure 6-7A-B), consistent with the 
Western data (Figure 6-6). However, FASN expression was more concentrated 
to the uppermost layers with drug treatment (Figure 6-7A). This confirms that 
mTORC1 regulates FL-SREBP1, but that nSREBP1 and FASN can be regulated 
independently from mTORC1 in epidermis. The restriction of FASN expression 
may not be a direct effect of mTORC1 inhibition and could be due to indirect 
changes in epidermal differentiation homeostasis.  
 
Figure 6-7: Rapamycin and Torin-1 reduce SREBP1 levels but not FASN in 
epidermis. Mouse embryo explants were grown at the air-liquid interface for 72 
hours in the presence of vehicle, rapamycin or Torin-1. A) Immunofluorescence 
for SREBP1 and FASN. Bar=50µm. B) Mean FASN fluorescence, + SD; 
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rapamycin n=3 with x3 fields taken per sample; Torin-1 n=1 with x4 fields taken 
per sample.  
Additionally, rapamycin treatment slightly reduced SREBP1 and had little effect 
on FASN expression in mouse epidermis in vivo (Figure 6-8). Therefore 
mTORC1 activity has little effect on the expression of FASN in epidermis, 
making it unlikely that rapamycin’s tumour suppressing activity in epidermis is 
due to inhibition of FASN expression during the early stages of tumourigenesis. 
 
 
 
Figure 6-8: Rapamycin treatment slightly reduces granular SREBP1 and 
FASN in vivo. Immunofluorescence for SREBP1 and FASN in C57 black mice 
treated with 8mg/kg rapamycin administered by IP injection over a 10 day period 
(Vehicle n=4, rapamycin n=5). Bar=50µm. 
  
6.3.4 Rapamycin may inhibit the cholesterol biosynthesis pathway 
The key enzymes involved in cholesterol biosynthesis, including HMG CoA 
reductase, are predominantly regulated by SREBP2 [155].  Rapamycin slightly 
reduced SREBP2 (Figure 6-9A), but had no significant effect on HMG CoA 
reductase levels in cultured keratinocytes (Figure 6-9A & B). In contrast, both 
rapamycin and Torin-1 reduced HMG CoA reductase expression in the basal 
layers in epidermal organ culture (Figure 6-10). Unfortunately, the effects of 
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mTORC1 inhibition on SREBP2 in mouse embryo epidermis could not be 
determined due to the limitations of the anti-SREBP2 antibodies available. 
Therefore the potential role for mTORC1 on the regulation of the cholesterol 
biosynthesis pathway in epidermis remains unclear, but cannot be dismissed. 
 
Figure 6-9: Rapamycin treatment has no significant effect on SREBP2 and 
HMG CoA reductase in REKs. Cells were treated with either vehicle or 
rapamycin. A) Immunoblot for Akt (S473) & S6 phosphorylation plus full-length 
SREBP2 (FL-SREBP2), nuclear SREBP2 (nSREBP2) and HMG CoA reductase 
after treatment for 0, 2, 4, 8 & 24 hours (n=2). B) RT-PCR for HMG CoA 
reductase mRNA levels + SD (n=3) after vehicle or rapamycin treatment for 4, 8, 
and 24 hours.  
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Figure 6-10: Rapamycin and Torin-1 reduce HMG CoA reductase in 
epidermis. Mouse embryo explants were grown at the air-liquid interface for 72 
hours in the presence of vehicle, rapamycin or Torin-1. Immunofluorescence for 
SREBP2 and HMG CoA reductase (rapamycin n=3, Torin-1 n=1). Bar=50µm. 
 
6.3.5 Rapamycin treatment inhibits the UV-induced increase in lipid 
synthesis in epidermis  
 
UV radiation disrupts epidermal lipids and reduces the epidermal barrier function 
[342-346]. I previously demonstrated that rapamycin treatment significantly 
increases lipids in the upper layers in epidermal organ culture (Figure 6-5). 
Therefore it was important to determine the effect of rapamycin treatment on 
lipid biosynthesis in response to UV radiation. 
 
UV treatment of cultured mouse epidermis significantly increased lipids in the 
upper layers of the epidermis 24 hours after irradiation (Figure 6-11A & B). This 
UV-induced increase in epidermal lipid synthesis is also reported in human skin, 
although it occurs slightly later, 72 hours after UV exposure [348]. The faster 
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lipid induction in mouse epidermis can be explained by the quicker barrier repair 
that occurs in mouse skin compared to human skin (reviewed by [413]). 
Rapamycin treatment increased lipid biosynthesis after 72 hours in culture, but 
inhibited the increase in lipids 24 hours after UV radiation (Figure 6-11A & B). 
Therefore rapamycin treatment may inhibit the UV-induced changes in lipid 
biosynthesis, helping to maintain barrier function. 
 
 
Figure 6-11: Rapamycin treatment protects against the UV-induced 
increase in epidermal lipid biosynthesis in response to UVB radiation in 
epidermis. Mouse embryo explants were grown at the air-liquid interface for 72 
hours in the presence of either vehicle or rapamycin. Skin was irradiated with 0 
or 6 mJ/cm2 UVB A) Nile red fluorescence at 0 hour and 24 hours after UVB 
irradiation. Bar=50µm. B) Mean Nile red fluorescence +SD (n=3) with x3 fields 
per sample. Two tailed paired Student’s T-test, **P< 0.05. 
 
 192 
6.3.6 Rapamycin does not protect against DNA damage in response to UV 
radiation  
 
Rapamycin treatment significantly increased lipids in the upper layers of the 
epidermis, which are important in maintaining epidermal barrier function 
(reviewed by [414]), and inhibited the UV-induced changes in lipid biosynthesis. 
The rapamycin-induced changes in lipids may be sufficient to maintain 
epidermal barrier function, reducing the penetration of UV radiation and 
protecting against DNA damage. Therefore it was important to determine 
whether rapamycin increases the barrier function and protects against UV-
induced DNA damage in skin.  
 
Mouse embryo epidermal explants were UV irradiated in the presence of 
rapamycin. UV radiation induced the development of sun-burn cells, with 
characteristic pyknotic nuclei, in the upper layers of the epidermis 24 hours after 
radiation, demonstrating UV-induced keratinocyte apoptosis (Figure 6-12) [51].  
 
 
Figure 6-12: UV radiation in epidermis. H&E for skin from mouse emrbyo 
explants grown at the air-liquid interface for 72 hours in the presence of either 
vehicle or rapamycin. Skin was irradiated with 0 or 6 mJ/cm2 UVB and cultured 
for a further 24 hours. Arrow shows sun-burn cell. Bar=50µm. 
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Keratinocyte apoptosis was measured using cleaved caspase 3 [415]. The 
number of cleaved caspase 3 positive keratinocytes increased 24 hours after UV 
radiation (Figure 6-13A & B), demonstrating a low level of UV-induced apoptosis 
in keratinocytes. Rapamycin treatment slightly reduced the number of UV-
induced cleaved caspase 3 positive cells (Figure 6-13A & B). This inhibition of 
UV-induced apoptosis could be due to rapamycin treatment protecting against 
keratinocyte DNA damage by increased barrier function, suggesting a 
mechanism for rapamycin’s tumour-suppressing role skin. Alternatively, 
rapamycin treatment may inhibit UV-induced cell death suggesting a pro-
carcinogenic role for rapamycin in skin. 
 
Figure 6-13: Rapamycin treatment slightly reduces keratinocyte apoptosis 
in response to UV radiation in epidermis. Mouse embryo explants were 
grown at the air-liquid interface for 72 hours in the presence of either vehicle or 
rapamycin. Skin was irradiated with 0 or 6 mJ/cm2 UVB and cultured for a 
further 24 hours. Bar=50µm. A) Immunofluorescence for cleaved caspase 3 
(D175). B)  Mean for cleaved caspase 3 (D175) positive cells + SD (n=3) with x3 
x40 fields per sample. 
UV radiation induces the formation of cyclobutane pyrimidine dimers (CPDs), 
covalent linkages between thymine bases, resulting in DNA damage [47]. I 
monitored changes in UV-induced CPD formation in response to rapamycin 
treatment to establish whether rapamycin protects against UV-induced on DNA 
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damage in epidermis. UV radiation immediately resulted in CPD positive nuclei 
in the upper layers of the epidermis (Figure 6-14A). Rapamycin treatment did 
not protect against this UV-induced CPD formation (Figure 6-14A &B). Therefore 
rapamycin does not protect keratinocytes against UV-induced DNA damage, 
suggesting that an increase in barrier function is not the mechanism responsible 
for rapamycin’s tumour-suppressing role in skin.  
CPDs are excised from the DNA by nucleotide excision repair machinery and 
replaced by newly synthesised DNA (reviewed by [416]). I monitored UV-
induced CPDs in response to rapamycin treatment 24 hours after UV radiation 
to determine whether rapamycin treatment affected the rate of DNA repair. The 
difference between the number of thymine dimer positive nuclei between the 
rapamycin and the vehicle treated samples was greater 24 hours after UV 
radiation than immediately after UV exposure (0 hr) (Figure 6-14A & B). This 
suggests that rapamycin treatment inhibits the excision of CPDs from DNA and 
delays the rate of DNA repair.  
In summary, rapamycin does not protect against DNA damage in response to 
UV in epidermal organ culture, strongly suggesting that rapamycin does not 
increase the barrier function of the epidermis to UV. Surprisingly the same 
doses of rapamycin treatment may slightly reduce cellular apoptosis and  
inhibited DNA repair of CPDs in response to UV, which are both pro-
carcinogenic effects in skin. 
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Figure 6-14: Rapamycin treatment does not protect against thymine dimer 
formation in response to UVB radiation in epidermis. Mouse embryo 
explants were grown at the air-liquid interface for 72 hours in the presence of 
either vehicle or rapamycin. Skin was irradiated with 0 or 6 mJ/cm2 UVB. A) 
Immunostaining for CPDs at 0 hour and 24 hours after UVB irradiation. 
Bar=100µm. B) Mean intensity of thymine dimers +SD (n=2) with x3 x20 fields 
per sample.  
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6.4 Discussion 
 
In this chapter I show that rapamycin treatment significantly increases lipids in 
the upper layers of epidermis in an organ culture model. However, although 
rapamycin treatment affected epidermal lipids, rapamycin did not protect against 
UV-induced DNA damage. Therefore it is unlikely that rapamycin’s tumour 
suppressing role in epidermis is due to an increase in barrier function. 
Surprisingly rapamycin treatment resulted in some pro-carcinogenic effects in 
epidermis, including increased DNA damage and delayed DNA repair in 
response to UV radiation and inhibition of apoptosis. 
 
Rapamycin treatment resulted in subtle increases in terminal differentiation 
marker expression in the embryo explant model. These changes were reversed 
by ATP-competitive mTOR inhibitors, suggesting a role for mTORC2 activity in 
keratinocyte differentiation. Activation of PKCα increases expression of terminal 
differentiation markers, including loricrin and filaggrin, in cultured keratinocytes, 
however PKCα over-expression in vivo has little effect on terminal differentiation 
marker expression [307, 417, 418], making it unclear whether PKCα is the 
downstream substrate responsible for promoting keratinocyte differentiation 
marker expression. Terminal differentiation may be regulated by other mTORC2 
substrates such as NDRG1, Akt1 and possibly SGK via EnaC [271, 272], which 
are implicated in cell differentiation [218, 278, 279, 281, 394]. 
 
Rapamycin significantly increased lipids in the upper layers of epidermis in 
organ culture, demonstrating a positive role for rapamycin treatment in lipid 
biosynthesis. However, the exact lipid species affected by rapamycin treatment 
remains unclear. Changes in epidermal lipid species in response to rapamycin 
treatment can be investigated by performing thin-layer chromotagraphy (TLC) on 
isolated stratum corneum (For example [419]). In depth analysis of changes in 
ceramide classes can also be determined using mass spectrometry techniques 
[420]. 
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Interestingly, patients on rapamycin and other rapalogues often have 
hyperlipidemia, with elevated triglycerides and cholesterol compared to the 
control groups (reviewed by [421]). Also, disruption of mTORC1 signalling in 
mice, by S6K1 deletion, results in increased free fatty acids [240]. Furthermore, 
acne-like eruptions develop in 13-46% of rapamycin treated patients, suggesting 
a disruption of epidermal lipids [174, 422, 423].  
 
The changes in epidermal lipids, in response to rapamycin and ATP-competitive 
mTOR inhibitors, correlated with changes in mTORC2 activity, suggesting that 
mTORC2 is important for the regulation of epidermal lipid biosynthesis. In yeast 
mTORC2 has a positive role in ceramide synthesis, via Ypk2, the yeast 
analogue of SGK1 [284]. The early steps of de novo sphingolipid synthesis are 
conserved and therefore it is possible that mTORC2 may also regulate ceramide 
synthesis in mammals (reviewed by [424]). Akt also regulates ceramide 
metabolism, having a positive role in the vesicular transport of ceramides from 
the ER to the Golgi for the biosynthesis of complex sphingolipids in glial cells 
[425]. Therefore mTORC2 signalling via Akt and SGK1 may be important for 
maintaining ceramide homeostasis in the epidermis. Tissue specific knock-out 
for rictor / mSIN1 and SGK1 are required to determine the role of mTORC2 
signalling in epidermal ceramide synthesis. 
 
Rapamycin treatment did not protect against UV-induced DNA damage, despite 
the increase in epidermal lipid synthesis. Therefore it is unlikely that rapamycin 
treatment promotes epidermal barrier function to protect against UV-induced 
DNA damage. This may be due to rapamycin only increasing a subset of 
epidermal lipid species, most likely ceramides, which alone are not sufficient to 
increase barrier function and may actually disrupt epidermal lipid homeostasis 
[399].  
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Rapamycin treatment may also delay the rate of DNA repair in response to UV 
radiation, as the rapamycin-treated samples had increased CPDs compared to 
the controls 24 hours after UV exposure (Figure 6-14). In support of this, 
rapamycin suppresses DNA double-strand break repair in breast cancer cells 
lines in response to radiation [426] and also inhibits the nucleotide excision 
pathway in a yeast model system, although this appears to be mTOR dependent 
[427]. 
 
However, everolimus does not affect DNA repair in all cell types [428] [429] 
(reviewed by [430]). These differences may be due to differences in doses, as 
everolimus only inhibits H2O2-induced DNA repair in peripheral blood 
mononuclear cells at high doses [431]. Therefore the effects of rapamcyin 
treatment on DNA repair pathways remain unclear with further work required in 
keratinocytes, including a timecourse monitoring the removal of photo-products 
following UV radiation in response to varying concentrations of rapamycin. 
 
Rapamycin treatment also slightly reduced keratinocyte apoptosis in response to 
UV. Rapamycin treatment may inhibit UV-induced apoptosis due to activation of 
pro-survival signals via Akt. Apoptosis of proliferating basal keratinocytes with 
irreparable DNA damage is important for preventing the passing of DNA 
mutations onto daughter cells [365] and therefore the reduction in apoptosis of 
UV-damaged keratinocytes in response to rapamycin is procarcinogenic. 
Rapamycin treatment is already known to have a tumour-suppressing role in 
skin [1, 2] and so it is surprising to find these pro-carcinogenic effects of 
rapamycin in epidermis in response to UV. 
 
In conclusion, rapamycin treatment significantly increases lipids in the upper 
layers of the epidermis through an unknown mechanism. Changes in epidermal 
lipids correlate with mTORC2 signalling, suggesting that mTORC2 may be 
important for epidermal lipid biosynthesis. Rapamycin treatment did not protect 
against UV-induced DNA damage, strongly suggesting that rapamycin does not 
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promote barrier function. Surprisingly, rapamycin had some pro-carcinogenic 
effects in epidermis including a reduced rate of DNA repair and less apoptosis in 
response to UV radiation. Therefore rapamycin has the potential to promote 
epidermal malignant transformation in response to UV radiation through 
inhibition of the two major defense mechanisms against DNA damage. 
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Chapter 7 – Final discussion 
 
Rapamycin inhibits both cSCC tumour formation and tumour development in 
transplant recipients [1, 2]. This tumour-suppressing activity is thought to be 
independent of rapamycin’s immunosuppressive properties.  This is because 
calcineurin inhibitors, which reduce IL-2 production in a similar fashion to 
rapamycin, do not reduce cSCC occurrence [74-76]. 
 
There are multiple proposed mechanisms as to how rapamycin reduces cSCC 
occurrence (reviewed by [3]). However, few studies have focused on the effects 
of rapamycin in normal keratinocytes [127, 171, 173, 178]. This study 
investigated the effects of rapamycin in normal keratinocytes in order to 
determine potential novel mechanisms for rapamycin’s tumour suppressive 
activity in skin. This study focused on the effect of rapamycin on PI3K/Akt 
signalling, mTORC2 activity and epidermal lipid biosynthesis. 
 
I show that rapamycin treatment activates the PI3K/Akt1 pathway in response to 
insulin via inhibition of mTORC1-dependent negative feedback loops acting on 
IRS proteins in cultured keratinocytes and in E18.5 epidermis. This 
demonstrates that insulin signalling is active in epidermis and is negatively 
controlled by mTORC1 signalling. Insulin signalling is important in the early 
stages of keratinocyte differentiation [432]. Therefore, I predict that mTORC1 
signalling is important in co-ordinating insulin signalling and keratinocyte 
differentiation, linking it with other cellular inputs (e.g. nutrient availability). 
Insulin regulates differentiation in other cell types where the mTORC1-
dependent negative feedback loops acting on IRS proteins are also active, for 
example in the differentiation of adipocytes [433, 434]. 
 
Interestingly, insulin treated elderly type 2 diabetes patients have reduced 
NMSC compared to diabetic patients on other treatments, suggesting that 
insulin signalling protects against tumourigenesis in skin [435]. It is proposed 
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that the excess insulin promotes IGF-1 signalling, which suppresses the 
initiation of UVB-induced carcinogenesis by promoting stress-induced 
senescence after UVB exposure (reviewed by [436]). However, insulin may also 
have other tumour-suppressing roles in epidermis. For example, insulin initiates 
early keratinocyte differentiation [374, 432,], which may inhibit tumourigenesis. 
Furthermore, insulin may promote the tumour-suppressive activities of epidermal 
PKCα [307] and Akt1 [4] through activation of mTORC2 signalling [260, 261].  
 
Prolonged rapamycin treatment activates mTORC2 signalling in cultured 
keratinocytes and in the embryo explant model, probably in part through 
inhibition of the mTORC1-dependent negative feedback loops acting on IRS 
proteins. Furthermore, mTORC2 is predominantly active in the upper layers of 
the epidermis where it is responsible for PKCα and Akt1 phosphorylation. Both 
Akt1 and PKCα have tumour suppressor roles in epidermis [4, 307], suggesting 
that mTORC2 also has anti-cancer activity in skin. Therefore activation of 
mTORC2 is a potential therapeutic target in epidermis. However, the role of the 
SGKs in epidermis remains unclear. It is also unclear whether mTORC2 is 
important in Akt2 and PKCε phosphorylation. An increase in Akt2 and PKCε 
signalling may promote tumourigenesis [4, 296, 299]. It is possible that 
mTORC2 has a tumour-suppressing role in normal skin, but is tumour-promoting 
after initiation oncogenic transformation. For example, IGF-1 signalling is 
tumour-suppressing in normal skin by inhibiting proliferation of DNA damaged 
cells, but promotes keratinocyte proliferation following initiation of 
tumourigenesis (reviewed by [436]).  
 
Surprisingly rapamycin demonstrated carcinogenic effects in epidermis, despite 
having an overall tumour-suppressing role in skin [2]. In a cultured epidermal 
model, rapamycin reduced the two major defense mechanisms against UV-
induced DNA damage, DNA repair and apoptosis. Monitoring rates of apoptosis 
and CPD removal in UV-exposed rapamycin-treated patient skin will confirm 
whether patients respond similarly to the culture models. Clinically relevant 
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doses of rapamycin may not affect DNA repair as only high doses inhibited 
H2O2-induced DNA repair in cultured blood cells [431]. Assuming rapamycin 
does inhibit DNA repair in human skin, then the tumour-suppressing role of 
rapamycin must have greater significance on malignant transformation than 
rapamycin’s effects on DNA repair and apoptosis.  
 
ATP-competitive mTOR kinase inhibitors have helped to determine some of the 
roles of mTORC2 in epidermis, however, they do not enable isolation of 
mTORC2 functions from mTORC1. Furthermore, higher concentrations of ATP-
competitive mTOR kinase inhibitors were required to overcome the mTORC1-
dependent negative feedback loops acting on IRS proteins, resulting in potential 
off-target activities against other members of the PI3K-related kinase family. For 
example, Torin-1 inhibits mTOR and DNA-PK in enzymatic kinase assays with 
half maximal inhibitory concentrations (IC50s) of 4.32 nM and 6.34 nM 
respectively [313]. Therefore, due to a lack of mTORC2 specific inhibitors and 
the potential off-target activity of ATP-competitive mTOR inhibitors, tissue 
specific knock-out rictor / mSIN1 is required to fully investigate mTORC2 
signalling in skin. 
 
The selective activation of Akt1 in response to rapamycin may be beneficial in 
treating some skin diseases, including Harlequin ichthyosis. The molecular 
cause of Harlequin ichthyosis is mutation of the ABCA12 lipid transporter 
resulting in severe hyperkeratosis and impaired barrier function [222-224]. The 
defective lipid transport leads to an accumulation of intracellular lipids and is 
predicted to be the cause for increased keratinocyte apoptosis in the granular 
layer of these patients [221]. Akt1 signalling is promoted in Abca12 -/- mice and 
may act as a compensatory mechanism against apoptosis in the granular layer 
of keratinocytes [221]. Therefore activation of Akt signalling is a therapeutic 
strategy for treating Harlequin ichthyosis [221]. Rapamycin treatment may 
promote Akt1 signalling, resulting in increased keratinocyte survival and 
improved barrier function in Harlequin ichthyosis patients. 
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Akt1 and mTORC1 signalling are both up-regulated in response to wounding. 
Akt1 expression and phosphorylation are up-regulated at the wound margin 
[219, 220] and activation of mTORC1 signalling promotes cutaneous wound 
healing [169]. mTORC1 inhibition with rapamycin delays wound closure [169]. 
This raises the question; does mTORC1 signalling regulate Akt1 in wound 
repair? Wound healing involves re-epithelialization by surrounding keratinocytes 
(reviewed by [437]). Several hours after wounding, epidermal migration begins, 
followed by a proliferative burst by keratinocytes just back from the wound 
margin [437]. Once the wound surface is repopulated by a layer of 
keratinocytes, epidermal migration ceases and keratinocytes undergo the 
standard differentiation programme [437]. Akt1 phosphorylation is increased at 
the wound margin during mid- and late stages of acute repair (days 7 and 13 
post-wounding) [220], when keratinocyte proliferation ceases and differentiation 
begins [437]. Therefore Akt1 is activated as the new population of keratinocytes 
undergoes terminal differentiation. In a second study, mTORC1 is active in the 
same layers as phosphorylated Akt in both the proliferating transitional 
epithelium and also in the migrating keratinocytes at the wound margin [169]. 
However, this study does not show which epidermal Akt isoform is up-regulated. 
This may be Akt2 up-regulated during the epidermal proliferative burst behind 
the wound margin, which is independent from mTORC1 activity. Therefore it is 
unclear whether the mTORC1-dependent negative regulation of PI3K/Akt1 
signalling is active in wounded epidermis. 
 
Another potential therapeutic role for rapamycin in skin involves its effects on 
epidermal lipid biosynthesis. Patients on rapamycin treatment report increased 
acne-like eruptions, suggesting epidermal lipid disruption in response to 
rapamycin [174]. This is supported by this study showing an increase in lipid 
levels in developing epidermis in response to rapamycin. It is of great 
importance to determine which epidermal lipid species are affected by 
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rapamycin treatment in order for rapamycin’s therapeutic use in treating skin 
disorders. 
 
Topical administration of rapamycin demonstrates antipsoriatic activity in skin 
[438]. Psoriasis compromises epidermal barrier function and is associated with 
dyslipidemia. Psoriatic skin has reduced ceramide levels, including ceramide 1 
[439] and increased triacylglycerols and cholesterol [440]. S6K is up-regulated in 
psoriatic skin lesions, strongly suggesting an increase in mTORC1 signalling 
[441]. The increase in mTORC1 signalling provides a mechanism, via SREBP 
proteins, for the increased triglyceride and cholesterol levels in these patients. 
Therefore, rapamycin may reduce triacylglycerols and cholesterol and increase 
in ceramide synthesis to improve lipid homeostasis and barrier function in 
psoriatic skin.  
 
An increase in ceramide biosynthesis would also be beneficial in treating other 
skin disorders, including atopic dermatitis. Skin of atopic dermatitis patients has 
reduced ceramide levels, with significant reductions in ceramide 1 and 3 
reported in several cases [35-38]. An increase in overall ceramide biosynthesis 
in response to rapamycin may be sufficient to compensate for the loss of 
ceramide 1 and 3 in atopic dermatitis patients and improve barrier function. 
However, atopic dermatitis is also linked with reduced sphingomyelinase activity 
[442] and impaired lamellar body formation [443]. An increase in ceramide 
synthesis would not be of any benefit under these circumstances. In support of 
this, rapamycin was not effective in treating patients with severe atopic 
dermatitis in a small study [444]. 
 
In conclusion, this study investigated the effects of rapamycin in epidermis in 
order to determine potential novel mechanisms for rapamycin’s tumour 
suppressive activity in skin. I have shown that rapamycin can selectively up-
regulate phosphorylation of Akt1, the isoform with a tumour-suppressing role in 
epidermis. Rapamycin may promote the recovery of Akt1 phosphorylation in 
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response to UV radiation, providing an alternative mechanism for rapamycin’s 
tumour-suppressive activity in skin.  
 
Rapamycin can also increase epidermal lipids. This rapamycin-induced increase 
is not sufficient to protect against UV-induced DNA damage, suggesting that 
rapamycin’s tumour-suppressor role in epidermis is not due to an increase in 
epidermal barrier function due to increased epidermal lipids. The changes in 
epidermal mTORC2 activity correlate with changes in epidermal lipid levels, 
suggesting that mTORC2 may have a role in epidermal lipid regulation. This 
opens the possibility of mTORC2 as a therapeutic target for some skin 
disorders.   
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Chapter 8 - Appendix 
8.1 Optimization of inhibitors in cultured REKs 
 
Optimal concentrations for kinase inhibitors in cultured REKs were established 
by titrating compounds in culture media and incubating with cells over a one 
hour period. The PI3K inhibitor, LY-294002, successfully inhibited AKT and S6 
phosphorylation at concentrations above 5.5 µM (Appendix 1-1A). The AKT 
inhibitor, API-2, which prevents activation of AKT via inhibition of an upstream 
effector molecules [371], inhibited AKT phosphorylation at concentrations above 
0.5 µM (Appendix 1-1B). The SH-5 AKT inhibitor, which prevents PIP3 formation 
and binding to AKT, was less potent and only inhibited AKT phosphorylation at 
the highest concentration tested, 50 µM (Appendix 1-1C). 
 
 
Appendix 1-1: Titration of inhibitors in REKs. A) Immunoblot of Akt (S473) 
and S6 phosphorylation following 0 to 50 µM LY-294002 for one hour (n=1). B) 
& C) Immunoblot of Akt (S473) phosphorylation following 0 to 5 µM API-2 (B) or 
0 to 50 µM SH-5 (C) for 1 hour (n=1). Quantification for changes in Akt (S473) 
phosphorylation relative to total Akt determined by densitometry. 
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8.2 Rapamycin treatment selectively increases HA-tagged Akt1 
phosphorylation 
 
The effect of rapamycin treatment on epidermal Akt isoform phosphorylation 
was investigated using HA-tagged transfected Akt1 and 2 constructs (Appendix 
1-2). Rapamycin increased HA-immunoprecipitated Akt1 S473 phosphorylation, 
but had no significant effect on HA-Akt2 levels. This demonstrates that 
rapamycin selectively increases Akt1 phosphorylation, but not Akt2, when the 
isoforms are over-expressed in keratinocytes. 
 
 
Appendix 1-2: Rapamycin treatment selectively increases HA-Akt1 
phosphorylation in transfected REKs. REKs were transfected with pcDNA, 
HA-Akt1 or HA-Akt2 for 48 hours followed by treatment with vehicle or 10 nM 
rapamycin for 2 hours. Immuno-blot of Akt S473 phosphorylation and Akt1, Akt2 
and HA from immunoprecipitated HA with immune-blot for corresponding lysates 
below. Transfection and Western blot performed by Olufolake Akinduro. 
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8.3 Levels of cellular stress and apoptosis in mouse foetal explants 
 
Changes in keratinocyte stress and cell death were monitored in the mouse 
embryo explant model in response to inhibitor treatment. Rapamycin and Torin-1 
had no detectable effect on cellular stress, shown by keratin-6 expression, and 
apoptosis, demonstrated by the number of cleaved caspase 3 positive cells, at 
concentrations up to 5 µM (Appendix 1-3A & B).  
 
 
Appendix 1-3: Rapamycin and Torin-1 have no detectable effect on keratin-
6 and cleaved caspase 3 in epidermis. Mouse embryo explants were grown at 
the air-liquid interface for 72 hours. Immunofluorescence for epidermal stress 
marker, keratin-6, and apoptosis marker cleaved caspase 3 (D175). Bar=50µm. 
A) Skin cultured in the presence of vehicle or 5 µM rapamycin. B) Skin cultured 
in the presence of vehicle or 5 µM Torin-1. 
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8.4 UV radiation has no significant effect on PKCα phosphorylation 
in epidermis 
 
To determine whether UV radiation affected mTORC2 signalling in epidermis, 
changes in phosphorylation of mTORC2 substrate, PKCα, was monitored in 
response to UV radiation in the mouse embryo explant model. There were no 
significant changes in PKCα phosphorylation immediately after and 24 hours 
after UV radiation (Appendix 1-4A & B), suggesting that UV radiation has little 
effect on mTORC2 signalling in this model.  
 
 
Appendix 1-4: UV radiation has no significant effect on PKCα 
phosphorylation in epidermis. Mouse embryo explants were grown at the air-
liquid interface for 72 hours followed by 0 or 6 mJ/cm2 UV radiation. Samples 
were either harvested immediately (0hr) or 24 hours after UV radiation. A) 
Immunofluorescence for PKCα (S657). Bar=50µm. B) Mean PKCα (S657) 
phosphorylation fluorescence, + SD, taken from n=3, with x3 fields taken per 
sample.  
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8.5 The effect of rapamycin on epidermal S6 phosphorylation in vivo 
 
Overall rapamycin treated mice had reduced epidermal S6 phosphorylation 
compared to the vehicle controls. However four out of the five rapamycin-treated 
mice had regional up-regulation of S6 in the upper layers of the epidermis 
(Appendix 1-5). These hyper-active S6 regions correlated with expression of 
epidermal stress marker, K-6 (Appendix 1-5). 
 
 
Appendix 1-5. In vivo rapamycin treated mice have regional up-regulation 
of S6 phosphorylation that correlates with K-6 expression. C57 black mice, 
obtained from Dr. Matthew Hardman, University of Manchester, were treated 
with 8mg/kg rapamycin (0.24 mg/dose, assuming average weight of 30g) over a 
10 day period. Immunofluorescence for S6 phosphorylation and K-6. 
Bar=100µm. 
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8.6 Torin-1 and rapamycin have little effect on PKCα/β 
phosphorylation within the TM 
mTORC2 regulates phosphorylation of PKCα within the HM, at S657, and in the 
TM, at T638 [105, 266, 268]. mTOR inhibition with Torin-1 and prolonged 
rapamycin treatment had little effect on PKCα phosphorylation within the TM 
(Appendix 1-6A-D) due to the TM phosphorylation event occurring during protein 
translation and independent from growth factor signalling.  
 
Appendix 1-6: Torin-1 and rapamycin have little effect on PKCα 
phosphorylation within the TM in keratinocytes. Immunoblot of PKCα/β 
(T638/641) and S6 phosphorylation in cells treated with vehicle, 1-100 nM Torin-
1 or 10 nM rapamycin A) 1 hour treatment in REKs. B) nHEKs seeded in 0.2 mM 
CaCl2 overnight followed by 0.2 or 1.2 mM CaCl2 for a further 24 hours before 1 
hour drug treatment. C) 24 hour treatment in REKs. D) nHEKs seeded in 0.2 
mM CaCl2 overnight followed by 0.2 or 1.2 mM CaCl2 for a further 24 hours in 
the presence of vehicle or 10 nM rapamycin. 
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8.7 The effect of KU0063794 in mouse embryo explants 
 
The alternative ATP-competitive mTOR inhibitor, KU0063794 [315], successfully 
inhibited phosphorylation of S6, PKCα (S657) and mTOR (S2481) and reduced 
total Akt1 levels in mouse embryo epidermis (Appendix 1-7), similar to the 
results seen with Torin-1 treatment. However, KU0063794 down-regulates 
phosphorylation of both epidermal Akt isoforms (Appendix 1-7), which differs 
from the Akt1 specific inhibition seen with Torin-1 treatment.  
 
KU0063794 demonstrated little toxicity in mouse embryo epidermis as shown by 
the low number of cleaved caspase 3 positive cells at concentrations up to 20 
µM (Appendix 1-8). KU0063794 affected terminal differentiation marker 
expression similar to Torin-1 treatment, with KU0063794 treated samples having 
fewer cell layers expressing filaggrin and loricrin (Appendix 1-8). KU0063794 
treated samples also demonstrated reduced epidermal thickness compared to 
vehicle treated samples (Appendix 1-8). 
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Appendix 1-7: KU0063794 inhibits PKCα, S6, Akt and mTOR S2481 
phosphorylation and total Akt1 levels in mouse embryo epidermis in vitro. 
Skin from torso region of CD1 mice at E15.5 was grown at the air-liquid interface 
for 72 hours cultured in vehicle or 20 µM KU0063794. A) Immunofluorescence 
for PKCα (S657), S6, Akt (S473) and mTOR (S2481) phosphorylation plus 
immunostaining for total Akt1. Bar=50µm. B) Mean PKCα (S657), Akt (S473) 
and mTOR (S2481) phosphorylation plus total Akt1 staining, + SD (n=3) with x3 
fields taken per sample. Two-tailed paired Student’s T-test; ** P<0.05; * P<0.10. 
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Appendix 1-8: KU0063794 reduces terminal differentiation marker 
expression and has little effect on cleaved caspase 3 in mouse embryo 
epidermis in vitro. Skin from the torso region of CD1 mice at E15.5 was grown 
at the air-liquid interface for 72 hours cultured in either vehicle or 20 µM 
KU0063794. Immunofluorescence for apoptosis marker, cleaved caspase 3 
(D175), terminal differentiation markers filaggrin and loricrin and H&E staining. 
Bar=50µm 
 
I also looked at the effects of KU0063794 on Akt phosphorylation in response to 
UV radiation. KU-0063794 treatment inhibited phosphorylation of both Akt 
isoforms and down-regulated total Akt1 levels (Appendix 1-9), as reported 
previously (Appendix 1-7). UV radiation increased Akt2 phosphorylation and 
reduced both Akt1 phosphorylation and total Akt1 levels (Appendix 1-9). UV 
radiation had little effect on Akt phosphorylation and total Akt1 levels in the 
presence of KU0063794 due to the large down-regulation of Akt with drug 
treatment (Appendix 1-9). 
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Appendix 1-9: KU0063794 inhibits changes in Akt in response to UV 
radiation in mouse embryo epidermis in vitro. Skin from the torso region of 
CD1 mice at E.15.5 was grown at the air-liquid interface for 72 hours in the 
presence of vehicle or 20 µM KU0063794, followed by 0 or 6 mJ/cm2 UV 
radiation. Samples were harvested 24 hours after UV radiation. A) 
Immunostaining for Akt (S473) phosphorylation and total Akt1 levels. Bar=50µm. 
B) Mean Akt (S473) phosphorylation and Akt1 staining, + SD (Vehicle n=2, 
KU0063794 n=3) with x3 fields taken per sample.  
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8.8 Quantification of Western blots by densitometry  
 
        
Quantification for Akt (S473 and T308) phosphorylation relative to total Akt in  
 response to rapamycin treatment in REK 
     
Time (min) Total Akt  S473 S473/total T308 T308/total   
0 81 45 0.6 25 0.3   
10 89 45 0.5 54 0.6   
20 96 63 0.7 67 0.7   
30 95 85 0.9 92 1.0   
60 119 147 1.2 152 1.3   
 
 
        
Quantification for Akt (S473) phosphorylation relative to total Akt in response to  
 rapamycin treatment in REKs 
      
Time (hr) Rapa-
mycin 
n=1  n=2 
S473 Total Akt S473/total S473 Total Akt S473/total 
2 - 243270 169830 1.4 160395 118830 1.3 
2 + 244290 140760 1.7 255255 118830 2.1 
4 - 158610 201960 0.8 115260 149685 0.8 
4 + 252960 174675 1.4 224145 137700 1.6 
6 - 93840 164220 0.6 104550 149940 0.7 
6 + 198135 161160 1.2 214965 158865 1.4 
8 - 119085 163965 0.7 117810 147135 0.8 
8 + 214710 158610 1.4 159630 187935 0.8 
        
Time (hr) Rapa-
mycin 
n=3  Average 
S473/total 
St. Dev. 
S473/total 
 
S473 Total Akt S473/total  
2 - 161160 204765 0.8 1.2 0.4  
2 + 242505 175950 1.4 1.8 0.4  
4 - 107355 139740 0.8 0.8 0.0  
4 + 212670 119595 1.8 1.6 0.2  
6 - 113475 132345 0.9 0.7 0.1  
6 + 231540 183345 1.3 1.3 0.1  
8 - 97920 123420 0.8 0.8 0.0  
8 + 180285 130050 1.4 1.2 0.3  
 
Two-tailed paired Student's T-test for -/+ rapamycin  Time (hr) P 
      2 0.06 
      4 0.01 
      6 0.02 
      8 0.15 
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Quantification for Akt (S473) phosphorylation and relative to keratin-14 in  
 response to rapamycin treatment in mouse embryo epidermis in vitro 
  
Rapamycin (µM) 
n=1  n=2  
S473 k-14 S473/k-14 S473 k-14 S473/k-14  
0 50490 80835 0.62 55080 99960 0.55  
1 78030 146880 0.53 91800 115260 0.80  
5 109650 93075 1.18 132855 40290 3.30  
        
Rapamycin (µM) 
n=3  Average 
S473/k-14 
St. Dev. 
S473/k-14 
  
S473 k-14 S473/k-14   
0 44370 130560 0.34 0.5 0.1   
1 83640 71655 1.17 0.8 0.3   
5 155550 86445 1.80 2.1 1.1   
 
 
Quantification for IRS-1 relative to keratin-14 in response to rapamycin treatment 
 in mouse foetal epidermis in vitro  
        
Rapamycin 
(µM) 
n=1  n=2  
IRS-1 k-14 S473/k-14 IRS-1 k-14 S473/k-14  
0 60945 80835 0.75 16065 99960 0.16  
1 176460 146880 1.20 179265 115260 1.56  
5 116025 93075 1.25 50235 40290 1.25  
        
Rapamycin 
(µM) 
n=3  Average 
S473/k-14 
St. Dev. 
S473/k-
14 
  
IRS-1 k-14 S473/k-14   
0 62475 130560 0.48 0.5 0.3   
1 139230 71655 1.94 1.6 0.4   
5 80325 86445 0.93 1.1 0.2   
 
Two-tailed paired Student's T-test  Rap. (µM) P S473 Rap. (µM) P IRS-1 
    0 & 5 0.1 0 & 1 0.08 
      0 & 5 0.08 
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Quantification for Akt (S473) phosphorylation, Akt1, Akt2 and Akt3 in response to 
 rapamycin treatment in REK 
      
Isoforms 
n=1  n=2  
No rap.  Rap. Rap./no rap. No rap.  Rap. Rap./no rap.  
Pan-S473 26520 81345 3.1 50490 98430 1.9  
Akt1 66810 160650 2.4 63750 82620 1.3  
Akt2 475065 389385 0.8 351390 374085 1.1  
Akt3 141270 82110 0.6 183090 192525 1.1  
        
Isoforms 
n=3  
Average 
Rap/no 
rap 
St. Dev. 
Rap/ no 
rap 
  
No Rap  Rap. Rap./no rap.   
Pan-S473 15555 37485 2.4 2.5 0.6   
Akt1 45645 120615 2.6 2.1 0.7   
Akt2 378165 294270 0.8 0.9 0.2   
Akt3 216495 165495 0.8 0.8 0.2   
 
Two-tailed paired Student's T-test Protein   P  
    Pan-S473 & Akt1 0.35  
    Pan-S473 & Akt2 0.06  
    Pan-S473 & Akt3 0.07  
 
        
Quantification for Akt (S473) phosphorylation in response to API-2 
  
API-2 (µM) Total Akt  S473 S473/total     
0 114 130 1.1     
0.005 104 116 1.1     
0.05 119 90 0.8     
0.5 120 44 0.4     
2.5 129 55 0.4     
5 120 55 0.5     
        
Quantification for Akt (S473) phosphorylation in response to SH-5 
   
SH-5 (µM) Total Akt  S473 S473/total     
0 46 69 1.5     
3.12 32 77 2.4     
6.25 58 73 1.3     
12.5 44 69 1.6     
25 40 56 1.4     
50 48 23 0.5     
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8.9 Quantification of RT-PCRs by densitometry  
        
Quantification for IRS-1 and IRS-2 mRNA relative to actin in response to  
 rapamycin treatment in REKs     
        
Time (hr) Rap. 
n=1  n=2 
IRS-1 actin IRS-1/actin IRS-1 actin IRS-1/actin 
0 - 127755 122400 1.0 155550 143565 1.1 
4 - 126990 124185 1.0 169320 143565 1.2 
4 + 112710 121380 0.9 167790 143820 1.2 
8 - 133875 120870 1.1 171615 146625 1.2 
8 + 124185 115515 1.1 166770 109650 1.5 
24 - 102255 105570 1.0 140505 119340 1.2 
24 + 128265 101235 1.3 131835 117045 1.1 
        
Time (hr) Rap. 
n=3  
Average 
IRS-1/ 
actin 
St. Dev. 
IRS-1/ 
actin 
 
IRS-1 actin IRS-1/actin  
0 - 879495 570690 1.5 1.2 0.3  
4 - 733635 570690 1.3 1.2 0.1  
4 + 750720 570690 1.3 1.1 0.2  
8 - 532695 570690 0.9 1.1 0.1  
8 + 785400 570690 1.4 1.3 0.2  
24 - 791775 570690 1.4 1.2 0.2  
24 + 787695 570690 1.4 1.3 0.1  
        
        
Time (hr) Rap. 
n=1  n=2 
IRS-2 actin IRS-2/actin IRS-2 actin IRS-2/actin 
0 - 167790 122400 1.4 207825 143565 1.4 
4 - 160140 124185 1.3 204765 143565 1.4 
4 + 167280 121380 1.4 221850 143820 1.5 
8 - 152235 120870 1.3 210120 146625 1.4 
8 + 126480 115515 1.1 216495 109650 2.0 
24 - 151215 105570 1.4 182835 119340 1.5 
24 + 133875 101235 1.3 158355 117045 1.4 
        
Time (hr) Rap. 
n=3  
Average 
IRS-2/ 
actin 
St. Dev. 
IRS-2/ 
actin 
 
IRS-2 actin IRS-2/actin  
0 - 725475 570690 1.3 1.4 0.1  
4 - 713490 570690 1.3 1.3 0.1  
4 + 825945 570690 1.4 1.5 0.1  
8 - 916980 570690 1.6 1.4 0.2  
8 + 1034790 570690 1.8 1.6 0.5  
24 - 915705 570690 1.6 1.5 0.1  
24 + 833340 570690 1.5 1.4 0.1  
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Quantification for FASN and HMG Co A reductase mRNA relative to actin in  
 response to rapamycin treatment in REKs    
        
Time (hr) Rap. 
n=1  n=2 
FASN actin FASN/actin FASN actin FASN/actin 
4 - 1410915 1387710 1.0 1061310 1242105 0.9 
4 + 1273470 1335180 1.0 1212015 1304835 0.9 
8 - 1356345 1404030 1.0 1315290 1375725 1.0 
8 + 1395615 1115370 1.3 852210 1258170 0.7 
24 - 1087575 943500 1.2 788970 1164585 0.7 
24 + 1053150 936615 1.1 583950 1038360 0.6 
        
Time (hr) Rap. 
n=3  Average 
FASN/actin 
St. Dev. 
FASN/actin 
 
FASN actin FASN/actin  
4 - 1499655 1614405 0.9 0.93 0.08  
4 + 1547595 1611345 1.0 0.95 0.02  
8 - 1525155 1772760 0.9 0.93 0.06  
8 + 1041675 1597065 0.7 0.86 0.34  
24 - 1189065 1237005 1.0 0.93 0.24  
24 + 1275255 1044735 1.2 0.97 0.36  
        
        
Time (hr) Rap. 
n=1  n=2 
HMG CoA actin HMG/actin HMG CoA actin HMG/actin 
4 - 1128120 1387710 0.8 643365 1242105 0.5 
4 + 941970 1335180 0.7 376635 1304835 0.3 
8 - 1175805 1404030 0.8 1542495 1375725 1.1 
8 + 1249755 1115370 1.1 1140105 1258170 0.9 
24 - 1201050 943500 1.3 1123275 1164585 1.0 
24 + 1110525 936615 1.2 928455 1038360 0.9 
        
Time (hr) Rap. 
n=3  Average 
HMG/actin 
St. Dev. 
HMG/actin 
 
HMG CoA actin HMG/actin  
4 - 1736805 1614405 1.1 0.80 0.28  
4 + 1747005 1611345 1.1 0.89 0.27  
8 - 2085390 1772760 1.2 1.05 0.18  
8 + 1715895 1597065 1.1 1.03 0.11  
24 - 1614915 1237005 1.3 1.18 0.19  
24 + 1153875 1044735 1.1 1.06 0.15  
 
  Value not included in analysis 
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8.10 Quantification of immunofluorescence  
       
NB: For all samples n value represents mean for x3 images taken per sample (* indicates 1 image 
taken per sample). 
       
Quantification of Akt1 (S473) phosphorylation in response to rapamycin 
 in mouse embryo epidermis in vitro    
       
Rapamycin (µM) 
Mean pAkt1 (S473) (au) 
Average Std. Dev. 
 
1 2 3  
0 0 8842 240883 83242 136593  
1 113444 259532 52619 141865 106344  
5 357344 348188 487956 397829 78186  
       
ANOVA for effect of rapamycin on pAkt1 S473   
Source df 
Sum of 
Squares 
Mean square Ratio P 
 
 
rapamycin  2 2.15E+11 1.07E+11 11.36 0.005  
residual 8 7.57E+10 9.46E+09    
Total 10 2.91E+11     
       
Quantification of Akt2 (S473) phosphorylation in response to rapamycin  
in mouse embryo epidermis in vitro    
       
Rapamycin (µM) 
Mean pAkt2 S473 (au) 
Average Std. Dev. 
 
1 2 3  
0 855228 1491607 240932 862589 625370  
1 258043 807021 635833 566966 280894  
5 738954 258351 339960 445755 257176  
       
ANOVA for effect of rapamycin on pAkt2 S473   
Source df 
Sum of 
Squares 
Mean square Ratio P 
 
 
rapamycin  2 6.52E+11 3.26E+11 1.779 0.229  
residual 8 1.47E+12 1.83E+11    
total 10 2.12E+12     
       
Quantification of Akt1 (S473) phosphorylation in response to UV and  
rapamycin in mouse embryo epidermis in vitro   
       
Rapamycin (µM) 
UV 
Mean pAkt1 S473 (au) 
Average Std. Dev. 
1 2 3 
0 - 3190645 2569465 7187005 4315705 2505941 
0 + 1667700 385475 3084650 1712608 1350148 
1 - 11417710 7301755 4415240 7711568 3519177 
1 + 1678665 3128850   2403758 1025436 
5 - 3851265 6494595 7923955 6089938 2066280 
5 + 1508155 1210910   1359533 210184 
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Rapamycin 
(µM) 
UV 
Mean pAkt2 S473 (au) 
Average Std. Dev. 
1 2 3 
0 - 657900 2527220 3508545 2231222 1448190 
0 + 2353395 6886105 5307995 4849165 2300926 
1 - 3192600 3725465 528105 2482057 1713018 
1 + 4309840 1099390   2704615 2270131 
5 - 1549380 289935 2541245 1460187 1128302 
5 + 5345310 2217225   3781268 2211890 
       
Two-tailed paired Student's T-test for -/+ UV Protein P 
     Akt1 0.08 
     Akt2 0.10 
       
Quantification of S6 phosphorylation in rapamycin treated adult mouse  
epidermis in vivo      
       
 Mean pS6 (au)  
  1 2 3 4 5  
Vehicle 6921805 4298195 7065200 1674160    
Rapamycin 1526260 1646620 5815658 4372230 4473210  
       
 
Average Std. Dev. 
    
      
Vehicle 4989840 2550275     
Rapamycin 3566796 1895953     
       
Quantification of PKCα (S657) phosphorylation in response to Torin-1 in 
 mouse embryo epidermis in vitro     
       
Torin-1 (µM) 
Mean pPKCα S657 (au) 
Average Std. Dev. 
1* 2* 3* 4* 
0 1565190 1680450 4660125 4240395 3036540 1642066 
2.5 852975 885870 492660 177735 602310 334428 
5 648720 94860 829260 844815 604414 351168 
       
Two-tailed paired Student's T-test   Torin-1 (µM) P 
     0 & 2.5 0.09 
     0 & 5 0.09 
       
Quantification of PKCα (S657) phosphorylation in response to rapamycin  
 in mouse embryo epidermis in vitro    
       
Rapamycin 
(µM) 
Mean pPKCα S657 (au) 
Average Std. Dev. 
 
1 2 3  
0 2927910 1756823 2811375 2498703 645124  
1 4504830 4559655 5060475 4708320 306205  
5 6076013 4277243 6411720 5588325 1147771  
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ANOVA for effect of rapamycin on pPKCα S657 
Source df 
Sum of 
Squares 
Mean 
square 
Ratio P 
 
 
rapamycin  2 3.48E+13 1.74E+13 4.545 0.063  
residual 6 2.30E+13 3.83E+12    
total 8 5.78E+13     
 
 
Quantification of Akt1 (S473) phosphorylation in response to Torin-1 in  
mouse embryo epidermis in vitro     
       
Torin-1 (µM) 
Mean pAkt1 (S473) (au) 
Average Std. Dev. 
1* 2* 3* 4* 
0 6879900 9339120 6113370 7575795 7477046 1377590 
2.5 4574700 6402030 11490810 6514740 7245570 2966551 
5 158100 108375 174420 47430 122081 57147 
       
Two-tailed paired Student's T-test   Torin-1 (µM) P 
     0 & 5 0.002 
       
Quantification of Akt2 (S473) phosphorylation in response to Torin-1 in  
mouse embryo epidermis in vitro     
Torin-1 (µM) 
Mean pAkt2 S473 (au) 
Average Std. Dev. 
1* 2* 3* 4* 
0 7906530 2477070 1266585 4405890 4014019 2899184 
2.5 2668065 14752515 16418685 20080485 13479938 7543640 
5 11492340 4022625 1737060 1541985 4698503 4667147 
       
Quantification of Akt1 in response to Torin-1 in mouse embryo epidermis  
in vitro       
Torin-1 (µM) 
Mean Akt1 (au) 
Average Std. Dev. 
1* 2* 3* 4* 
0 19198950 25711905 15412965 17090355 19353544 4513049 
2.5 21156585 13904130 21161430 26494755 20679225 5169871 
5 1825290 725730 1704930 1125060 1345253 513841 
       
Two-tailed paired Student's T-test   Torin-1 (µM) P 
     0 & 5 0.005 
       
Quantification of mTOR (S2448) phosphorylation in response to 
rapamycin in mouse embryo epidermis in vitro   
       
Rapamycin 
(µM) 
Mean pmTOR S2448 (au) 
Average Std. Dev. 
 
1 2 3  
0 3757294 4338736 3521926 3872652 420446  
1 2891922 2756754 4250363 3299679 826085  
5 4635529 2910987 2685900 3410806 1066596  
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Quantification of mTOR (S2448) phosphorylation in response to Torin-1 
 in mouse embryo epidermis in vitro    
       
Torin-1 (µM) 
Mean pmTOR S2448 (au) 
Average Std. Dev. 
 
1* 2* 3*  
0 9304440 14783880 14136180 12741500 2994147  
2.5 4075410 10058220 4515540 6216390 3334392  
5 762195 4132020 3283125 2725780 1752685  
       
ANOVA for effect of Torin-1 on pmTOR S2448   
Source df 
Sum of 
Squares 
Mean 
square 
Ratio P 
 
 
rapamycin  2 1.55E+14 7.75E+13 10.05 0.012  
residual 6 4.63E+13 7.72E+12    
total 8 2.01E+14     
       
Quantification of mTOR (S2481) phosphorylation in response to  
 rapamycin in mouse embryo epidermis in vitro   
       
Rapamycin 
(µM) 
Mean pmTOR S2481 (au) 
Average Std. Dev. 
 
1 2 3  
0 0 0 0 0 0  
1 1040270 1179497 1460030 1226599 213808  
5 1853728 3663441 3125381 2880850 929307  
       
ANOVA for effect of rapamycin on pmTOR S2481   
Source df 
Sum of 
Squares 
Mean 
square 
Ratio P 
 
 
rapamycin  2 1.25E+13 6.27E+12 20.69 0.002  
residual 6 1.82E+12 3.03E+11    
total 8 1.44E+13     
       
       
Quantification of mTOR (S2481) phosphorylation in response to Torin-1 in 
 mouse embryo epidermis in vitro     
       
Torin-1 (µM) 
Mean pmTOR (S2481) (au) 
Average Std. Dev. 
1* 2* 3* 4* 
0 7089510 3889770 4332960 4328625 4910216 1467663 
2.5 4003245 2276385 5677320 2697390 3663585 1530616 
5 2151180 3533790 3083715 832830 2400379 1193158 
       
ANOVA for effect of Torin-1 on pmTOR S2481   
Source df 
Sum of 
Squares 
Mean 
square 
Ratio P 
 
 
rapamycin  2 1.26E+13 6.30E+12 3.192 0.09  
residual 9 1.78E+13 1.97E+12    
total 11 3.04E+13     
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Quantification of PKC (S657) phosphorylation in response to UV in mouse 
 embryo epidermis in vitro     
       
Time after UV 
(hr) 
UV 
Mean pPKC S657 (au) 
Average Std. Dev. 
1 2 3 
0 - 2120835 3583175 2215950 2639987 818208 
0 + 2072555 2496705   2284630 299919 
24 - 1950240 1381080   1665660 402457 
24 + 2922555 767125 1237430 1642370 1133337 
       
Quantification of mTOR (S2481) phosphorylation in response to UV in  
mouse embryo epidermis in vitro     
       
Time after UV 
(hr) 
UV 
Mean pmTOR S2481 (au) 
Average Std. Dev. 
1 2 3 
0 - 2132565 4782950 2912015 3275843 1362136 
0 + 5407785 4440740 2582130 4143552 1436079 
24 - 427508 983450 1517250 976069 544909 
24 + 497590 440385 967045 635007 288973 
       
Quantification of filaggrin in response to rapamycin in mouse embryo  
 epidermis in vitro      
      
Rapamycin 
(µM) 
Mean filaggrin (au) 
Average Std. Dev. 
 
1 2 3  
0 40 50 63 51 12  
1 55 48 53 52 4  
5 63 72 72 69 5  
       
Quantification of filaggrin in response to Torin-1 in mouse embryo 
 epidermis in vitro 
      
Torin-1 (µM) 
Mean filaggrin (au) 
Average Std. Dev. 
1 2 3 4 
0 7645920 20107260 15276540 25371225 17100236 7531299 
2.5 15309435 13804425 12547020 11451540 13278105 1660737 
5 5859390 11025690 12504690 20707020 12524198 6154244 
       
Quantification of loricrin in response to Torin-1 in mouse embryo epidermis  
 in vitro       
Torin-1 (µM) 
Mean loricrin (au) 
Average Std. Dev. 
1 2 3 4 
0 21613290 19140045 20878890 17177310 19702384 1977199 
2.5 20774850 13255410 15545565 15949740 16381391 3160125 
5 12831855 12752805 14813970  13466210 1167863 
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Quantification of Nile red in response to rapamycin in mouse embryo 
 epidermis in vitro      
      
Rapamycin 
(µM) 
Mean Nile red (au) 
Average Std. Dev. 
 
1 2 3  
0 69 123 79 90 29  
1 124 67 9 67 58  
5 404 359 415 393 30  
       
Two-tailed paired Student's T-test   Rapamycin (µM) P 
     0 & 5 0.012 
       
Quantification of Nile red in response to Torin-1 in mouse embryo epidermis  
 in vitro       
       
Torin-1 (µM) 
Mean Nile red (au) 
Average Std. Dev. 
1* 2* 3* 4* 
0 23267220 21333300 24479490 18385755 21866441 2657669 
2.5 18281715 9178725 25886835 17589390 17734166 6830870 
5 14573760 7968495 11516310 9639510 10924519 2831755 
       
Two-tailed paired Student's T-test   Torin-1 (µM) P 
     0 & 5 0.003 
       
Quantification of FASN in response to rapamycin in mouse embryo 
 epidermis in vitro      
      
Rapamycin 
(µM) 
Mean FASN (au) 
Average Std. Dev. 
 
1 2 3  
0 42 63 112 72 36  
1 94 153 212 153 59  
5 164 156 111 144 29  
       
Quantification of FASN in response to Torin-1 in mouse embryo epidermis 
 in vitro       
       
Torin-1 (µM) 
Mean FASN (au) 
Average Std. Dev. 
1 2 3 4 
0 4787115 8308155 10643955 5942265 7420373 2601185 
2.5 9628800 7343235 3773490 8236245 7245443 2498406 
5 3934140 6894945 9578820 9483450 7472839 2666712 
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Quantification of Nile red in response to UV and rapamycin in mouse  
 embryo epidermis in vitro     
       
Rapamycin 
(µM) 
UV 
Mean Nile red (au) 
Average Std. Dev. 
1 2 3 
0 - 94860 325380 577490 332577 241395 
0 + 285685 561000 116365 321017 224413 
1 - 526830 32640   279735 349445 
1 + 684226 124270 1456730 755075 669049 
5 - 1745815 671245 4258415 2225158 1840998 
5 + 277270 6736505 5081470 4031748 3355125 
       
Quantification of Nile red in response to UV and rapamycin in mouse 
 embryo epidermis in vitro     
       
Rapamycin 
(µM) 
UV 
Mean Nile red (au) 
Average Std. Dev. 
1 2 3 
0 - 5547780 43095 765 1863880 3190421 
0 + 10914850 9614690 5061495 8530345 3073645 
1 - 3042660 2820470 2929950 2931027 111099 
1 + 1472710 4072010   2772360 1837983 
5 - 705670 2277575 5585095 2856113 2490628 
5 + 14881460 1020765 3840725 6580983 7325400 
       
Two-tailed paired Student's T-test   UV P 
     UV & no UV 0.044 
       
Quantification of CPDs in response to UV and rapamycin  
 immediately after UV treatment in mouse embryo epidermis in vitro 
       
Rapamycin 
(µM) 
UV 
Mean CPDs (au) 
Average Std. Dev. 
1 2 3 
0 + 80580 231030 196605 169405 78827 
1 + 604095 224910 303705 377570 200093 
5 + 122400 222870 234345 193205 61587 
       
Quantification of CPDs in response to UV and rapamycin 24  
hours after UV treatment in mouse embryo epidermis in vitro  
       
Rapamycin 
(µM) 
UV 
Mean CPDs (au) 
Average Std. Dev. 
1 2 3 
0 + 17170 75225 33660 42018 29916 
1 + 300305 266985   283645 23561 
5 + 267070 208165 194055 223097 38730 
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Quantification of PKCα, Akt and mTOR phosphorylation and total Akt1 in 
 response to KU0063794 in mouse embryo epidermis in vitro  
       
KU0063794 
(µM) 
Mean PKCα S657 (au) 
Average Std. Dev. 
 
1 2 3  
0 2120835 3583175 2215950 2639987 818208  
10 1757630 505835 2744395 1669287 1121892  
       
KU0063794 
(µM) 
Mean Akt1 (au) 
Average Std. Dev. 
 
1 2 3  
0 9864335 15739960 10966785 12190360 3123074  
10 389130 100555 778685 422790 340316  
       
Two-tailed paired Student's T-test   KU0063794 P 
     0 & 10 0.026 
       
KU0063794 
(µM) 
Mean pmTOR S2481 (au) 
Average Std. Dev. 
 
1 2 3  
0 2132565 4782950 2912015 3275843 1362136  
10 769250 627938 187425 528204 303464  
       
Two-tailed paired Student's T-test   KU0063794 P 
     0 & 10 0.076 
       
KU0063794 
(µM) 
Mean pAkt1 S473 (au) 
Average Std. Dev. 
 
1 2 3  
0 4102865 516375 12990550 5869930 6422083  
10 255 324998 18700 114651 182399  
       
KU0063794 
(µM) 
Mean pAkt2 S473 (au) 
Average Std. Dev. 
 
1 2 3  
0 13301140 9125048 19878440 14101543 5421194  
10 2060825 2751068 2059635 2290509 398856  
       
Two-tailed paired Student's T-test for pAkt2 KU0063794 P 
     0 & 10 0.071 
       
       
Quantification of pAkt S473 in response to UV and KU0063794 24 hours 
 after UV radiation in mouse embryo epidermis in vitro   
       
KU0063794 
(µM) 
UV 
Mean pAkt1 S473 (au) 
Average Std. Dev. 
1 2 3 
0 - 1487585 1362805 942310 1264233 285689 
0 + 56270 129880  93075 52050 
10 - 1055615 460445  758030 420849 
10 + 22695 47175 304725 124865 156244 
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KU0063794 
(µM) 
UV 
Mean pAkt2 S473 (au) 
Average Std. Dev. 
1 2 3 
0 - 5996240 3905580 5518795 5140205 1095542 
0 + 5278330 19212380 10996450 11829053 7004239 
10 - 1973275 1535440   1754358 309596 
10 + 2041190 786760 890800 1239583 696158 
       
       
Quantification of Akt1 in response to UV and KU0063794 24 hours after  
 UV radiation in mouse embryo epidermis in vitro   
       
KU0063794 
(µM) 
UV 
Mean Akt1 (au) 
Average Std. Dev. 
1 2 3 
0 - 4073285 467670 6571435 3704130 3068582 
0 + 1544025 826795 259420 876747 643758 
10 - 329205 82450 449565 287073 187149 
10 + 26095 12750 1131690 390178 642203 
 
 
